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Abstract
Parasitic protozoa cause many widespread diseases known to man such as 
malaria, African sleeping sickness, leishmaniasis and Chagas’ disease. These 
diseases are particularly prevalent in the developing world and the need for new, safe 
and affordable drugs to treat them is urgent. Current drug treatments often result in 
adverse side effects and the continual emergence of resistance is extensive.
The main function of nucleic acid DNA is to preserve and store genomic 
information in all living organisms and its integrity must be scrupulously maintained by 
the cell. The ubiquitous enzyme dUTP nucleotidohydrolase (dUTPase) catalyses the 
hydrolysis of dUTP to dUMP and can be considered as the first line of defence against 
incorporation of uracil into DNA. Inhibition of this enzyme results in overincorporation of 
uracil into DNA, leading to DNA fragmentation and cell death and is therefore lethal.
By taking advantage of structural differences between the human and parasitic 
forms of dUTPase, selective inhibitors of the enzyme can be designed and synthesised 
with the aim of being developed into novel anti-parasitic drugs.
Analogue based design was used to target the Plasmodium falciparum 
dUTPase (PfdUTPase). The structures of previously discovered selective inhibitors of 
the PfdUTPase were modified by insertion of an amide bond. A series of tritylated 
uracil acetamide derivatives were synthesised and assessed for inhibition of the 
enzyme and parasite growth in vitro. Unfortunately these compounds were not potent 
inhibitors of the PfdUTPase but do show good in vitro activity.
Following the elucidation of the crystal structure of the PfdUTPase, work was 
focused on the improvement of known selective inhibitors of the enzyme. Structure 
based design methodologies were used to search for interactions within the active site 
and to design potentially more potent analogues in silico. The biological results are 
currently being awaited.
Structure based design was also used to design potential lead inhibitors of the 
Trypanosoma cruzi dUTPase (TcdUTPase), for which no previous selective inhibitors 
were known. A library of uracil amino acid conjugates were synthesised by solid phase 
methodology. Unfortunately, the compounds did not inhibit the enzyme or parasite 
growth in vitro.
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Protozoal Infections
1 Background
This project was concerned with the design and synthesis of anti-protozoal 
agents for the treatm ent of neglected tropical diseases. In particular, these compounds 
were targeted toward the inhibition of the essential enzym e dUTP nucleotidohydrolase. 
This is as of yet an un-investigated drug target.
1.1 Protozoal infections
Parasites which are transm itted by some means through a vector host to a 
human host are the causative organisms of many serious and debilitating parasitic 
diseases. Most o f these diseases predominantly affect people living in tropical and sub­
tropical regions and constitute a great burden on the developing world.
Disease Infective organism Transmission
vector
DALYs* Deaths per 
annum
African
trypanosomiasis
Trypanosoma brucei T setse fly 1,525,000 48,000
Dengue Flaviviridae viruses Some mosquitoes 616,000 19,000
Leishmaniasis Leishmania donovani Phlebotomine
sandflies
2,090,000 51,000
Malaria Plasmodium spp. Anopheles
mosquito
46,486,000 1,272,000
Schistosomiasis Schistosoma mansom Freshwater snails 1,702,000 15,000
Tuberculosis Mycobacterium
tuberculosis
Airborne 34,736,000 1,566,000
Chagas disease Trypanosoma cruzi Triatomine bugs 667,000 14,000
Leprosy Mycobacterium leprae Human-to-human 199,000 6,000
Lymphatic
filariasis
Wuchereria bancrofti, 
Brugia timori, Brugia 
malayi
Some mosquitoes 5,777,000 0
Onchocerciasis Onchocerca volvulus Blackflies 484,000 0
Table 1-1: WHO Tropical Disease Research (TDR) list of target diseases. *DALYs - Disability 
Adjusted Life Years (the number of healthy years of life lost due to premature death and 
disability)1 Parasitic protozoal diseases highlighted in grey
Due to the lack of econom ic incentive, com panies are generally unwilling to 
invest in combating these diseases. Many of the current drug treatments were 
developed more than 50 years ago and are unsatisfactory due to toxicity, emerging 
resistance and their parenteral mode of adm inistration or expense. Lack of clinical 
efficacy is a major issue with many current drug treatments.
1 World Health Report, 2004. May be accessed at http://www.who.int/tdr/diseases.default.htm
- 1 -
1 Background
The need for new, efficient, cheap and orally bioavailable drugs to treat these 
diseases is therefore urgent. Of interest to this project are the parasitic protozoal 
diseases African trypanosomiasis, Chagas’ disease, leishmaniasis and malaria, 
highlighted in grey in Table 1-1.
1.2 The Trypanosomiases
Genus
Group
Subgenus
Species
Subspecies
Trypanosoma
&
Stercoraria
*
Schizotrypanum
*
T. cruzi
Salivaria
*
Trypanozoon
*
T. brucei
*
T. b gambiense 
T. b. rhodesiense 
(T. b. brucei)
Figure 1-1: Classification of trypanosomes2 
The trypanosomiases are parasitic protozoa that belong to the order 
kinetoplastida. They are divided into two major groups, the Stercoraria and the 
Salivaria. (Figure 1-1)
1.2.1 Human African trypanosomiasis
The two subspecies T. b. gambiense  and T. b. rhodesiense  are responsible for 
African trypanosomiases in humans and belong to the group Salivaria. African sleeping 
sickness is a severe disease and fatal if left untreated. The disease is prevalent in sub- 
Saharan Africa (Figure 1-2) and it is estimated that approximately 60 million people are 
at risk of contraction.3
The disease occurs in two forms. A chronic disease is caused by T. brucei 
gambiense  and occurs in W est and Central Africa. An acute form is caused by T. 
brucei rhodesiense  and occurs in East and Southern Africa. The chronic infection can 
last for years, whilst the acute disease may only last for weeks.4
2 James, D. M.; Gilles, H. M. Human Antiparasitic Drugs: Pharmacology and Usage; Wiley and 
Sons, 1985
3 http://who.int/tdr
4 Barett, M. P.; Burchmore, R. J. S.; Stich, A.; Lazzari, J. O.; Frasch, A. C.; Cazzulo, J. J.; 
Krishna, S. The trypanosomiases. The Lancet 2003, 362, 1469-1480.
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Distribution of Human African Trypanosom iasis
: 1  Epidemic 
n Highly endemic 
I~1 Endemic 
I I Al risk
Figure 1-2: Distribution of African trypanosomiasis5
1.2.1.1 Symptoms
There are two stages to the disease. During the first stage parasites can be 
detected in the blood, lymph and tissue, though are sometimes below detection levels. 
This is the haem olym phatic stage of the disease. Symptoms include general malaise, 
headache and irregular fevers. In the more acute rhodesiense infection, inflammation 
of the heart, congestive heart failure and pulmonary oedema can cause fatalities at this 
early stage.
In the second stage of the disease parasites invade internal organs and the 
CNS. This stage of the disease is characterised by severe headaches, sleeping 
disorders, personality changes, various other neurological disorders and endocrine 
malfunctions. Progressive CNS involvem ent leads to eventual coma and death. This 
stage can last for m onths and years with the gam biense infection but death may occur 
within a few  weeks with the rhodesiense infection.4
1.2.1.2 Transmission of the parasite
T. brucei are known as salivaria because they are transm itted in the saliva of 
the vector, the tsetse fly. The small, infective metacyclic trypom astigotes in the saliva of 
the tsetse fly are transferred to the bloodstream of the mammalian host. The 
trypom astigotes in the bloodstream undergo antigenic variation to evade the host 
immune system. At this stage, they are mostly slender trypom astigotes but change to 
the stumpy forms, which can then enter the CNS as the disease progresses. 
Transm ission from the host to the vector occurs when the bloodstream form s are 
ingested by the tsetse as it takes its blood meal. In this case, the parasites differentiate
5 http://www/who.int/emc/diseases/tryp/trypanogeo.html
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into procyclic trypom astigotes within the gut of the tsetse and subsequently migrate to 
the saliva glands of the vector. After reaching the saliva glands, the procyclic 
trypomastigotes transform into epimastigotes and attach to the epithelia l cell wall where 
they divide before developing into mature, infective, m etacyclic trypom astigotes again 
(Figure 1-3).
LIFE CYCLE
Metacyclic trypomastigotes 
ransform into bloodstream 
trypomastigotes.
Tsetse fly takes
a blood meal
(injects metacyclic
trypom astigotes).
Epimastigotes multiply in 
salivary gland and transform 
into metacyclic trypomastigotes?
Procyclic trypomastigotes 
leave the tsetse fly’s 
midgut and transform  
into epimastigotes.
Bloodstream trypomastigotes 
transform into procyclic 
trypomastigotes In tsetse fly’s midgut.( 6  
Procyclic trypomastigotes multiply
by binary fission.
Tsetse fly takes 
a blood meal
(trypomastigotes 
are Ingested).
4
Trypom astigotes
In blood
Trypomastigotes multiply 
by binary fission in 
various body fluids.
HoN
HoN. ,c o 2h
c h f 2
Figure 1-5: Eflornithine
Figure 1-4: Suramin ^
H2N ^ / N ^ N
As
NH2 S
Figure 1-6: Melarsoprol
HN NH
Figure 1-7: PentamidineNH NH
OH
6 Baliani, A. Design and Synthesis of New Potential Drugs for the Treatment of Human African 
Trypanosomiasis. In Welsh School o f Pharmacy: University of Wales, Cardiff: Cardiff, 2005.
Figure 1-3: Life cycle of Trypanosoma brucei6 
1.2.1.3 Drug treatment
4 drugs are currently registered for the treatment of human African trypanosomiasis.
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Suramin Accumulated in the cell by receptor mediated endocytosis of drug bound
(1920) to low density lipoprotein (LDL) and maybe other carriers. Suggested
(Figure 1-4) mechanisms include: 1) Inhibition of glycolytic enzymes; 2) Inhibition of
polyamine biosynthesis; 3) Promiscuous enzyme inhibitor with many 
targets. Unwanted side effects include nausea, vomiting, shock, 
dermatitis, anaemia, jaundice, and diarrhoea. Suramin must be injected 
intravenously and does not cross the BBB (blood brain barrier). It has a 
long half life due to tight protein binding and also undergoes very little 
^  metabolism. Used for initial phase against T. b. rhodesiense.
§> Pentamidine Actively transported into the cell by the P2 transporter and also by a high(O
55 (1941) affinity and low affinity purine transporter (HAPT1 andLAPH). It has been
(Figure 1-7) shown that the drug binds to negatively charged cellular components such
as phospholipids and nucleic acids and that it disrupts the structure of 
kinetoplast DNA. It also inhibits S-adenosylmethionine decarboxylase 
(AdoMetDC) in vitro, which is involved in polyamine biosynthesis. It may 
cause damage to liver and kidneys and also to the pancreas which may 
cause diabetes. It has poor bioavailability, must be injected 
intramuscularly and does not penetrate the BBB. Pentamidine is used 
against T. b. gambiense but is not as effective against T. b. rhodesiense.
A prodrug of melarson oxide, which is taken up by the P2 transporter into 
the parasitic cell. It has been shown that a stable adduct with 
trypanothione (MelT), which is a competitive inhibitor of trypanothione 
reductase, is formed. It may be that this compound therefore interferes 
with polyamine metabolism but trivalent arsenicals are promiscuous 
inhibitors. Melarsoprol causes serious reactive encephalopathy in 5-10% 
of patients. Vomiting, abdominal colic, peripheral neuropathy, joint pain 
and blood clotting are other unwanted side effects. Melarsoprol is 
administered intravenously in a 3.6% w/v solution of propylene glycol. It is
used against late stage T. b. rhodesiense and T. b. gambiense infections.
Eflornithine Eflomithine is an irreversible inhibitor of ornithine decarboxylase, an
(1977) essential enzyme in the biosynthesis of polyamines. Selectivity is
(Figure 1-5) probably due to the limited ability of parasites to uptake trace amount of
polyamines in response to starvation or differences in turnover rates of
human and parasitic ODC. Side effects include anaemia and diarrhoea.
Eflornithine however, is costly as it requires infusions of 400mg kg"1 4 
times day'1 for 14 days. T. b. rhodesiense also show poor response.
Table 1-2: Drugs used to treat African trypanosomiasis7,8
7 Fairlamb, A. H. Chemotherapy of human African trypanosomiasis: current and future 
prospects. Trends Parasitol. 2003, 19, 488-494.
Melarsoprol 
(1949) 
(Figure 1-6)
CM
OO)
*■>
C/5
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1.2.2 Chagas’ disease
The causative agent for South American trypanosom iases or Chagas’ disease 
is Trypanosoma cruzi which belongs to the Stercoraria group of trypanosomes. It is 
estimated that approximately 120 million people, i.e. 25% of the inhabitants of Latin 
America (Figure 1-8) are at risk of contracting the disease.3 In the past decade, 
transmission control programmes utilising insecticides to kill the transm ission vector 
have been successful in several endemic countries in substantially reducing the 
incidence of Chagas’ disease in Latin America but not eradicating it. Current drug 
treatm ent is unsatisfactory and there is, at present no effective treatm ent for the 
chronic stage of the disease.
Distribution of Chagas’ Disease
i A
|  Chagas Endemic Countries
WHQ/CTD, May 1996
Figure 1-8: Distribution of Chagas’ disease9
1.2.2.1 Symptoms
The acute stage of the disease manifests itself 6-10 days after infection and can 
last 1-2 months. Frequently, inflammation at the site of infection leads to oedematous 
swelling known as chagoma. Romana’s sign is a swelling of the eyelids that occurs 
after infection at this site and is often used to detect the disease at early stage. The 
acute phase can pass unnoticed with symptoms typical of general malaise. However, 
death can ensue at this stage due to inflammation of the heart or brain. Other 
symptom s include fever, rash, oedema, increased heart rate and autoimmune 
responses. During this stage parasites are easily detected in the blood and this phase 
of the disease ends when the host immune system greatly reduces the number of 
circulating trypomastigotes to an undetectable level.
A fter the acute phase patients become asymptomatic, this phase is known as 
the indeterminate form of Chagas’ disease. Approximately 70% -85%  of people remain
8 Fries, D. S.; Fairlamb, A. H. Burger's Medicinal Chemistry and Drug Discovery, Wiley and 
sons, 2003.
9 http://www.who.int/ctd/chagas/geo.htm.
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in this state for the rest of their lives. However, 10% -15% of patients reach the chronic 
stage of the disease 10-25 years after initial infection when they start to show 
sym ptom s of serious organ damage such as digestive and nervous complications, 
chest pain, palpitations, dizziness and peripheral oedema. Arrhythm ia and 
throm boem bolism  are frequent and death normally ensues due to heart failure. 
Congenital infection accounts for stillbirths and early postnatal death.2 4
1.2.2.2 Transmission of the parasite
Cutaneous (Chagoma) or 
ocular (Romanas sign)
Amastigotes 
(dividing stage) 
intracellular in 
tissues
Infection by 
triatomine faeces
Trypomastigote 
(nondividing) 
in blood
Trypomastigotes 
in blood, taken up 
by blood sucking 
triatomine vector
Metayclic 
trypomastigote 
in faeces of 
vector
Figure 1-9: Life cycle of T. cruz/'10 
T. cruzi are transm itted by arthropods belonging to the subfamily Triatomoniae 
in the fam ily Reduviidae through the faeces of the vector as they bite the human host.
Trypanosom es taken up by the vector, change into epimastigotes before 
multiplying and transform ing into contaminating metacyclic trypomastigotes. In the 
human host circulating trypom astigotes enter the tissues where they change into the 
amastigote form. These divide and some enter other tissues or are released into the 
blood as circulating trypom astigotes where they may again be taken up by the vector or 
infect other tissues (Figure 1-9).2,4
1.2.2.3 Drug treatment
Only two drugs are currently in use for the treatm ent of Chagas’ disease. They
are nifurtimox and benznidazole. Both drugs occasionally induce serious side effects 
and neither has high efficacy against chronic C hagas’ disease. The trypom astigotes 
are cleared form the blood but treatm ent has to be adm inistered over a long period of
10 http://www.uta.edu/chagas/html/biolTcru.html.
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time to ensure that trypom astigotes released from the tissues are elim inated. Neither 
drug is sufficiently well tolerated for the long administration needed for a complete cure. 
Other drugs such as diuretics, ACE inhibitors, (3-blockers and antiarrythm ics are used 
to treat symptomatic complications of the disease.2,4' 8
Drug
f f ^ l  H ,N°2
o W  
Benznidazole (1979)
o2^ nA
r*** n 
0
Nifurtimox (1964)
Mode of 
action
Acts via reductive stress that involves 
covalent modification of macromolecules 
by nitroreduction intermediates. It does 
not induce production of superoxide 
radical anions as does nifurtimox.
Acts via oxidative stress. The nitro 
group is reduced to give nitroanion 
radicals which in turn lead to the 
production of highly toxic reduced 
oxygen metabolites including 
superoxide radical anion.
Side
effects
Fewer than those of nifurtimox. Nausea, vomiting, abdominal pain, 
restlessness, insomnia, seizures, 
dermatitis, fever, anaphylaxis.
Notes Drug of choice against Chagas’ disease. 
Given orally at a dose of 5-7mg kg'1 day"1 
in 2 divided doses for 30-90 days
Given orally at a dose of 8-1 Omg kg'1 
day'1 in 4 divided doses for 90-120 
days.
Table 1-3: Drugs used to treat American trypanosomiasis4,8,11,12
1.3 The Leishmaniases
Leishmania  are parasitic protozoa that belong to the same order as the 
trypanosomiases, that is the kinetoplastida. Together they comprise the fam ily 
Trypanosomastidae which are often simply called the haemoflagellates. More than 20 
different species and subspecies of Leishmania  are known to be pathogenic to man.2
1.3.1 Leishmaniasis
Leishmaniasis is endem ic in 88 countries on four continents. It is estimated that 
350 million people are at risk and overall prevalence is 12 million people. Annual 
incidence is estimated at 1-1.5million cases of cutaneous le ishm aniasis and 500,000 
cases of visceral leishmaniasis. There are three main forms of the disease, depending 
on the infective parasite.3,13
11 Urbina, J. A. Parasitological cure of Chagas disease: Is it possible? Is it relevant? Mem. Inst. 
Oswaldo Cruz 1999, 94, 349-355.
12 Maya, J. D.; Bollo, S.; Nunez-Vergara, L. J.; Squella, J. A.; Repetto, Y.; Morello, A.; Perie, J.; 
Chauviere, G. Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran 
derivatives. Biochem. Pharmacol. 2003, 65, 999-1006.
13 Herwaldt, B. L. Leishmaniasis. Lancet 1999, 354, 1191-1199.
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i) Visceral leishmaniasis (VL):
(L  donovani, L. infantum, L. 
Chagasi) (Fig. 1-10) This is caused 
by infection of the lymphatics after 
the parasites have multiplied in the 
macrophages. VL is characterised 
by irregular bouts of, swelling of the 
spleen and liver and anaemia. It is 
the most serious form of the disease 
and if left untreated has a fatality 
rate of nearly 100%. Post-kala-azar 
dermal le ishm aniasis (PKDL) is a 
form of dermal leishmaniasis that 
occurs as an outcome of visceral 
leishmaniasis when therapy for VL 
has been unsuccessful.2,3
ii) Cutaneous (CL):
(L. major, L. tropica, L. aethiopica, L. 
mexicana, L. amazonensis, L. 
pifanoi, L.guyanensis, L. 
panamensis, L. peruviana) (Fig 1-11,
1-12) This is the most common form 
of the disease. 1-200 simple skin 
lesions form. These are self healing 
but can leave unsightly and 
debilitating scars. Diffuse cutaneous 
leish-maniasis (DCL) causes dis­
seminated skin lesions resembling lep- 
rotamous leprosy. Treatm ent is d ifficult.2,3
iii) Mucocutaneous: (MC)
(L. braziliensis) This starts with skin ulcers 
which spread causing massive tissue 
destruction especially o f the nose and 
mouth (Fig. 1-13). This form of the 
disease occurs only in South America. It 
can often have fatal consequences.2,3
Distribution of Visceral leishmaniasis
v i a m  iM O M M M ia c  
□
Figure 1-10: Visceral leishmaniasis and it global 
distribution3
Distribution of cutaneous leishmaniasis
O r
Figure 1-11: Global distribution of cutaneous 
leishmaniasis3
t m
Figure 1-12:
Cutaneous leishmaniasis
Figure 1-13:
Mucocutaneous
leishmaniasis
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1.3.2 Transmission of the parasite
Samlfly stages
Divide in midgut and 
migiate to proboscis
Amastigotes transform  
into promastigote stage 
in midgut
Ingestion of 
parasitized cell
Sandfly takes a blood 
meal and injects 
promastigotes into 
the skin
Human stages
/
Promastigotes are 
phagocytized by 
maci ophages
Promastigotes transform  
into amastigotes inside 
macrophages
/zI
Amastigotes multiply in cells 
(including macrophages) of 
various tissues
Sandfly takes a blood meal 
and ingests infected 
macrophages
Figure 1-14: Life cycle of leishmaniau  
The fem ale sandfly is the vector that transm its these parasites. As the vector 
feeds on the blood of a human, promastigote forms of the parasite enter the host via 
the insect’s proboscis. These are ingested by macrophages in the host, where they 
metamorphosise into the amastigote form. The parasites then multiply by binary fission 
until the host cell bursts. The amastigotes then infect more macrophages where they 
multiply or are taken up again by feeding vectors (Fig. 1-14). In visceral leishmaniasis 
the parasites cause a widespread infection of the lymphatics. In cutaneous 
leishmaniasis, the lesions remain localised to the skin and skin ulcers develop.3
Figure 1-15: Amphotericin B
1.3.3 Drug treatment
Currently 5 drugs are registered for the treatment of Leishmaniasis. (See Figure
1-7 for penatmidine)
Figure 1-17: Meglumine antimonate Figure 1-18: Sodium stibogluconate
Figure 1-16: Miltefosine
14 Hailu, A.; Mudawi Musa, A.; Royce, C.; Wasunna, M. Visceral Leishmaniasis: New Health 
Tools Are Needed. PLoS Medicine 2005, 2, e211.
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Used 
to treat
Mode
of
action
Side
effects
Notes
Pentamidine 
(Figure 1-7)
VL, CL, ML 
See table 2.
See table 2.
Considered a 
back up
therapy for
pentavalent 
antimonials 
and
amphotericin 
B lipid
complex.
Miltefosine 
(Figure 1-16)
VL (so far only licensed in India)
Thought to perturb ether-lipid 
remodelling in Leishmania by 
inhibiting key enzymes involved in 
ether-lipid metabolism including 
acycl-coA acyl transferases.
Gastrointestinal distress. Elevated 
aspartate aminotransferase and 
creatine levels.
Was developed as an anti-cancer 
agent. It is a bioisostere for 
phosphatidyl-choline where the ester 
moiety has been changed for an 
ether. Resistance may become a 
problem. The drug is teratogenic. 
Given orally at a dose of 100-150mg
day' for 28 days.
Table 1-4: Drugs
Meglumine antimonite and 
sodium stiboglconate (Figure 1- 
17,1-18)
VL, CL, ML
Prodrugs requiring reduction from 
Sb5+ to Sb3+ which occurs in 
amastigotes. They are found to 
inhibit trypanothione reductase and 
probably inhibit other sulfhydryl 
containing enzymes.
Fatigue, body aches, electrocardio­
graphic abnormalities, raised amin­
otransferase levels, pancreatitis 
Are first line treatments for all types 
of Leishmaniasis, however, long 
duration of therapy is required and 
they are not always effective. 
Resistance is an issue. They are 
administered as polymeric mix­
tures. Both given at 20mg Sb kg 1 
day1 intramuscularly or intraven­
ously for 20-28 days, 
used to treat leishmaniasis213,14
Amphotericin B 
(Figure 1-15)
VL, ML (deoxycholate complex, Fungizone ®) 
VL (lipid formulations)
Complexes with ergosterol in cell membrane 
of leishmania leading to pore formation, ion 
leakage and cell death.
Nephrotoxicity, fever, chills, muscle spasms, 
vomiting, headache, hypotension, 
anaphylaxis.
Lipid complex allows for increased dosing 
without extra side effects. Effective against 
antimonial resistant strains. Disadvantages 
include high cost, need for hospitalisation and 
long treatment periods. Lipid complex given 
at a dose of 3mg kg'1 day'1 for days 1-5, 14, 
21. Deoxycholate given at dose of 0.5-1.0mg 
kg'1 day'1 for 8 weeks.
3
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1.4 Plasmodium
The genus Plasmodium  are parasitic protozoa that belong to the class 
Sporozoea.
Four species of the parasite are responsible for malaria in man.
Parasite species 
(clinical disease form)
Distribution Percentage 
of total 
cases
Survival time 
of host if left 
untreated
P. falciparum  
(falciparum malaria)
Tropical and subtropical, Africa, 
Nepal and southeast Asia
50 1 -4 years
P.vivax
(vivax malaria)
Tropical, subtropical, temperate, 
South America, Asia
42 2-8 years
P. malariae 
(quartan malaria)
Tropical and subtropical, Africa, 
Nepal, Southeast Asia
7 4-53 years
P. ovale 
(ovale malaria)
Tropical Africa and Western 
Pacific
1 1-5 years
Table 1-5: Species of plasmodium parasitic to man2
1.4.1 Malaria
Malaria is a health problem in more that 90 countries, placing about 40% of the 
world’s population at risk of contracting the disease (Fig. 1-19). It is endemic to tropical 
and subtropical regions. The economic burden of this disease is also extremely high, 
accounting for an estimated reduction of 1.3% in economic growth in malaria endemic 
countries.3 90% of deaths due to malaria occur in Africa south of the Sahara, mostly 
among young children.
Figure 1-19: Worldwide distribution of malaria15 
15 http://www.rollbackmalaria.Org/cmc_upload/0/000/015/372/RBMInfosheet_1.htm
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Plasmodium falciparum  is the main cause of severe clinical malaria and death 
and is also the most common form of the disease complex. For this reason it is often 
called malignant tertian malaria. The other form s caused by P. vivax, P. malariae, and 
P. ovale  are often termed benign malarias as they are less severe.2
Sym ptom s of malaria include fever, headache, muscular aches and weakness, 
vomiting, diarrhea and cough. Cycles o f fever, chill and drenching sweats develop. 
Death may ensue due to infected red blood cells blocking blood vessels supplying the 
brain (cerebral malaria) or damage to other vital organs.3
The diseases cause periodic fevers, the periodicities of which differ among the 
infective species and may be indistinguishable in falciparum malaria. They are 
coincidental w ith the rupture o f mature blood schizonts and the release of merozoites 
into the circulation. The severities o f the symptoms are also clinically distinguishing 
features among the different disease forms. The four species are morphologically 
d istinguishable at all stages of erythrocytic developm ent.2 Relapses with vivax and 
ovale malaria can occur due to persistence of the latent liver forms and is more 
common with vivax malaria. Recrudesces due to persistent residual erythrocytic forms 
can occur with all four species, however they are more common in quartan malaria.2,3
Figure 1-20: Female anopheles vector3 Figure 1-21: A child with malaria3
1.4.2 Transmission of the parasite
Malaria is transm itted through the fem ale Anopheles mosquito vector (Fig 1-20). 
As the vector feeds on the blood of a human, parasite sporozoites enter the host’s 
blood. They are carried to the liver where they enter hepatocytes and undergo exo- 
erythrocytic schizogony. The hepatocytes eventually rupture and merozoites are 
released into the bloodstream. These then invade red blood cells where they transform 
into trophozoites and undergo asexual schizogony again. The schizonts eventually 
rupture releasing more m erozoites into the blood and inducing an attack of fever in the 
host. Some trophozoites differentiate into gam etocytes and are taken up by the vector 
within which they form a zygote and initiate sporogony (Figure 1-22).16
16 Menard, R. Medicine: Knockout malaria vaccine? Nature 2005. 433, 113-114.
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Figure 1-22: Life cycle of plasmodium16
1.4.3 Drug treatment
Antim alarials can be divided into four arbitrary groups based on close 
sim ilarities in their antimalarial activity.2
The first group are the rapidly acting blood schizontocides. The oldest of this 
group is quinine; it was one of the first antimalarials ever used and was found as the 
active component from the bark of the cinchona tree. From quinine, the other 4- 
aminoquinolines and 4-quinolinemethanols were developed. Chloroquine is one of the 
most potent and widely used of this class of drugs but resistance to it has developed. 
Am odiaquine is active against chloroquine resistant strains but some adverse reactions 
to it have been observed due to in vivo activation to a reactive metabolite. Isoquine, 
which is a regioisom er of amodiaquine that does not form toxic metabolites is currently 
undergoing preclinical evaluation.17 Mefloquine and lumefantrine are other commonly 
used drugs in this category. The site of action of this class of drugs is limited to the 
stages of the parasite life cycle which are actively involved in haemoglobin 
degradation. These drugs accumulate in the food vacuole of the trophozoite in the 
human red blood cell. The postulated mode of action is that as the parasite degrades 
human haemoglobin into the potentially toxic ferriprotoporphyrin IX (FePPIX, free 
haem) and the essential globin, the drugs bind to FePPIX, preventing it from being 
crystallised into the non toxic haemazoin form by the parasite (Figure 1-23).18' 19
17 O'Neill, P.; Mukhtar, A.; Stocks, P. A.; Randle, L. E.; Hindley, S.; Ward, S. A.; Storr, R. C.; 
Bickley, J. F.; O'Neill, I. A.; Maggs, J. L.; Hughes, R. H.; Winstanley, P. A.; Bray, P. G.; Park, K.
B. Isoquine and Related Amodiaquine Analogues: A New Generation of Improved 4- 
Aminoquinoline Antimalarials. J. Med. Chem. 2003, 46, 4933-4945.
18 Pandey, A. V.; Bisht, H.; Babbarwal, V. K.; Srivastava, J.; Pandey, K. C.; Chauhan, V. S.
Mechanism of malarial haem detoxifiction inhibition by chloroquine. Biochem. J. 2001, 355, 333- 
338.
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Figure 1-23: Mechanism of action of 4-aminoquinolines and 4-quinolinemethanols
Chloroquine resistance was originally thought to be due to an efflux 
mechanism20, however, it is now thought that chloroquine resistance is related to 
diminished uptake of the drug.21
Also belonging to the group of blood schizontocides are the sesquiterpene 
lactones. They emerged from artemisinin (qinghaosu), which was used in China for 
multidrug resistant P. falciparum. The parasites in the erythrocytic cells take up 
haemoglobin into their food vacuoles to use it as a source of food. The haemoglobin is 
broken down into FePPIX (free heme) and globin. The free heme bioactivates the 
endoperoxide bridge of artemesnin to a cytotoxic radical species. It has been proposed 
that following lipid peroxidation, a variety of reactive oxygen species such as hydroxyl 
radicals and superoxide radicals are generated. These reactive species cause 
oxidative damage to cellular proteins resulting in parasite death (Figure 1-24).22
Radical species Parasite death
Figure 1-24: Mechanism of action of artemisinin
19 Sullivan, D. J.; Matile, H., Jr.; Ridley, R. G.; Goldberg, D. E. A Common Mechanism for 
Blockade of Haem Polymerization by Antimalarial Quinolines. J. Biol. Chem. 1998, 273, 31103- 
S1107.
20 Krogstad, D. J.; Gluzman, I. Y.; Kyle, D. E.; Oduola, A. M. J.; Martin, S. K.; Milhous, W. K.; 
Schlesinger, P. H. Efflux of Chloroquine from Plasmodium-Falciparum - Mechanism of 
Chloroquine Resistance. Science 1987. 238, 1283-1285.
21 Bray, P. G.; Mungthin, M.; Ridley, R. G.; Ward, S. A. Access to hematin: The basis of 
chloroquine resistance. Mol. Pharmacol. 1998, 54, 170-179.
22 O'Neill, P. M.; Posner, G. H. A Medicinal Chemistry Perspective on Artemesinin and Related 
Endoperoxides. J. Med. Chem. 2004. 47, 2945-2964.
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Although the exact mechanism by which these compounds produce radical 
species in the cell is debatable, it is known that the endoperoxide bridge is essential for 
activity. There are a num ber of synthetic and sem i-synthetic endoperoxide analogues 
(F igure 1-25) under developm ent w ith the  aim o f increasing w ater solubility, resistance 
to first pass m etabolism  and ease o f synthesis o f these com pounds. They are 
chem ically stable and active against the parasite in the low nM range.
0-0
1,2,4-Tioxolanes 
R
p V
o - o
/
R
O'
Tetraoxanes
O
1,2,4-Trioxanes
F
CF
S 0 2Ph
Figure 1-25: Some semi-synthetic and synthetic endoperoxide analogues under development22
Artem isin in com bination therapy (ACT) is a strategy in use fo r the  control of 
em erging resistance to antim alaria ls. It involves the com bination o f artem isin in with 
another antim alarial agent to  treat the disease. It exploits the fact tha t the artem isin in 
derivatives cause a rapid reduction in parasite  biomass, leaving few er parasites to  be 
eradicated by the second drug, therefore decreasing the  chance o f resistance 
em erging. This strategy is recom m ended by WHO fo r control o f m alaria in A frica .22
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Plasmodium
The second group of antimalarials are the antifolates which can be divided into 
two subclasses; The antifolate type 1 inhibitors which include sulphonamides and 
sulphones and the antifolate type 2 drugs consisting of the biguanidines and 2,4- 
diaminopyridines. Malaria parasites cannot transport folate, they must synthesise it de 
novo. These drugs act in the folate pathway (Figure 1-26).2 Resistance to 
pyrimethamine and proguanil has occurred through point mutations of the PfDHFR  
gene, the principal mutation being the S108N substitution which reduces the drug’s 
affinity without affecting the enzym e’s operation.23
The basis of selectivity o f the type 1 inhibitors is that this pathway is not present 
in mammalian cells. The DHFR enzyme, is present in mammalian cells; However, the 
structure of the human enzyme is very different to that of the plasmodial DHFR and it 
has a much lower affinity for the drug, therefore selective inhibition is viable.24
Pteridine + PABA
Dihydropteroate
synthase
Type 1 inhibitors: 
Sulphonamides, sulphones
Dihydropteroate
Pathway NOT 
present in humans Di hydrofolate synthase
Pathway present 
in humans and 
oarasites Dihydrofolate
reductase
Dithydrofolate
Type 2 inhibitors: 
Pyrimethamine 
and proguanil
Tetrahydrofolate
Thymidilate synthase
Figure 1-26: Targets of antifolate antimalarials 2 5
23 Kongsaeree, P.; Khongsuk, P.; Leartsakulpanich, U.; Chitnumsub, P.; Tarnchompoo, B.; 
Walkinshaw, M. D.; Yuthavong, Y. Crystal structure of dihydrofolate reductase from Plasmodium 
vivax: Pyrimethamine displacement linked with mutation-induced resistance. Proc. Natl. Acad. 
Sci. U. S. A. 2005. 102, 13046-13051.
24 Yuvaniyama, J.; Chitnumsub, P.; Kamchonwongpaisan, S.; Vanichtanankul, J.; Sirawaraporn, 
W.; Taylor, P.; Walkinshaw, M. D.; Yuthavong, Y. Insights into antifolate resistance from 
malarial DHFR-TS structures. Nat. Struct. Biol. 2003, 10, 357-365.
25 Le Bras, J.; Durand, R. The mechanisms of resistance to antimalarial drugs in Plasmodium 
falciparum. Fundam. Clin. Pharmacol. 2003, 17, 147-153.
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The third group of antimalarials are the tissue schizontocides. Currently 
primaquine is the only drug belonging to this group. It is the only drug effective in 
clearing persistent liver forms of the parasite responsible for relapses in P. vivax and P. 
ovale. Its exact mechanism of action is unknown but it is thought to be an oxidative- 
reductive agent similar to the 4-aminoquinolines.26
The last group of antimalarials is comprised of other drugs that do not belong to 
any one of the above groups in particular. Doxycycline, a tetracycline molecule belongs 
to this group. It can be used in areas of high chloroquine and mefloquine resistance. It 
acts by binding to the ribosome 30S subunit and therefore inhibiting protein synthesis.26
Some more recently developed antimalarials also do not belong to the three 
classical groups described above. One such compound is atovaquone which is a 
hydroxynaphthoquinone. It is a weak inhibitor of dihydroorotate dehydrogenase, an 
enzyme in the de novo pyrimidine biosynthetic pathway in P. falciparum and it also acts 
on the mitochondrial electron transport pathway by mimicking ubiquinone. Its effect on 
the mitochondrial membrane potential is enhanced by proguanil.29
26 Casteel, D. A. Burger's Medicinal Chemistry and Drug Discovery; Sixth ed.; Wiley and sons, 
2003.
27 Britain, B. M. A. a. R. P. S. o. G. British National Formulary, 2003.
28 Edwards, G.; Biagini, G. A. Resisting resistance: dealing with the irrepressible problem of 
malaria. Br. J. Clin. Pharmacol. 2006, 61, 690-693.
29 Srivastava, I. K.; Vaidya, A. B. A mechanism for the synergistic antimalarial action of 
atovaquone and proguanil. Antimicrob. Agents Chemother. 1999, 43, 1334-1339.
30 Lang, T.; Greenwood, B. The development of Lapdap, an affordable new treatment for 
malaria. Lancet Infectious Diseases 2003, 3, 162-168.
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Drug Mechanism of action Side effect Notes Refs.
Artemether + lumefantrine (Riamet®)
“ C Q  rvOoT
Artemether acts by forming 
radical species that damage 
cellular components and 
lumefantrine is a relative of 
mefloquine which acts by 
preventing polymerisation of 
free haem.
Abdominal pain, anorexia, 
diarrhoea, vomiting, nausea, 
palpitations, cough, headache, 
dizziness, sleep disturbances, 
rash
Used for treatment of acute 
uncomplicated falciparum malaria. 
Cost is an issue. Given as an oral 
tablet.31
22, 26
;o
o Chloroquine Prevents polymerisation of Gl disturbances, headache, Widespread resistance has
2, 17,
o+■>
c r ^ N ^ toxic free haem to non-toxic convulsions, visual occurred. Only used for prophylaxis
26, 27
o
N
JS T  ^
haemazoin disturbances, depigmentation, of malaria in areas where
o(0 loss of hair, skin reactions, very resistance is low. Also used for
"Ooo toxic in overdosage benign malarias. Sulphate or
DO phosphate salts as oral tablets.
Mefloquine Prevents polymerisation of Nausea, vomiting, diarrhoea, Used for prophylaxis of malaria in 2,26,
toxic free haem to non-toxic abdominal pain, loss of areas where high chloroquine 27
n c y l j hemazoin balance, dizziness, headache, resistance is known. Used for
H
f Y i sleep disorders, visual falciparum treatment, also if
y ^ n cf3 disturbances, neuropsychiatric infection is not known or is mixed.
c f 3 disorders, chest pain, muscle Not used for treatment if has been
weakness, rash, fatigue, fever used for prophylaxis. Oral tablets.
Table 1-6a: Currently used antimalarials
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Drug Mechanism of action Side effects Notes Refs.
Quinine
HO^
H3C 0 - / ^ /
5 b
I
Prevents polymerization 
of toxic free heme to non­
toxic hemazoin.
Cinchonism, headache, hot and 
flushed skin, nausea, abdominal 
pain, rashes, visual disturbances, 
confusion, renal failure, 
hypoglycaemia, cardiovascular 
effects, very toxic in overdosage
Used for falciparum treatment or if 
infective agent is not known or is 
mixed. Not suitable for prophylaxis. 
Oral tablets of hydrochloride or 
sulphate salts.
2, 26, 
27
Primaquine
H a C C L /
h 2n - ^ y
f V
NH
Acts on mitochondria of 
parasite cell causing 
them to swell and 
inhibiting their activity. 
Proposed mechanism 
involves oxidation to a 
quinine-imine derivative 
which may mimic 
ubiquinone.
Nausea, vomiting, anorexia, 
abdominal pain, less common 
methaemoglobinaemia in G6PD 
deficient patients
Used to eliminate liver stages of P. 
vivax or P. ovale following 
chloroquine treatment. Given at a 
dose of 15mg daily for 14 to 21 
days.
2,27
Proguanil
HN
/ = \
C\~\ y~ NH )= N H
1'  / Y NH
Was thought that 
proguanil was a prodrug 
of cycloguanil which acts 
exclusively on P. 
falciparum DHFR. 
However proguanil may 
have other targets.
Mild gastric intolerance, diarrhoea, 
mouth ulcers, skin reactions.
Hydrochloride salt taken orally is 
used for prohylaxis of malaria but 
not suitable alone for treatment. 
Used in combination with 
atovoquone (Malorone) for 
treatment of acute uncomplicated 
malaria.
2, 26, 
27
Table 6b: Currently used antimalarials
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Plasmodium
Drug Mechanism of action Side effects Notes Refs.
Pyrimethamine + sulfadoxine Structurally similar to Depression of blood cell formation Used as treatment for falciparum 2, 25,
(Fansidar®) proguanil, pyrimethamine and proliferation with high doses, malaria. Oral tablets of 25mg 26, 27
NH2
acts as a DHFR inhibitor. rash, insomnia pyrimethamine and 500mg
V)0)
4->CO
I
v .  L  1  0 N^N  
^ ^ N ^ N H 2 ^  U JL II
Sulfadoxine is an 
inhibitor of dihydropterate 
synthase by competing 
with the natural substrate
sulfadoxine. Not recommended for 
prophylaxis.
PABA.
c Proguanil + atovaquone (Malarone®) Proguanil, in this case is Nausea, vomiting, mouth ulcers, Used for treatment of acute 25, 26,
HN
known to enhance the diarrhoea, anorexia, fever, uncomplicated falciparum malaria. 27,29
/ = \
C I- ( \  /)—NH )= N H
A  r ^ V cl
effect of atovaquone on 
mitochondrial membrane
headache, dizziness, 
insomnia.
rash, Also for prophylaxis in areas of high 
mefloquine or chloroquine
o potential. Atovaquone resistance. 4 tablets (100mg PG
acts as described above. and 250mg atov.) given 4 times
^ Y ^ O H
0
daily for 3 days.
Table 6c: Currently used antimalarials
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Drug Mechanism of action Side effects Notes Refs.
Clorproguanil + dapsone 
(Lapdap®)
Y
hn^ hn- Y Y CI
h n ^ n ^ n h ^ Y i
H
h2n —/ ~ ^ V - s — NH2 \ = /  ^ \—
Chlorproguanil inhibits 
DHFR while dapsone is 
an inhibitor of 
dihydropteroate 
synthetase.
Still under post-marketing 
surveillance but most commonly 
noted side effect has been 
anaemia.
Used to treat uncomplicated P. 
falciparum malaria. Given as oral 
tablets twice daily for 3 days.
2, 25, 
26, 28, 
30
Doxycycline
o h  o o
'Nh2 
0H
1 O H /N ^
Acts by inhibiting protein 
synthesis by binding to 
the 30S ribosome unit.
Nausea, vomiting, diarrhoea, 
oesophageal irritation, 
hepatotoxicity, photosensitivity and 
hypersensitivity, headache, visual 
disturbances.
Used for prophylaxis in areas of 
high CQ or MQ resistance. Also 
used as adjunct to quinine in 
falciparum treatment. Oral hyclate 
capsules.
6, 27
Table 6d: Currently used antimalarials
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Function o f the enzyme
2 The dUTPase enzyme
2.1 Function of the enzyme
Deoxyuridine triphosphate nucleotidohydrolase, also called dUTP 
pyrophosphatase or dUTPase is an enzyme which catalyses the hydrolysis of dUTP to 
dUMP in the presence of magnesium ions (Figure 2-1).31,32
NH NH
O - P - O - P - O - P - O - 0 - P - 0.2+
-O -P -O -P -O -  + nH
OH OH
Figure 2-1: dUTPase catalysed hydrolysis of dUTP
The dUTPase catalysed reaction is part of the elaborate network of reactions 
that control nucleotide metabolism (Figure 2-2).
DNA polymerase
dCTP
NDP
kinase
NTP
reductase
CTP
dCTP deaminase  
«-
dUTP
NDP
kinase I f
C TP
synthase'
UTP NTPreductase
NDP
kinase It
NDP
kinase
dCDP P H D h i  i n p
NDP NDP
auur
dCM P
kinase
reductase
i t CM Pkinase
UMP
kinase It
reductase
CMP
dUM P
kinase
dTTP
dCMP dUMP < -
rtPMD Hoaminaco V J dTMP
NDP
kinase
t i
r
dTDP
dTM P
kinase
j i
r
dTMP
synthase
Figure 2-2: De novo synthesis of pyrimidines33
31Bertani, E. L.; Haggmark, A.; Reichard, P. Synthesis of Pyrimidine Deoxyribonucleoside 
Diphosphates with enzymes from Escherichia coli. J. Mol. Biol. 1961, 236, 67-68.
32Greenberg, G. R.; Somerville, R. L. Deoxyuridylate Kinase Activity and 
Deoxyuridinetriphosphatease in Eschericia Coli. Proc. Natl. Acad. Sci. U.S.A. 1962, 48, 242- 
247.
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The enzyme has two major roles in maintaining the correct free nucleotide 
balance in the cell.33,34
1. It provides dUMP, a major cellular source for dTMP which is in turn needed for 
dTTP formation.
2. It maintains the concentration of dUTP 10'5 times lower than that of dTTP thereby 
minimising mistaken incorporation of dUTP into DNA.
The catalytic reaction is Mg2+ dependent35 36 37 and it has been shown that this is due 
to the fact that divalent metal ions bind to the triphosphate moiety of the substrate, 
holding it in the correct orientation and making it more susceptible to nucleophilic attack 
by an appropriately positioned nucleophile through product stabilisation.38 39 40 41
2.2 dUTPase, cell proliferation and thymineless death
Uracil is not normally a constituent of DNA, however its misincorporation does 
occur occasionally due to either i) deamination of cytosine or ii) DNA polymerases 
using dUTP as a substrate in mistake for dTTP. When uracil incorporation occurs, the 
base excision repair (BER) process is initiated. The enzyme uracil-DNA glycosylase 
(UNG) catalyses the initial step. UNG specifically removes uracil residues from DNA by 
cleaving the N-glycosyl bond, releasing uracil and creating an apyrimidinic (AP) site.42
33 Nyman, P. O. dUTPases: Essential Factors in Preventive DNA Care - Introduction. Curr. 
Protein Pept. Sci. 2001, 2, 277-285.
34 Studebaker, A. W.; Ariza, M. E.; Balendiran, G. K.; Williams, M. V. Novel Approaches for 
Modulating dUTPase and Uracil-DNA Glycoylases: Potential Uses for Cancer and Viral 
Chemotherapy. Drug Design Reviews 2004, 1, 1-13.
35 Hoffmann, I.; Widstrom, J.; Zeppezauer, M.; Nyman, P. O. Overproduction and Large-Scale 
Preparation of Deoxyuridine Triphosphate Nucleotidohydrolase from Escherichia-Coli. Eur. J. 
Biochem. 1987, 164, 45-51.
36 Climie, S.; Lutz, T.; Radul, J.; Sumnersmith, M.; Vandenberg, E.; McIntosh, E. Expression of 
Trimeric Human Dutp Pyrophosphatase in Escherichia-Coli and Purification of the Enzyme. 
Protein Expression Purif. 1994, 5, 252-258.
37 Larsson, G.; Nyman, P. O.; Kvassman, J. O. Kinetic characterization of dUTPase from 
Escherichia coli. J. Biol. Chem. 1996, 271, 24010-24016.
38 Mustafi, D.; Bekesi, A.; Vertessy, B. G.; Makinen, M. W. Catalytic and structural role of the 
metal ion in dUTP pyrophosphatase. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 5670-5675.
39 Mol, C. D.; Harris, J. M.; McIntosh, E. M.; Trainer, J. A. Human dUTP pyrophosphatase: uracil 
recognition by p hairpin and active sites formed by three seperate subunits. Structure 1996, 4, 
1077-1092.
40 Persson, R.; Cedergen-Zeppezauer, E. S.; Wilson, K. S. Homotrimeric dUTPases; Structural 
solutions for Specific Recognition and Hydrolysis of dUTP. Curr. Protein Pept. Sci. 2001, 2, 287- 
300.
41 Barabas, O.; Pongracz, V.; Kovari, J.; Wilmanns, M.; Vertessy, B. G. Structural insights into 
the catalytic mechanism of phosphate ester hydrolysis by dUTPase. J. Biol. Chem. 2004, 279, 
42907-42915.
42 Krokan, H. E.; Drablos, F.; Slupphaug, G. Uracil in DNA - occurrence, consequences and 
repair. Oncogene 2002, 21, 8935-8948.
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Under normal dUTP concentrations the AP site would then be filled with the 
correct base by the action of DNA polymerase.43 In the latter case this would be dTTP. 
Since DNA polymerases, however, do not discriminate between nucleotide bases well, 
the insertion of the correct nucleotide depends on its cellular concentration.34 Under 
elevated concentrations of dUTP the BER can become self-perpetuating where, at the 
final stage, dUTP is again incorporated by DNA polymerases into DNA.
Inhibition or mutation of the dUTPase enzyme leads to a large increase in the 
dUTP:dTTP ratio in the cell and extensive incorporation of uracil into DNA. This has 
been observed in bacteria,44 yeast,45 and is likely in all cellular systems.46 The BER 
then becomes self-perpetuating and eventually leads to single/double strand breaks,47 
DNA fragmentation and cell death.44 45
This phenomenon has also been induced by thymidylate synthase inhibitors 
such as the anti-cancer agent 5-fluorouracil or dihydrofolate reductase inhibitors such 
as methotrexate (Figure 2-3) and is termed “thymineless death”. It has been shown in 
mammalian cell lines that inhibitors of thymidylate synthase and DHFR induce elevated 
intracellular dUTP:dTTP ratios and promote incorporation of uracil into DNA48 and this 
then induces DNA strand breakage leading to increased cell death.49 50
NH,
T x  a X :O H2N N N
HO.
OH
N
H
15-Fluorouracil Methotrexate
Figure 2-3: 5-Flourouracil, an inhibitor of TS and methotrexate, an inhibitor of DHFR
43 Augusto-Pinto, L.; Regis da Silva, C. G.; de Oliveira Lopes, D.; Machado-Silva, A.; Machado,
C. R. Escherichia coli as a model system to study DNA repair genes of eukaryotic organisms. 
Genetics and Molecular Research 2003, 2, 77-91.
44 El-Hajj, H. H.; Zhang, H.; Weiss, B. Lethality of a dut (deoxyuridine triphophatase) mutation in 
Escherichia Coli. J. Bacteriol. 1988, 170, 1069-1075.
45 Gadsden, M. H.; McIntosh, E. M.; Game, J. C.; Wilson, P. J.; Haynes, R. H. dUTPase is an 
essential enzyme in Saccharomyces cerevisiae. EMBO J. 1993, 12, 4425-4431.
46 McIntosh, E. M.; Haynes, R. H. dUTP pyrophosphatase as a potential target for 
chemotherapeutic drug development. Acta Biochim. Pol. 1997, 44, 159-172.
47 Kouzminova, E. A.; Kuzminov, A. Chromosomal fragmentation in dUTPase-deficient mutants 
of Escherichia coli and its recombinational repair. Mol. Microbiol. 2004, 51, 1279-1295.
48 Curtin, N. J.; Harris, A. L.; Aherne, G. W. Mechanism of cell death following thymidilate 
synthase inhibition, 2,-deoxyuridine-5'-triphosphate accumulation,DNA damage, and growth 
inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991, 51, 2346-2352.
49 Barclay, B. J.; Kunz, B. A.; Little, J. G.; Haynes, R. H. genetic and biochemical consequences 
of thymidilate stress. Can. J. Biochem. 1982, 60, 172-194.
“ Goulian, M.; Bleile, B.; Teng, B. Y. Methotrexate-induced misincorporation of uracil into DNA. 
Proc. Natl. Acad. Sci. U. S. A. 1980, 77, 1956-1960.
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In addition, correlations have been made between resistance of certain cancer 
cell lines to drugs acting on the folate pathway and dUTPase activities within the 
cells.34,51 It is therefore possible that inhibition of the dUTPase enzyme could act as an 
alternative or adjunct therapy to the use of TS and DHFR inhibitors as anti-infective or 
anti-cancer agents.
dUTPase is classified into three groups of homologous proteins according to 
the associative state of their subunits. The three groups are monomeric, homodimeric 
and homotrimeric (Figure 2-4).
Figure 2-4: Surface representation of A) the dimeric T. cruzi dUTPase and B) the trimeric
human dUTPase52
2.3.1 Trimeric dUTPases
These are the most well known and best characterised group of dUTPase 
enzymes. They include the dUTPase enzymes from animals, higher plants, fungi, most 
bacteria and most viruses.
The crystal structure of that from E. coli53 (PDB entries 1DUD, 1DUP), human39 
(PDB entries 1Q5U, 1Q5H), FIV54 (PDB entries 1EU5, 1DUT), EIAV55 (PDB entries
51 Canman, C. E.; Radany, E. H.; Parsels, L. A.; Davis, M. A.; Lawrence, T. S.; Maybaum, J. 
Induction of Resistance to Fluorodeoxyuridine Cytotoxicity and DNA-Damage in Human Tumor- 
Cells by Expression of Escherichia-Coli Deoxyuridinetriphosphatase. Cancer Res. 1994, 54, 
2296-2298.
52 Harkiolaki, M.; Dodson, E. J.; Bernier-Villamor, V.; Turkenburg, J. P.; Gonz£lez-Pacanowska,
D.; Wilson, K. S. The Crystal Structure of Trypanosoma cruzi dUTpase Reveals a Novel 
dUTP/dUDP Bindind Fold. Structure 2004, 12, 41-53.
53 Larsson, G.; Svensson, L. A.; Nyman, P. O. Crystal Structure of the Eschericia coli dUTPase 
in Complex with a Substrate Analogue (dUDP). Nat. Struct. Biol. 1996, 3, 532.
54 Prasad, G. S.; Stura, E. A.; McRee, D. E.; Laco, G. S.; Hassekus-Light, C.; Elder, J. H.; Stout,
C. D. Crystal structure of dUTP pyrophosphatase from feline immunodeficiency virus. Protein 
Sci. 1996, 5, 2429-2437.
55 Dauter, Z.; Persson, R.; Rosengren, A. M.; Nyman, P. O.; Wilson, K. S.; Cedergren- 
Zeppezauer, E. S. Crystal structure of dUTPase from Equine Infectious Anaemia Virus; active 
site metal binding in a substrate analogue complex. J. Mol. Biol. 1999, 285, 655-673.
2.3 Structure and classification
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1DUN, 1DUC), M. tuberculosis56 (PDB entries 1MK7, 1SJN) are known with both 
liganded and unliganded forms and that of Plasmodium falciparum  with a novel 
inhibitor bound has recently been published57 (PDB entry 1VYQ).
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Figure 2-5: Sequence alignment of some of the trimeric dUTPase showing the 5 conserved
motifs in green boxes (also see Figure 2-6)55
The trim ers consist of three identical subunits consisting of approximately 150 
amino acids each and composed primarily of (3-pleated sheets. There are three active 
sites per molecule and amino acids from all three subunits contribute to each active 
site. Sequence comparison studies have shown that the trimeric dUTPases all possess 
five highly conserved motifs which are positioned in the active site (Figure 2-5).58
56 Chan, S.; Segelke, B.; Lekin, T.; Krupka, H.; Cho, U. S.; Kim, M.; So, M. Y.; Kim, C. Y.; 
Naranjo, C. M.; Rogers, Y. C.; Park, M. S.; Wald, G. S.; Pashkov, I.; Cascio, D.; Perry, J. L.; 
Sawaya, M. R. Crystal structure of the Mycobacterium tuberculosis dUTPase: Insights into the 
catalytic mechanism. J. Mol. Biol. 2004. 341, 503-517.
57 Whittingham, J. L.; Leal, I.; Nguyen, C.; Kasinathan, G.; Bell, E.; Jones, A. F.; Berry, C.; 
Benito, A.; Turkenburg, J. P.; Dodson, E. J.; Perez, L. M. R.; Wilkinson, A. J.; Johansson, N. G.; 
Brun, R.; Gilbert, I. H.; Pacanowska, D. G.; Wilson, K. S. dUTPase as a Platform for Antimalarial 
Drug Design: Structural Basis for the Selectivity of a Class of Nucleoside Inhibitors. Structure 
2005, 13, 329-338.
58 McGeoch, D. J. Protein sequences show that 'pseudoproteases' encoded by poxvirus and 
certain retroviruses belong to the dexyuridine triphosphatase family. Nucleic Acids Res. 1990, 
18, 4105-4110.
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Both nuclear and mitochondrial forms of the human dUTPase have been 
characterised.59, 60 In contrast to the dimeric dUTPases, the trimeric group are 
extremely exclusive towards dUTP as the substrate (Table 2-1).
The subunit monomers (Figure 2-6) of these enzym es have a (3-strand core. 
Two [3-sheets are formed, which combine to form a 3-barrel structure, the interior of 
which is closely packed with hydrophobic residues. The 3-strands are connected by 
loops, some of which are regular 3-turns, one of which normally contributes to the 
active site of the enzyme. There is one a-helical structure on the surface of the 
enzyme.40 Extended loops are found on the surface of the human and E. co li enzymes. 
(Figure 2-6) The outermost C-terminal part of the polypeptide forms a tail that is 
disordered in unliganded X-ray structures but becomes ordered on ligand binding in the 
human and FIV enzymes. Here it can be seen this “arm” traverses the face of the 
trim er and contributes a 3-strand to the 3-barrel of a neighbouring subunit. A  conserved 
proline residue acts as a hinge for this “arm”.39
Figure 2-6: Superimposition of the human (yellow), E. coli (red), EIAV (blue) and FIV (green)
monomeric subunit backbones55
E. coli
FIV
EIAV
59 Ladner, R. D.; McNulty, D. E.; Carr, S. A.; Roberts, G. D.; Caradonna, S. J. Characterization 
of distinct nuclear and mitochondrial forms of human deoxyuridine triphosphate 
nucleotidohydrolase. J. Biol. Chem. 1996, 271, 7745-7751.
60 Ladner, R. D.; Caradonna, S. J. The human dUTPase gene encodes both nuclear and 
mitochondrial isoforms - Differential expression of the isoforms and characterization of a cDNA 
encoding the mitochondrial species. J. Biol. Chem. 1997, 272, 19072-19080.
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The exception to this is the Plasmodium falciparum  dUTPase (PfdUTPase) 
where the C-terminal chain is redirected (Figure 2-7), executing a sharp turn and the 
last (3-strand interacts with the first (3-strand of the same monomer. This is facilitated by 
the substitution of a normally bulky side chain by a Gly residue in the PfdUTPase. 
Therefore many of the intersubunit interactions present in other trimeric dUTPases 
involving the C-termini of neighbouring subunits are absent in PfdUTPase.57
Hum an
Figure 2-7: Superimposition of monomeric subunits from human (green), P. falciparum (red)
and M. tuberculosis (blue)57
The monomers arrange themselves around a three-fold axis to form a 
homotrimer (Figure 2-8) and interact in three ways (Figure 2-8). Firstly, through “arm” 
exchange as described above. Secondly, side chain interactions along the three fold 
axis which vary from purely hydrophobic interactions in the E. coli dUTPase to 
alternating layers of positively and negatively charged residues in the human dUTPase 
that enhance trim er stability. Thirdly, subunit-subunit interface contacts along the 
perimeter of the trim er.37 In the FIV dUTPase crystal structure, the presence of an octa- 
coordinating Mg2+ within the axis may also stabilise trim er association.54 Aromatic 
clusters have also been found within the channel of some of the dUTPase enzymes, 
these again may interact in such a way as to stabilise the homotrimer.39 Thus, while the 
overall subunit arrangement is highly conserved between the dUTPase enzymes, the 
specific interactions providing their stabilities vary.
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EIAV
Figure 2-8: Trimeric backbone structure of human (yellow), E. coli (red), EIAV (blue) and FIV
(green) dUTPases55
The PfdUTPase contains large insertions in each monomer known as low 
complexity regions (LCRs) which are composed of 24 hydrophilic amino acid residues 
and are absent in the other dUTPases. They form three large loops gathered together 
at the top of the trim er (Figure 2-9). Their function is not certain but it is known they do 
not interfere with substrate binding or trimer formation.57 However, these LCR regions 
are known to be typical of P. falciparum  proteins.61
Figure 2-9: A) PfdUTPase, LCRs in yellow. C-termini are folded back B) Human dUTPase57
61 Brocchieri, L. Low-complexity regions in Plasmodium proteins: In search of a function. 
Genome Res. 2001, 11, 195-197.
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The mechanism of catalysis was shown from 180  studies to be a nucleophhilic 
attack of water on the a-phosphate (Figure 2-10) which is in contrast to the dimeric 
enzymes where there is an attack on the (3-phosphate.37 The crystal structures of the E. 
coli, wild type and mutant,41 and M. tubercolsis56 enzyme complexed with the non- 
hydrolysable a,(3-imino-dUTP inhibitor have also shed light on the mechanism of 
catalysis which is facilitated by i) the coordination of the Mg2+ ion to all three phosphate 
groups, holding the phosphate chain in an orientation optimal for catalysis and ii) a 
number of non-covalent bonding interactions between conserved residue side chain 
and backbone atoms to various water molecules and the triphosphate groups. The 
residues which are proposed to interact with the catalytic water molecule (Wcat) are 
highly conserved between species (Figure 2-10).
Asp 32
Catalytic water
Gln119
W 4
Asp90
.eu88
Monomer A
Tyr93
Figure 2-10: Proposed mechanism of phosphate (shown in orange) ester hydrolysis in the
trimeric dTUPases41
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2.3.2 Dimeric dUTPases
dUTPase enzymes from trypanosomes,62, 63, 64 Cam pylobacter je jun i 65 and 
some other bacteria and T4 bacteriophages function as physiological dimers of 
approximately 62-64kDa. The crystal structures of the T. c ru z i52 (PDB entrieslO G K, 
10GL) and C. je ju n i65 (PDB entry 1W2Y) dUTPases have been solved.
There is no significant sequence similarity, however between this family of 
dUTPases and the monomeric and trimeric forms. This group of enzymes possess five 
conserved motifs (Figure 2-11) but they are different to the five conserved motifs that 
are present in the other fam ilies of dUTPases. In fact this group of enzymes is so 
different that it is suggested that they reached their catalytic potential through very 
different evolutionary routes.52,63
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Figure 2-11: Sequence alignment of dUTPase from C. jejuni, L. major and T. cruzi showing the
5 conserved motifs boxed in black66
The dimeric dUTPase enzymes show significant specificity toward the uracil 
base and the deoxyribose sugar as do the trimeric enzymes, they are less specific 
toward the phosphate moiety. A  characteristic difference of the dimeric dUTPases is 
that they also hydrolyse dUDP, which acts as a weak competitive inhibitor toward the 
monomeric and trimeric forms. The Km values are higher than those obtained for dUTP 
but the specificity constants are similar. (Table 2-1)
62 Camacho, A.; Arrebola, R.; PenaDiaz, J.; LuisPerez, L. M.; GonzalezPacanowska, D. 
Description of a novel eukaryotic deoxyuridine 5'-triphosphate nucleotidohydrolase in 
Leishmania major. Biochem. J. 1997, 325, 441-447.
63 Camacho, A.; Hidalgo-Zarco, F.; Bernier-Villamor, V.; Ruiz-Perez, L. M.; Gonzalez­
Pacanowska, D. Properties of Leishmania major dUTP nucleotidehydrolase, a distinct 
nucleotide-hydrolysing enzyme in kinetoplastids. Biochem. J. 2000. 346, 163-168.
64 Bernier-Villamor, V.; Camacho, A.; Hidalgo-Zarco, F.; Perez, J.; Ruiz-Perez, L. M.; Gonzalez­
Pacanowska, D. Characterization of deoxyuridine 5 '-triphosphate nucleotidohydrolase from 
Trypanosoma cruzi. FEBS Lett. 2002, 526, 147-150.
65 Moroz, O. V.; Harkiolaki, M.; Galperin, M. Y.; Vagin, A. A.; Gonzalez-Pacanowska, D.; Wilson, 
K. S. The crystal structure of a complex of Campylobacter jejuni dUTPase with substrate 
analogue sheds light on the mechanism and suggests the "basic module" for dimeric 
d(C/U)TPases. J. Mol. Biol. 2004, 342, 1583-1597.
66 Moroz, O. V.; Murzin, A. G.; Makarova, K. S.; Koonin, E. V.; Wilson, K. S.; Galperin, M. Y. 
Dimeric dUTPases, HisE, and MazG belong to a new superfamily of all-alpha NTP 
pyrophosphohydrolases with potential "house-cleaning" functions. J. Mol. Biol. 2005, 347, 243- 
255.
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Nucleotide T. cruzi L. Major E. coli EIAV HSV-1 MMTV
dUTP:Km(kcat//Km) 0.53 
(5.2 106)
2.11 
(2.3 107)
0.2 
(4 107)
1.1
(2 107)
0.3 
(2 107)
0.8 
(2 106)
dTTP:Km(kcat//Km) >800 
(2.5 103)
1514
(5.5 103)
>20000
(34)
260
(<2000)
400
(1000)
nd
(2000)
dCTP:Km(kcat//Km) nd >2500 
(5.0 103)
4000
(<100)
3000
(1000)
1000
(2000)
nd
UTP:Km(kcat//Km) nd 2500 
(2.0 103)
2500
(<100)
nd 1000
(200)
nd
dUDP:Km(kcat//Km) 6.23 
(1.7 106)
62.7
(1 106)
Ki=15 Kj=3.6 Kj-17 nd
dUMP:Kjp
I _
18.4 13.05 1500 130 170 nd
Table 2-1: Michaelis-Menten, specificity and inhibition constants of viral, bacterial and 
trypanomastid dUTPases for different nucleotides. Units for Km and K are pM and for kcat/Km M'
The crystal structure for the dimeric T. cruzi dUTPase (TcdUTPase) enzyme, 
native and with dUDP bound has been published but Mg2+ ions are not present (Figure 
2-12 B).52 Nevertheless, it elucidated the fact that the enzyme undergoes a very 
significant conformational change on binding the substrate, which effects almost all of 
the protein topology (Figure 2.15). The active site is also very open in the unbound 
form but closes around the substrate in the bound form, effectively burying the ligand 
within the active site (Figure 2-14). The crystal structure, of C. je jun i dUTPase 
(CjdUTPase), however, revealed the Mg2+ binding sites (Figure 2-16) but has only been 
determined as a closed, substrate-bound form (Figure 2-12).65
Figure 2-12: Crystal structures of A) The CjdUTPase and B) the TcdUTPase. Both are in the
liganded forms52 65
67 Hidago-Zarco, F.; Gonzalez-Pacanowska, D. Trypanosomal dUTPases as potential targets 
for drug design. Curr. Protein Pept. Sci. 2001, 2, 389-397.
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Both structures are very similar with some small differences. The subunits are 
predominantly helical in structure. CjdUTPase consists of 11 a-helices and 2 (3-strands 
in the complexed form and TcdUTPase is comprised of 12 a-helices in the native 
conformation (with the formation of two new (3-strands on complexation) which are 
arranged into two distinct domains termed “rigid” and “mobile” . The molecular units are 
homodimers, formed through association of the rigid dom ains of two subunits, 
complimented by insertion o f the latch of one subunit into the groove of its partner 
(Figure 2-13).
Latch
Figure 2-13: A) The native subunit of TcdUTPase with helices represented as rods B) The 
subunit of TcdUTPase complexed with dUDP52
There are two active sites per dimer, each residing in the groove formed at the 
interface of the two subunits. Amino acids from both subunits contribute to ligand 
binding in the active site. W hen an active site becomes occupied the mobile domain 
moves to engulf the nucleotide through a series of structural rearrangements that 
effectively bury the molecule beneath the subunit surface (Figure 2-14).
Figure 2-14: Surface representations of the active site of A) the native and B) the complexed
TcdUTPase. Generated using VMD 1.8
- 34-
Structure and classification
The “open” or “native” form refers to the ligand free and the “closed” form refers 
to the ligand bound conformation of the enzyme. The rigid domains retain the native 
conformation upon nucleotide binding. Figure 2-15 shows the structure of the dimeric 
TcdUTPase in its native and complexed form where the structural rearrangements 
which the enzymes undergo can be clearly seen.52
Figure 2-15: Superimposition of the native (blue) and complexed (red) TcdUTPase. Generated
using VMD 1.8
Two mechanisms of binding and conformational change can be proposed. One 
proposal is that the uracil and deoxyribose moieties are initially recognized by helix 1 
and helix 4 followed by the recognition and hydrogen bonding of the a and (3- 
phosphates. The second proposal is that the phosphates are recognized first, bringing 
the rest of the molecule into its docking site where it is recognized in a sequential 
fashion.52
The crystal structure of the CjdUTPase reveals the presence and positions of 
three Mg2+ ions shown in orange in Figure 2-16 and 2-17.
Figure 2-16: Crystal structure of CjdUTPase with ligands dUpNHp and Mg ions bound.
Generated using MolSoft Browser.
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The presence of these Mg2+ ions can help to propose a mechanism by which 
the enzyme catalyzes hydrolysis. There are three Mg2+ ions per active site. They are 
hexa-coordinated to three conserved Glu residues, one Asp and many water atoms. 
Two of the Mg2+ ions, coordinate one of the water atoms in such a way that they 
orientate it in the correct position for direct nucleophilic attack on the (3-phosphate 
(Figure 2-17). At the same time all metal ions increase the nucleo-fugality of the leaving 
group.65
dUTP
u4 9
Lys60
Wat 1
Glu20
Figure 2-17: Hypothetical y-phosphate position and proposed catalytic mechanism for dimeric
dUTPases. Mg2+ shown in orange.65
The structures o f the active sites differ dramatically to those of the trimeric 
enzymes and will be discussed in more detail in section 2.3.4.
2.3.3 Monomeric dUTPases
The herpes virus dUTPases are active as monomers.68, 69 The crystal structure 
of the dUTPase from the EBV (Epstein-Barr virus, a y-herpesvirus) in complex with 
dUMP and a,(3-imino-dUTP has been published (PBD entry 2BSY).70
68 Williams, M. V. Deoxyuridine Triphosphate Nucleotidohydrolase Induced by Herpes-Simplex 
Virus Type-1 - Purification and Characterization of Induced Enzyme. J. Biol. Chem. 1984, 259, 
10080-10084.
69 Bjornberg, O.; Bergman, A. C.; Rosengren, A. M.; Persson, R.; Lehman, I. R.; Nyman, P. O. 
Dutpase from Herpes-Simplex Virus Type-1 - Purification from Infected Green Monkey Kidney 
(Vero) Cells and from an Overproducing Escherichia-Coli Strain. Protein Expression Purif. 1993 
4, 149-159.
70 Tarbouriech, N.; Buisson, M.; Seigneurin, J. M.; Cusack, S.; Burmeister, W. P. The 
monomeric dUTPase from Epstein-Barr virus mimics trimeric dUTPases. Structure 2005, 13, 
1299-1310.
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In terms of evolution, it is thought that the ancestral gene for the monomeric 
enzymes arose from a gene coding for a trimeric one.71
Figure 2-18: A) Crystal structure of the EBV dUTPase complexed with dUMP (PDB entry 
2BSY) B) comparison of the trimeric and monomeric dUTPase enzyme folds and localisation of 
the conserved motifs l-V around the active sites represented by red dots
The monomeric dUTPases contain the same 5 conserved motifs as the trimeric 
enzymes but in a different order and they are spread out over a single polypeptide 
chain 249 residues long (twice as long as one subunit from a trimeric enzyme). The 
EBV dUTPase has shown to be almost an entirely (3-strand structure and folds into 3 
domains, each of which can be corresponded to a subunit of the trimeric form (Figure 
2-18). The monomeric dUTPase has one active site located at the interface of domain I 
and II. The 5 conserved motifs interact within the active site in some way. One unusual 
feature of the monomeric dUTPases is a disulfide bridge found between Cys4 and 
Cys246 which locks motif 5 in such a way as to cover the active site during catalysis.70
Kinetic stereospecificity studies have been carried out on HSV-1 versus E. coli 
and EIAV (equine infectious anaemia virus) homotrimeric dUTPases.72 The enzymes 
are highly specific towards dUTP. Other nucleotides such as dTTP, dCTP, UTP and 
dUTPaS are also hydrolysed but at a much slower rate. dUMP and dUDP act as weak 
inhibitors of these enzymes.
71 McGeehan, J. E.; Depledge, N. W.; McGeoch, D. J. Evolution of the dUTPase gene of
mammalian and avian herpesviruses. Curr. Protein Pept. Sci. 2001, 2, 325-333.
a  Domain III
D
Domain II
Subunit m
Subunit II Domain ISubunit I
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Substrate HSV E. coli EIAV Inhibitor HSV E. coli EIAV
dUTP dUMP
Km(pM) 0.3 0.2 1.1 Ki (pM) 170 1500 150
dUTPaS dUDP
Km 0.2 0.9 Nd Ki 17 15 3.6
dTTP dU
. __.J
Km 400 >20000 260 K, 400 1000 1500
dCTP Uracil
Km 1000 4000 3000 Ki 5000 >10000 nd
UTP dUMPaS
Km 1000 2500 Nd Ki 900 nd nd
!      1   1
Table 2-2: Catalytic parameters of viral (HSV, EIAV) and bacterial (E. Coli) dUTPases towards 
nucleoside triphosphates and uracil containing compounds72
2.3.4 Comparison of active sites
In dUTPase active sites, specific structural arrangements confer highly selective 
ligand binding for both dimeric and trim eric forms. However, the way in which they do 
so differs greatly between the different associative forms.
The five conserved motifs that are seen throughout the dimeric dUTPases all 
contain residues that play crucial roles in substrate binding and specificity. Figure 2-19 
and 2-20 show the interactions of the ligands, dUpNHp and dUDP, with the active sites 
of the CjdUTPase and TcdUTPase respectively.
For the dimeric enzymes, base pairing mimics bind uracil through selective 
hydrogen bonding with side chains from conserved motif 1 and motif 3. Motif 3 presides 
on the latch of the neighbouring subunit. There is an extra Asn hydrogen bonding 
residue in the CjdUTPase. The hydrogen bonding His58 in C jdUTPase and Trp61 in 
TcdUTPase from motif 3 are the main residues for discrim ination of the enzyme against 
cytosine as they would repel the NH2 form cytosine due to its positive charge potential. 
The bulky Trp39 in C jdUTPase and His83 in TcdUTPase from conserved motif 2 aids 
in discrim ination against thym idine by preventing binding of substrates with substitution 
on C-5.
The deoxyribose sugar moiety hydrogen bonds to an Asn residue from 
conserved motif 5 in both proteins and is flanked by two arom atic residues of Phe and 
His from motif 4.
Bergman, A. C.; Nyman, P. O.; G., L. Kinetic Properties and Stereospecificity of the 
Monomeric dUTPase from herpes simplex virus type 1. FEBS Lett. 1998, 441, 327-330
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The Gly rich site for phosphate binding which is present in the trimeric 
dUTPases, is absent in the dimeric forms, instead the phosphates form an intricate 
network of hydrogen bonds with charged residues from Motifs 2, 3, 4 and 5 and also 
coordinate to Mg2+ ions as well as water molecules. In CjdUTPase, the Mg2+ ions can 
be seen to be hexa-coordinate with charged residues from motifs 2, 3, 4 and also water 
molecules.52,65
Gln14
Trp39 , f
Phe81
Ly*175
dUpNHp
Trp59
Glu74
Lys194
Figure 2-19: A LIGPLOT diagram of the active site of the C. jejuni dUTPase complexed with
dUDP65
Trp61
As«i26
2 68Met29{sH\'- Phe64
Gln22
Asn201
* 3  2®
Aig204
/
Glu49 f
' - • V v C
■3 oo-- -4
•  m.i77
Trp62
■2 64
2=4
**  205
Glu52
Asn224
Figure 2-20: A LIGPLOT diagram of the active site of the T. cruzi dUTPase in complex with
dUpNHp52
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The trim eric dUTPases contain three active sites per molecule, each buried in 
shallow depressions at the subunit interfaces. W ithin each active site all three subunits 
are involved in ligand binding. All 5 conserved motifs from each subunit contribute 
ligand binding residues. Motif 1, 2 and 4 are contributed by one subunit, motif 3 by a 
second subunit and motif 5 by the third subunit (Figure 2-22, Figure 2-23)..40
Motif 3 form s a (3-hairpin pocket, of mainly hydrophobic nature which mediates 
the binding of the uracil and sugar moiety at its open end (Figure 2-21). As with the 
dimeric enzymes, the uracil base binds to the enzyme in a mode mimicking base pair 
hydrogen bonding. However, due to the hydrophobic nature of the (3-hairpin residues, 
the uracil base hydrogen bonds to main-chain atoms. This is in contrast to the dimeric 
enzymes, where hydrogen bonding is mainly to side-chain atoms. 0 -4  of the uracil 
base also hydrogen bonds through a conserved water molecule. Specificity towards the 
uracil over the cytosine base is maintained by the formation of a strong hydrogen bond 
between a main chain carbonyl atom and N-3 of the base which is a hydrogen bond 
donor in uracil but not in cytosine. Steric hindrance also excludes thym ine from binding 
in the (3-hairpin region, as the (3-hairpin is narrow and steric clashes between the 5 ’- 
methyl group and the polypeptide would occur.
Figure 2-21: The (3-hairpin recognition motif for uracil in human dUTPase:
Binding of the deoxyribose moiety occurs at the turn of the (3-hairpin which also 
renders the enzyme specific towards the deoxyribose over ribose. A  tyrosine residue 
(Phe in MMTV) which is highly conserved throughout the enzym es is stacked against 
the sugar ring and its OH group is hydrogen bonded to the opposite (3-hairpin wall 
which stabilizes its position. This Tyr together with another highly conserved lie 
residue, sandwich the sugar moiety and this tight packing sterically precludes ribose 
binding. An aspartate residue that hydrogen bonds to the 3 ’-0 H  is also strictly 
conserved.40
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Motif 2 and 4, both from a second subunit contribute to binding interactions to 
the (3 and y phosphate through side chain interaction with basic residues and a 
conserved Ser. Motif 5 from the flexible arm of a third subunit is Gly rich. On ligand 
binding, the flexible arm of the third subunit becomes ordered and this Gly rich 
sequence from motif 5 is essential for catalysis in the trim eric dUTPases. This is in 
contrast to the dimeric enzymes where the phosphate binding region of the active site 
consists of many charged and hydrophilic residues.52
Motif 3
Lys91
Asn77
Tyr86
>83 water
Arg64
Arg140 •
Asp24
Asp28
Motif 1
Figure 2-22: Active site of M. tuberculosis with a,(3-imido dUTP ligand bound. Motif 1(blue), 
motif 2(green), motif 3( yellow), motif 4(orange), motif 5 (red) are shown.56
Gly-74Val-89
HOH
Gly-76
Gly-87
Gly-136Ser-63
Phe-135
Gly64
o — p — o — P— o Gly-87
Arg-62 O — P — O
HO Tyr-82
Arg-130 Asp-79Arg-105
Figure 2-23: Binding in the active site of the human dUTPase enzyme. Different colours
represent residues from the different subunits'
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2.4 dUTPase enzymes as potential chemotherapeutic 
targets
It has been shown that the role of dUTPase is essential for cell viability in 
Escherichia coli,44 Saccharom yces cerevisiae45 and Leishm ania m a jo r73 The 
fundamental role of the enzym e in mammalian cells is inferred from the observations 
made to thym ineless death induced by certain anti-folates and the preceding reduction 
in the intracellular dTTP:dUTP. dUTPase is clearly, then a valid target for inhibition by 
anti-cancer and anti-infective agents.34
The structural differences between the human dUTPase and that of the dimeric 
dUTPases can be taken advantage of in designing novel anti-parasitic agents.67 When 
the nucleotide ligands from trim eric dUTPase complexes and that of dUDP from the 
dimeric T. cruzi dUTPase are superimposed, it can be seen that the ligands bind with 
very different conformation with respect to the uracil ring, sugar moiety and especially 
the phosphate chain (Figure 2-24).
Figure 2-24: Superimposition of ligand models from trimeric (washout) and dimeric (bold)
enzyme complexes52
Considering the large differences between the active sites as well as the overall 
structure of the dimeric and trim eric enzymes, it should be possible to selectively inhibit 
the dimeric dUTPase enzymes. These inhibitors could then possibly be used as 
therapeutic agents to treat diseases caused by the trypanom astidae protozoa such as 
HAT, Chagas’ disease and leishmaniasis.
The only known inhibitors of the dimeric dUTPases are dUMP, which causes 
product inhibition and a,(3-imido-dUTP, a non hydrolysable nucleotide analogue.73 Both, 
however, are unsuitable drug candidates due to there inherent physicochemical 
properties and poor cell permeability. One of the aims of th is project is to utilise 
available structural data of the dimeric enzymes to design novel inhibitors in silico and 
to test these compounds against the dimeric enzym es and intact parasites.
73 Hidalgo-Zarco, F.; Camacho, A. G.; Bernier-Villamor, V.; Nord, J.; Ruiz-Perez, L. M.; 
Gonzalez-Pacanowska, D. Kinetic Properties and Inhibition of the Dimeric dUTPase-dUDPase 
from Leishmania major. Protein Sci. 2001 , 10, 1426-1433.
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Previously designed and synthesised cyclic and acyclic nucleoside analogues 
have been shown to be selective inhibitors of the P. falciparum dUTPase (PfdUTPase) 
enzyme over the human dUTPase (Figure 2-25).74, 75 The crystal structure of the 
PfdUTPase complexed with one of these inhibitors has been solved (Figure 2-26), 
showing subtle differences within the active site of the PfdUTPase that may be 
exploited to design novel anti-malarial therapeutic compounds.57 It was shown that 
deoxyuridine derivatives with triphenylmethyl (Trt), tert-butyldiphenylsilyl (TBDPS) or 
triphenylsilyl (TPS) substituents on the 5’ position, which have been synthesised in the 
group, were selective inhibitors of PfdUTPase.74 Subsequently, acyclic nucleoside 
analogues, in which the Trt, TBDPS or TPS groups were positioned at varying 
distances from the uracil ring, were synthesised. These also proved to be selective 
inhibitors of the PfdUTPase.75
wsp870
K,=0.67jjM
ICso=0.90|jM
^  Si~Q
wsp1001 
K,=2.24pM 
ICso=0.36|jM
wsp1060 
K|=0.90pM 
IC5o=3.80mM
^ N H
H \ ' wsp870 
d>H K,=0.20mM 
IC5o=4.50mM
wsp869
K,=4.98|jM
ICso=2.00mM
Figure 2-25: Previously synthesized PfdUTPase inhibitors 
The selectivity of these compounds is thought to be due to the interactions of 
the bulky hydrophilic groups with the side chains of residues Phe46 and Ile117 (Figure 
2-26) in the PfdUTPase which are substituted by two small, less hydrophobic Val42 
and Gly87 in the human dUTPase. These compounds also show good anti-parasitic in 
vitro activity and are therefore successful leads for the design of novel anti-malarial 
drugs. Another aim of this project was to design and synthesise further Trt or TBDPS 
uracil nucleoside analogues using structure based and analogue based design with the 
objective of improving the activity of these compounds.
74 Nguyen, C.; Kasinathan, G.; Leal-Cortijo, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz- 
Perez, L. M.; Johansson, N. G.; Gonzalez-Pacanowska, D.; Gilbert, I. H. Deoxyuridine 
triphosphate nucleotidohydrolase as a potential antiparasitic drug target. J. Med. Chem. 2005, 
48, 5942-5954.
75 Nguyen, C.; Ruda, G. F.; Schipani, A.; Kasinathan, G.; Leal, I.; Musso-Buendia, A.; Kaiser, 
M.; Brun, R.; Ruiz-Perez, L. M.; Sahlberg, B. L.; Johansson, N. G.; Gonzalez-Pacanowska, D.; 
Gilbert, I. H. Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J. 
Med. Chem. 2006, 49, 4183-4195.
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Asn103
l le l  17
Ala119
^ t* i «
Phe46
Figure 2-26: A LIGPLOT diagram of the active site of PfdUTPase complexed with 5’-Trt-
deoxyuridine inhibitor57
Other reported trim eric dUTPase inhibitors include the non-hydrolysable a ,[3 -  
im ido-dUTP76 and some mercury (II) compounds,77 again, these compounds are 
unlikely drug candidates due to their chemical and enzymatic instability and poor 
bioavailability and membrane permeability.
It is known that levels of dUTPase vary between individual cell types. dUTPase 
levels are usually low in breast, lung and colon cancers whereas neuroblastomas and 
hematopoietic malignancies have high levels of the enzym e.34 Thus the human 
dUTPase enzyme could be targeted with anti-cancer dUTPase inhibitors for the former 
group of cancers. DHFR inhibitors, such as methotrexate and thym idylate synthase 
inhibitors such as FUdR are already used as to perturb the dUTP.dTTP ratio in cancer 
cells but resistance has emerged. It is thought that dUTPase over expression could 
play a role in this resistance.51 Therefore, dUTPase inhibitors could act as alternatives 
or adjuvants on DHFR inhibition cancer chemotherapy.
In this project we are particularly interested in targeting parasitic protozoa 
dUTPases. W hereas kinetoplastida protozoa cannot synthesise purines “de novo”, they 
do possess the enzym atic machinery required for pyrim idine synthesis including 
dUTPase.67 With regard to the plasmodium species, anti-folate drugs are already a 
successfully used chemotherapy, though resistance is emerging. Given the necessity 
of this enzyme for cell viability and the differences in sequence and structure from the 
human enzyme, it seems a good choice of target for anti-parasitic agents.
Persson, T.; Larsson, G.; Nyman, P. O. Synthesis of 2'-deoxyuridine 5'-(alpha,beta- 
imido)triphosphate: A substrate analogue and potent inhibitor of dUTPase. Bioorganic & 
Medicinal Chemistry 1996, 4, 553-556.
77 Williams, M. V. Effects of Mercury (li) Compounds on the Activity of Dutpases from Various 
Sources. Mol. Pharmacol. 1986, 29, 288-292.
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3 Aims and Objectives
The aim of this project was to design, synthesise and evaluate novel inhibitors 
of the essential enzyme dUTP nucleotidohydrolase for use as anti-parasitic agents by 
employing both analogue based and structure based drug design methodologies.
3.1 The trimeric Plasmodium dUTPase
•Analogue based design in which the insertion of an amide bond into previously 
synthesised selective inhibitors of the PfdUTPase was initially to be carried 
out, (Scheme 3-1) resulting in the synthesis of uracil acetamide derivatives. 
The rationale behind this modification is explained in Chapter 4.
NH
NH
Si-O.
NH
H
N
Structural modification: 
insertion of an amide bond
NH
Lead inhibitors Target compounds: uracil acetamides
Scheme 3-1: Analogue based design and introduction of an amide bond
• Branched chain derivatives (Figure 3-1), as well as single chain derivatives 
were to be synthesised, allowing for further diversification studies to be carried 
out, without introducing a chiral centre in to the molecules.
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O
x M n y  x  = n h 2- NHTrtO Y = NH2, NHTrt, NHCbZ, OH, OPO3H
Y? V
.........
NH
Figure 3-1: Branched chain uracil acetamides
• Following the elucidation of the crystal structure of the PfdUTPase in 2005,57 
structure based design strategies were then be employed and used in 
combination with the analogue based design results to attempt to increase the 
potency of our inhibitors toward the enzyme.
3.2 The dimeric Trypanosom dUTPase
• In contrast to the trimeric PfdUTPase, no selective lead inhibitors of the 
dimeric enzymes were known. However, the crystal structure of the 
TcdUTPase was elucidated in 2004 and therefore allowed for structure based 
design approaches to be utilised from the beginning in order to find potential 
lead inhibitors for these dimeric enzymes. Docking studies were to be carried 
out on the closed form of the enzyme, followed by the syntheses of some of 
the successfully docked compounds, which ultimately was to result in a library 
of uracil amino acid conjugates (Fig. 3-3) to be evaluated for biological activity.
Figure 3-3: Uracil amino acid conjugates for the inhibition of the dimeric dUTPases
O
G = C 0 2H, CONR.,R2
Figure 3-2: Proposed modified compounds from structure based design
O
Amino 
acid 2
Amino 
acid 1
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4 Triphenylmethylamino and
butyldiphenylsilyloxy uracil
acetamide derivatives
4.1 Rational drug design and isosteric replacement
Classical isosteres can be defined as atoms, ions or molecules in which the 
peripheral layers of electrons can be considered to be identical. They are often used in 
rational drug design to determine whether one particular group in a molecule is 
important in binding to the target receptor. Replacement of one group with an isostere 
can tell us about the effect of factors such as steric tolerance, electronic distribution 
and hydrogen bonding in as controlled a manner as possible. Nonclassical 
bioisosteres, more broadly, do not necessarily have the same number of electrons in 
their outer shells but they do produce a similar biological effect. They are often used to 
introduce structural diversity into the molecule of interest or to replace an easily 
metabolised moiety of the molecule by one which is more metabolically stable.78
Group Isosteres
Classical c h 3 n h 2 OH F
isosteres c h 2 NH 0 S
Halogen CO
LLO CN N(CN)2
Nonclassical
bioisosteres
O
A . X
O
ii
/ S . ,
0 ^ 0
" I
OH o 0 H
- A A ^ N H o NH H
Table 4-1: Examples of classical isosteres and nonclassical bioisosteres
78 Silverman, R. B. The Organic Chemistry of Drug Design and Drug Action; 2nd ed.; Elsevier 
Academic Press, 2004.
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In this part of the project the aim was to introduce an amide bond into the 
structures of some of the lead compounds already designed and synthesised in our 
laboratories. The primary advantage of this modification is tha t structural diversity can 
be introduced through the ease in which amide coupling can be carried out. The 
potential for hydrogen bonding between the amide moiety and the dUTPase active site, 
as well as the introduction of a certain degree of rigidity into the molecule by the 
insertion of an amide moiety in place of a short alkyl chain are factors that may lead to 
a change in how potently and selectively these compounds inhibit the dUTPase 
enzymes. The logD values would be predicted to decrease and this may also effect the 
pharmacokinetic properties of these compounds as anti-parasitic agents.
NH
^  Structural modification
N ^ O
n=1,2,3 
X=N O 
Y=Si, C 
Z=t-Bu, Ph
Lead compounds
n=2,3,4 
X=N, O 
Y=Si, C 
Z=t-Bu, Ph
Target compounds
•Adds rigidity 
•1 logD
• ease of synthesis
Scheme 4-1: Introduction of an amide bond
4.2 Triphenylmethoxy and triphenylmethylamino
monoalkyl chain derivatives -  coupling of 
primary amines to 1-carboxyuracil
A small series of mono alkyl chain uracil acetamides were synthesised. The 
overall strategy involved the coupling of 1-carboxymethyluracil w ith diam ino alkanes
and amino alcohols of various chain lengths. In the case of the amino alcohols, the 
hydroxyl group was protected with the te/f-butyldiphenylsilyl (TBDPS) group to ensure 
selective coupling to the amine moiety. In the case of the diam ines protection was not 
necessary and selective monotritylation was carried out by adding triphenylmethyl 
chloride (TrtCI) dropwise at 0°C to a ten fold excess of the diamine.
The overall synthetic strategy is as follows:
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o
( V
H O ^ J
TrtH N A^H z /  o  \  TBDPS0^ nNH2r f t i
o
H H N ^ O
N^ ; V
o
Si-O^
O
fi NH
*
O H W V  '
o
Scheme 4-2: Overall synthesis of monoalkyl chain derivatives (n = 2,3,4)
4.2.1 Synthesis of 1-carboxymethyluracil
HO> O
V s"o
i) H20, KOH, reflux 1h
NH
HON" ‘0 HCI, 4°C. Overnight
H 70%
Scheme 4-3: Synthesis of 1-carboxymethyluracil
The first step was to prepare 1-carboxymethyluracil (Schem 4-3), originally 
synthesised in 1908,79 and was carried out according to the procedure of Jacobsen et 
a lso Uracil was reacted with chloroacetic acid in the presence of KOH and the 
mechanism involved a nucleophilic substitution at the acid chloride by the N-1 of the 
uracil ring. After acidification, the product was precipitated out as the free acid. The 
monosubstituted product was the sole product isolated as determined by mass 
spectrometry and NMR analysis.
79 Wheeler, H. L.; Liddle, L. M. Researches on pyrimidines: Synthesis of uracil-3-acetic acid. J. 
Am. Chem. Soc. 1908, 30, 1152-1156.
80 Jacobsen, J. R.; Cochran, A. G.; Stephans, J. C.; King, D. S.; Schultz, P. G. Mechanistic 
studes of antibody-catalyzed pyrimidine dimer photocleavage. J. Am. Chem. Soc. 1995, 117, 
5453-5461.
- 4 9 -
4 Trityl-amino and TBDPSoxy uracil acetamide derivatives
4.2.2 Attempted coupling with 1,2-ethanolamine
Initially, coupling was attempted with the unprotected ethanolamine according 
to the procedure by Ahn et a/.81 This selective amide coupling could be achieved using 
1-ethyl-3-(3’-dimethylaminopropyl)carbodiimide (EDC) in dimethylformamide (DMF) 
conditions and subsequently, direct tritylation could be carried out. The reaction mixture 
was left stirring overnight and a new spot with a higher Rf than the starting materials 
could be seen by thin layer chromatography (TLC). However, following aqueous work 
up and column chromatography on silica gel, no pure product could be isolated. A 
complex mixture, which by NMR showed the presence of the uracil ring and EDC was 
isolated from the column. The product could not be seen by mass spectrometry. The 
reaction was repeated and aqueous work up was avoided as the product was possibly 
water soluble. Following purification by column chromatography, however, only starting 
materials were isolated.
It is possible that the (3-oxygen effect in which the hydroxy function (3 to the 
amino function deactivates the amine through an inductive effect may be responsible 
for a decrease in nucleophilicity of the amine. Alternatively, intramolecular hydrogen 
bonding may be responsible for the deactivation of the amino function. A method by 
which the hydroxy function was first protected was therefore employed. Due to the 
hydrophilic nature of these compounds, the use of a lipophilic protecting group was 
logical as this would aid solubility and purification.
4.2.3 Synthesis of the triphenylmethoxy derivatives
4.2.3.1 Protection with TBDPS
A silyl protecting group was chosen to selectively protect the hydroxyl group 
over the amino group due to the strong nature of the silicon oxygen bond. Initially, 
attempts were made to protect with tert-butydimethylsilyl (TBDMS) chloride as this
81 Ahn, D.; Mosimann, M.; Leumann, C. J. Syntesis of cyclopentane amide DNA (cpa-DNA) and 
its pairing properties. J. Org. Chem. 2003, 68, 7693-7699.
n O O
Scheme 4-4: Attempted unprotected coupling with ethanolamine
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moiety is stable under most conditions.82 However, the product crystallised on the silica 
column during purification, resulting in isolation in low yield.
HO' .NH2 +
DMF, imidazole, RT, <10%
Si—Cl -Si-O' NH:
Scheme 4-5: Synthesis of TBDMS protected compound 3
It was thought that increasing the lipophilicity of the protecting group further 
might improve the purification and isolated yields. The TBDPS group was then chosen 
as a protecting group. The TBDPS is more stable than TBDMS under acidic conditions 
but less stable in basic conditions.83
H O ^ rf lH s  + 
11=2,3,4
DMF + f / >  RT- 18h
N
or
pyridine, RT, 18h
0 'f^ S IH 2
4, n=2, 35%
5, n=3, 7%
6, n=4,14%
Scheme 4-6: Synthesis of TBDPS protected compounds 4, 5, 6
A mixture of TBDPSCI and imidazole were added to the relevant amino alcohol 
in DMF and the reaction was left at room temperature overnight (Scheme 4-6). The 
yields of these reactions however were still quite low after purification. The TBDPS 
group, though normally resistant to cleavage on silica columns may, in this case have 
been cleaved under the conditions used. The basic amino moieties of the compounds 
would also have a high affinity for the slightly acidic silica used and therefore caused 
much of the product to stick to the column.
In the case of 4, it was found that the yield of the reaction could be increased 
slightly to 38% by carrying out the reaction in pyridine. In this case pyridine acts as 
both solvent and base and therefore the addition of imidizole is not necessary. Traces 
of imidazole impurity were therefore eliminated, however, column chromatography on 
silica gel still resulted in a low yield.
82 Corey, E. J.; Venkateswarlu, A. Protection of hydroxyl groups as tert-butyldimethylsilyl 
derivatives. J. Am. Chem. Soc. 1972, 94, 6190-6191.
83 Hanessian, S.; Lavellee, P. The Preparation and Synthetic Utility of tert-Butyldiphenylsilyl 
Ethers. Can. J. Chem. 1975, 53, 2975-2977.
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4.2.3.2 Coupling with 1-carboxymethyluracil
The next stage was coupling to the 1-carboxymethyluracil 1. EDC was again 
used as a coupling reagent as it was thought the by-product produced, 1-ethyl-3-(3’- 
dimethylaminopropyl)carbourea (EDU) could be simply removed by washing with 
water. Coupling with the propyl and butyl chains were successful, though initially the 
yields were low. It was found that by avoiding aqueous work up yields could be 
increased from 25% to 68%. The EDU could still easily be removed by purification on a 
silica gel column.
Scheme 4-7: Coupling of the protected amino alcohols to 1-carboxymethyluracil
1-Carboxymethyluracil in DMF was added to the relevant TBDPS-oxyamine in 
DMF and EDC in a solution of DMF was then added. The reaction was performed 
under N2 and left overnight for completion.81
This method was successful for the propyl (n=3) and butyl (n=4) derivatives. In 
the case of the ethyl chain derivatives however, no coupling was achieved and only 
starting material was recovered. The reaction was attempted at higher temperatures 
and also using dicyclohexylcarbodiimide (DCC) as a coupling reagent but proved 
fruitless. There may have been too much steric hindrance around the amino function 
for the reaction to occur due to the presence of the bulky TBDPS group attached to the 
p-oxygen. With the longer propyl and butyl chains, it is possible for the amino function 
to extend out further and attack the activated intermediate. The failure of the reaction 
may also have been due to the inductive effect of the (3-oxygen which would result in 
reducing the nucleophilicity of the amino group rendering it less reactive. This p-oxygen 
effect is not present in the propyl and butyl derivatives.
EDC is a carbodiimide coupling reagent84 and is often used as its product of 
reaction EDU is water soluble.86 The mechanism of carbodiimide mediated amide bond 
formation is shown in Scheme 4-8.
84 Sheehen, J. C.; Hess, G. P. A new method of forming peptide bonds. J. Am. Chem. Soc. 
1955, 77, 1067-1068.
85 Sheehen, J. C.; Cruickshank, P. A.; Boshart, G. L. A convenient synthesis of water-soluble
carbodiimides. J. Org. Chem. 1961, 26, 2525-2528.
EDC, DMF, 18h
O
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The protonated carbodiimide (i) undergoes nucleophilic attack by the 
carboxylate, forming the activated O-acylisourea intermediate (ii) which after a 
reprotonation will form a delocalized carbocation (iii). A nucleophilic addition-elimination 
reaction by the amine then results in the release of the desired amide and the 
carbourea (iv).
O R2
II + n=C=N . .... w
R OH R;
N=C=NH
(iii)
Ri R2 
H N ^ N HT
o
,Xn-R4
O H
(iv)
Scheme 4-8: Mechanism of carbodiimide mediated amide bond formation86'87r88
4.2.3.3 Desilylation
The standard utilisation of tetrabutylammonium floride (TBAF) to cleave the 
TBDPS group83 proved difficult as the product could only be isolated in the water layer 
from the aqueous work up as the TBAF salt. Desilylation was carried out, therefore 
using the methanolic hydrochloride method which avoided work up and proved to be a 
clean reaction.89 The product could then be recrystalised from ethanol. The mechanism 
involves protonation of the silyl oxygen and then attack of a water or hydroxide 
molecule on the silicon to release silanol and the desired alcohol.
NH NH
MeOH, HCI
n 10, n = 3,65% 
O 11,n = 4, 52%O
Scheme 4-9: Removal of the TDBPS protecting group
86 Rebek, J.; Feitler, D. Improved Method for Study of Reaction Intermediates - Mechanism of 
Peptide Synthesis Mediated by Carbodiimides. J. Am. Chem. Soc. 1973, 95, 4052-4053.
87 Nakajima, N.; Ikada, Y. Mechanism of Amide Formation by Carbodiimide for Bioconjugation in 
Aqueous-Media. Bioconjugate Chemistry 1995, 6, 123-130.
88 Marder, O.; Albericio, F. Industrial application of coupling reagents in peptides. Chimica Oggi- 
Chemistry Today 2003, 21, 35-40.
89 Magaraci, F. Design and synthesis of novel potential 24-methyltransferase inhibitors. In 
Welsh School of Pharmacy, University Wales Cardiff: Cardiff, 2002.
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4.2.3.4 Tritylation
5N xo NHh N
u V
TrtCI, Pyridn IAP, 70°C, 4d
12, n = 3
13, n = 4
Scheme 4-10: Attempted tritylation 10 and 11
The tritylation of both the propyl and butyl chain derivatives was attempted by 
dissolving DMAP, TrtCI and the starting material in pyridine. However after one week, a 
total of 4 eq TrtCI had been added and the mixture was heated 70°C and still no 
product could be seen by TLC. Only starting material was isolated.
4.2.4 Synthesis of the triphenylmethylamino derivatives
4.2.4.1 Tritylation
0.1M equivTriCI, DCM, RT, 18h
iNH2 N ^ H 2
14, n *  2, 51%
15, n = 3, 20%
16, n = 4, 31%
Scheme 4-11: Mono tritylation of diamines
In the case of the diamino alkyl series, the compounds were mono-tritylated 
selectively by using 0.1M equivalents of TrtCI and adding it dropwise at 0°C.90 By mass 
spectrometry and integration of NMR it was found that only the mono-tritylated 
compound had been isolated. The second amino moiety was therefore free to react 
with the 1-carboxymethyluracil.
90 Tilley, J. W.; Levitan, P.; Kierstead, R. W.; Cohen, M. Antihypertensive (2- 
Aminoethyl)Thiourea Derivatives .1. J. Med. Chem. 1980, 23, 1387-1392.
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4.2.4.2 Coupling with 1-carboxymethyluracil
A
H
EDC, DMF, RT, 18h 
No work up
+
HO- NH
17, n = 2, 33%
18, n = 3, 42%
19, n = 4, 26%
Scheme 4-12: Coupling of mono tritylated diamines to 1-carboxymethyluracil
EDC was again used as the coupling reagent as it could be easily separated 
from the product. The procedure was the same as that described in 4.2.1.2 and the 
mechanism of EDC coupling is shown in scheme 4-8. In contrast to the TBDPS 
derivatives, the reaction was successful with n=2. This was probably due to the 
absence of the p-oxygen effect in the Trt-amino derivatives
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4.3 Triphenylmethylamino and hydroxy (triphenyl 
methyl)amino dialkyl chain derivatives -  coupling 
of secondary amines to 1-carboxymethyluracil
Subsequent to the synthesis of monoalkyl chain acetamide uracil derivatives, 
dialkyl chain derivatives were synthesised. The extra “arm” on these molecules could 
be used to probe for extra interactions as well as steric tolerance within the active site 
of the enzyme.
The overall synthetic strategies were as follows:
H TBDPSCI H TrtCI, DCM
H O ^ ^ N^ ^ N H ,  -----------► T B D P S O ^ ^  " ^ N H 2 ------------- --
TBDPSCT
1-CU
DCC, DhbtOH NH TBAF NH
NHTrt
O,
NTBDPSO NHTrt HO NHTrt
Scheme 4-13: Overall synthetic strategy for hydroxy diamino compounds 1-CU = 1-
carboxymethyluracil
H2N'^'nN'H'rNH2   — CbZHN^N^NHCbZ  CbZHN NHCbZ
H O H ° O'
NH 0 _ N .
N-O
O o
O
T  TrtCI, 0°C f  T  if  NLH
H2 Pd/C ^ N ' ^ r )  Slow addn. ^ n O + N ^ x )
,0  ^  k ^ O  k / . O
H2N ^ N ^ N H 2 H2N ^ .N ^ N H T r t  T r tH N ^ N ^ N H T r t
n n n n n n
Scheme 4-14: Overall synthetic strategy for the triamino compounds
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4.3.1 Triphenylmethylamino dialkyl chain derivatives
4.3.1.1 Carbobenzoxy protection of primary amines
2 days, RT
^ nNH r
CbZ-imidazole
CbZHNA r nA tyJHCbZ 
H
A
O
21, n = 2,2, 9%
22, n = 3,3, 35%
23, n = 3,4, 38%
20 0°C
RT 10mins 
80%
O
Scheme 4-15: Carbobenzoxy protection of primary amines
As coupling of 1-carboxymethyluracil to the secondary amine of these 
compounds was required, the first step was to selectively protect the terminal, primary 
amines of the starting triamino compounds. It can be argued that the more nucleophillic 
secondary amine will react more readily with electrophiles and therefore selective 
protection may be difficult. However, the primary amines are more reactive for steric 
reasons and this can be exploited for selective primary amino protection. By using 
bulky protecting groups it has been found that selective primary amino over secondary 
amino protection can be achieved.91,92
Much work has been carried out on developing methods for the selective 
functionalisation of spermidine and other naturally occurring polyamines. Reagents 
such as 3-benzyloxycarbonyl-1,3thiozolidine-2-thione,93 and [2-(tert-butoxycarbonyl 
oxyimino^-phenylacetonitrile94 have been used for this purpose.
91 Sharma, S. K.; Miller, M. J.; Payne, S. M. Spermexatin and spermexatol: new synthetic 
spermidine-based siderophore analogues. J. Med. Chem. 1989, 32, 357-367.
Alummoottil, V.; Scott, J.; Scott, J. R. A simple ethod for the bis-acylation of the primary 
amino groups in spermidine an dother linear triamines. Tetrahedron Lett. 1984, 25, 5725-5728.
93 Nagao, Y.; Miyasaka, T.; Hagiwara, Y.; Fujita, E. Total Synthesis of Parabactin, a Spermidine 
Siderophore. J. Chem. Soc., Perkin Trans. 1 1984, 183-187.
94 Bergeron, R. J.; Stolowich, N. J.; Porter, C. W. Reagents for the Selective Secondary N- 
Acylation of Linear Triamines. Synthesis-Stuttgart 1982, 689-692.
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Carbobenzoxy-imidazole (CbZ-imidazole) has also been shown to selectively 
protect an unhindered primary amine in the presence of hindered primary and 
secondary amines and this reagent is easily prepared by treatment of CbZ-CI with 
imidazole.91 It was the reagent of choice in this case.
CbZ-imidazole was prepared by reaction of CbZ-CI with imidazole at 0°C and 
then at room temperature for 10min. After washing with citric acid to remove the side 
product of imidazole, the pure product was isolated in good yield.91
The relevant triamines were reacted with the CbZ-imidazole in the presence of 
a catalytic amount of dimethylaminopyridine (DMAP).91 The reaction proved to be more 
difficult with the shorter chain (n=2) analogues. It was found aqueous work up had to 
be avoided as the amines could not be recovered from either the organic or aqueous 
phase. After attempts at recrystallisation from various solvents, it was found that the 
best method for purification was column chromatography. The eluent had to have a 
high percentage of MeOH and some NH3 present to prevent the amines from sticking 
to the acidic silica in the columns. For n=2,2 the fractions collected were washed 
further with H20. For n=3,3 recrystallisation of the pure product from the fractions 
collected could be achieved from EtOAc. For n=3,4 the fractions collected were 
washed with 0.5% w/v HCI to remove imidazole after which the remaining impurities 
were precipitated out form CHCI3.
4.3.1.2 Coupling of 1-carboxymethyluracil to secondary amines
It has been proposed that in compounds such as these triamines, especially 
where n=3,4, intramolecular hydrogen bonding can be responsible for the reduction in 
nucleophilicity of the secondary amino group.93
However, use of appropriate coupling reagents can overcome this barrier. For 
n=3,3 and n=3,4 coupling reactions were successful with the use of the activated 
succinimidyl ester of 1-carboxymethyluracil in the presence of a catalytic amount of 
DMAP.91
O
A
Scheme 4-16: Intramolecular hydrogen bonding on triamines93
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o  o CbZHN \ r^HCbZ
n DCC ft
r, NH n  0°C, 3hr f| NH DMAP O
A  RT24hr, °  l A n  3d'60°c ,
HOV + 1 ^cC 10% WN V  CbZHN'H'nN^, HNrlMHCbZ
6  0  b  o  H 0
25, n = 3,3, 69%
26, n = 3,4, 89%
Scheme 4-17: Coupling of 1-carboxymethyluracil to secondary amines (n=3,3 or 3,4)
The succinimidyl ester of 1-carboxymethyl uracil was prepared by adding a 
solution of DCC to a mixture of N-hydroxysuccinimide (NHS) and 1- 
carboxymethyluracil at 0°C. The succinimidyl ester could be precipitated out form 
MeOH and was isolated in quantitative yields. The mechanism of carbodiimide ester 
formation is similar to that shown in Scheme 4-8. The OH group of the NHS acts as the 
nucleophile which attacks the activated intermediate (iii), releasing the ester and urea 
by-product.
This activated succinimidyl ester and relevant protected triamine along with a 
catalytic amount of DMAP were dissolved in DMF under N2. Reactions were heated to 
60°C for 3d. It was found that after work up, no product could be isolated. Therefore 
aqueous work up was avoided. It was also found that 24 was completely decomposed 
after 2 months, even at -18°C and should be newly synthesised for the reaction to take 
place. The pure product (25 and 26) was obtained in good yields after recrystallisation 
from EtOAc. The mechanism is as follows:
O O
NH
N-O.
R
NH
Ri
N
Scheme 4-18: Coupling to activated succinimidyl ester
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Where n=2,2, however, this coupling procedure resulted in very low yields of 
still impure product being isolated. This was most likely due to steric hindrance around 
the amino function due to the shorter alkyl chain lengths to which the CbZ group was 
attached. An alternative coupling procedure using DCC as a coupling reagent and 3- 
hydroxy-1,2,3-benzotrian-4(3H)-one (DhbtOH) as an activating agent was therefore 
used.95
1-carboxymethyluracil and DhbtOH were added to a solution of the protected 
triamine in DMF under N2 atmosphere. After cooling to 0°C, a solution of DCC in DMF 
was added. The mixture was left stirring at 0°C for 1h and then at RT for 2 days after 
which time a precipitate had formed. The side product, DCU was removed by 
precipitation from EtOAc. The product was then precipitated out of the remaining 
solution with diethyl ether.
Scheme 4-19: Coupling of 1-carboxymethyluracil to secondary amines(n=2,2)
The mechanism of this reaction is as follows with the initial reaction of 
carbodiimide activation as described is Scheme 4-8 followed be reaction with DhbtOH 
to give an activated ester intermediate which then undergoes nucleophilic attack by the 
amine to release the desired amide.96 97
95 Wenninger, D.; Seliger, H. Synthesis and Hybridization Properties of Modified 
Oligonucleotides With PNA-DNA Dimer Blocks. Nucleosides Nucleotides 1997, 16, 977-980.
96 Konig, W.; Geiger, R. A New Method for Synthesis of Peptides - Activation of Carboxy Group 
with Dicyclohexylcarbodiimide and 3-Hydroxy-4-Oxo-3,4-Dihydro-1,2,3-Benzotriazine. 
Chemische Berichte-Recueil 1970, 103, 2034-&.
97 Atherton, E.; Holder, J. L.; Meldal, M.; Sheppard, R. C.; Valerio, R. M. Peptide-Synthesis .12. 
3,4-Dihydro-4-Oxo-1,2,3-Benzotriazin-3-YI Esters of Fluorenylmethoxycarbonyl Amino-Acids as 
Self-Indicating Reagents for Solid-Phase Peptide-Synthesis. J. Chem. Soc., Perkin Trans. 1 
1988, 2887-2894.
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Scheme 4-20: Mechanism of coupling with DCC and DhbtOH
4.3.1.3 Deprotection of acylated primary amines - removal of the CbZ 
group
0 o
fl NH (I NH
H2, Pd/c, MeOH/EtOH I  28, n = 2,2 41%
1  ► ^ I 29, n = 3,3 50%
30, n = 3,4 69%
CbZHN ^  N ^  N HCbZ H2N ^  N ^  NH2
Scheme 4-21: Deprotection of primary amines
Removal of the CbZ group can be easily achieved by hydrogenation.91 
However, this must be carried out selectively in the presence of the uracil ring which 
may also be hydrogenated at the double bond. It has been shown previously that no 
hydrogenation of the uracil ring occurs when 5% Pd/C is used as a catalyst.98 Under 
these conditions, using MeOH:EtOH as solvent, selective hydrogenation using a 
hydrogen balloon was successful.
It has been reported that N—>N acyl migration may occur with compounds such 
as these when in solution at room temperature.95
98 Ruda, G.-F. Design and synthesis of potential inhibitors against dUTPase, a novel drug target 
for the control of protozoal and bacterial infections. In Welsh School of Pharmacy, University of 
Wales, Cardiff: Cardiff, 2005.
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NH NH
<20% piperidine in DCM 
25°C, 1h
NHFmoc Acyl migration TBDPSO NHTBDPSO
NHNH
10% piperidine in DCM 
0°C, 0.5h
No acyl migration
TBDPSOTBDPSO NHFmoc
Scheme 4-22a: N,N acyl migration reported by Wenniger et al.,96
OA,NH
N,N acyl migration
O
O
A nk
[ A o
H2N t ) ^ N^ 0 ; N H
H O
h 2n ^ V n ^ ; nh
Scheme 4-23b: N,N acyl migration
NMR analysis of the products of this reaction as shown below, suggested that 
acyl migration to the terminal amino group had taken place to some extent, leading to a 
mixture of products (28, 28a and 29, 29a). This was seen by the fact that the 
CH2NUracil peaks and CH2NH2 peaks were not pronounced trip lets as previously 
observed and instead were a mixture of multiplets. Peaks corresponding to the two 
isomers could also be seen in the 13C NMR.
Figure 4-1: NMR analysis of 28. Inset: expansion of CH2NUracil and CH2NH2 peaks
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Di-alkyl chain derivatives
CbZHN
NH
CbZHN^^^-^N.
NH NH
29a
6 . 0  5 . 0  4.0  3 . 0  2 . 0  1 . 0
"Figure 4-2: NMR analysis of 29. Inset: (top) expansion of CH2NUracil and CH2NHCbZ peaks 
from 25, clear triplets can be seen (bottom) expansion of CH2NUracil and CH2NH2 peaks from
29, triplets are no longer pronounced
CbZHN. b
NH
CbZHN
H2N
NH NH
H,N
30a
V  \
6 . 0  5 . 0  4 . 0  3 . 0  2 . 0
p p m  (fl)
Figure 4-3: NMR analysis of 30. Inset: (top) expansion of CH2NUracil and CH2NHCbZ peaks 
from 26, clear triplets can be seen (bottom) expansion of CH2NUracil and CH2NH2 peaks from
30, triplets are no longer pronounced
It is probable that the two isomers of 28 and 29 are interconverting structures in
equilibrium and that this equilibrium is shifted to the right by the addition of the trityl
group to one of the terminal amines. As explained in section 4.3.1.4, the presence of
the bulky trityl group would favour the isomer in which the uracil acetamide is on the
terminal nitrogen due to steric hindrance which is shown to be the evident case.
- 6 3 -
4 Trityl-amino and TBDPSoxy uracil acetamide derivatives
4.3.1.4 Mono and di trytilation of the diamino acetamide compounds
N "O
O.
NH TrtCI, 0°C, Slow addn. ||
70°C, 24h + NA i
H2N ^ |N ^ N H 2 H2N ^ N ^ N H T r t  T rtH N ^N ^N H Trt
31, n = 3,3 33, n = 3,3
32, n = 3,4 34, n = 3,4
Scheme 4-24: Tritylation of diamino acetamide compounds (n=3,3 n=3,4) * Putative structures
It was thought that monotritylation of these compounds could be achieved by 
slow addition of TrtCI (over 3h) at 0°C to a very dilute solution of the diamino acetamide 
compound. For n=3,3 and n=3,4, tritylation was attempted in this way. Pyridine was 
used as a solvent due the insolubility of the compounds in DCM. This reaction, 
however proceeds more slowly in pyridine that in DCM and after 24h, a lot of starting 
material remained. The reactions, therefore, were heated to 70°C and left stirring for a 
further 24h in order to bring them to completion. For n=3,3, a mixture of mono and 
ditritylated compounds was obtained. These were separated by column 
chromatography. Some of the tritylated and CbZ protected side product, 31b (Figure 4- 
10), present from the previous reaction, was also isolated. For n=3,4, no products 
could be isolated and only unidentifiable impurities were obtained.
For n=2,2, tritylation was carried out in CHCI3 in the presence of Et3N at RT. 
Although initially the starting material was quite insoluble, on addition of TrtCI the 
solution became less cloudy. The insolubility of the starting material was therefore 
insignificant as the intermediate formed was soluble and the reaction proceeded 
nevertheless. In contrast to the pyridine method, this reaction was complete after only 
2h and did not require heating. Mono and di tritylated products were separated by 
column chromatography.
S T ~
n ^ S d
y
'  ^  NH2 H2N' ^  'NHTrt T r tH N '" ^ N's^ A H T r t
35 36
Scheme 4-25: Tritylation of diamino acetamides (n=2,2) * Putative structure
NH
U 1  TrtCI, EtN3, DCM 
RT 2h
N. N
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NMR analysis of the mono-tritylated compounds again revealed that N—>N 
migration had taken place. In this case it could be proven by comparison of the 
integration of the CH2NUracil (2H instead of 4H) and the CH2NHX peaks (4H instead of 
2H). The expected 1H NMR would show: a triplet at 2.2ppm corresponding to 2 protons 
from CH2NHTrt, a multiplet at 2.6ppm corresponding to 2 protons from CH2NH2 and a 
multiplet or 2 triplets at 3.3ppm corresponding to 4 protons form CH2NUracil. Instead 
what is observed in the 1H NMR is: a triplet at 2.2ppm corresponding to 2 protons from 
CH2NHTrt, a multiplet at 2.6ppm corresponding to 4 protons from CH2NH and a triplet 
at 3.3ppm corresponding to 2 protons form CH2NUracil (Figure 4-4 and 4-5)
The effect was even more pronounced in this case and it could be seen that 
migration had occurred 100%, where as previously, a mixture of migrated and un­
migrated products was isolated (28, 28a and 29, 29a). The presence of the bulkly trityl 
groups in compounds 31 and 35 most likely favoured migration of the carboxymethyl 
uracil to the term inal N for steric reasons.
O n
N,N acyl migration, 
isomers in equilibrium
Bulky terminal group 
attached and equilibrium 
shifted to the right
Scheme 4-26: Equilibrium of N, N acyl migration
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H N 40CX
H N
30CX
20CX
10CX
0
T
8.0 7.0 6.0 5.0 4.0 3.0 2.0
ppm (f1) a
Figure 4-4: H NMR of 31. Inset: expansion of CH2NH peaks and their corresponding
integrations
HN
15CK
HN.
a, a
5CXX
I j y  w  L J  U 0
8.0 
ppm (f1)
7 .0 6.0 5 .0 4 .0 3 .0 2.0 1.0 0.0
Figure 4-5: 1H NMR of 33. Inset: expansion of CH2NH peaks and their corresponding
integrations
- 6 6 -
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4.3.2 Hydroxy(triphenylmethyl)amino dialkyl chain derivatives
Once again, for these compounds, the terminal functional groups must first be 
protected in order to couple the secondary amine to 1-carboxymethyluracil. The 
protecting groups must be orthogonal in order that they be selectively cleaved at the 
end. The initial strategy was to use that of Wenniger et a/;95 That is to first protect the 
hydroxyl function with the TBDPS group which is cleaved under acidic conditions or by 
TBAF. Fmoc-succinimide can then be used to selectively protect the terminal amino 
group. After amide coupling has been carried out, the Fmoc group can be cleaved. The 
amino group then tritylated and finally the TBDPS group cleaved using TBAF.
I_l TBDPSCI Fmoc-succ
H0— N— NH2 -----------^  T B D P S O ^ - n ^ N H 2  -
H O
NH
H 1-CU, DCC, DhbtOH Pipendine
TBDPSOVn^ xv^ N Vv^ ' - \ /  NHFmoc N u
O;
TBDPSO>Sn^ \ s^ N Vv /^ \ ^  NHFmoc
O O
'NH (| NH [| NH
A c  TrtCI l NA 0  MeOH, HCI k NA Q
j  O,
T B D P S O ^ ^ ^ n ^ ^ / N H z TBDPSOV v /- ^ N . s^ / \ / NHTrt H O .^ ^ v ^ N ^ ^ — ^ N H T rt
Scheme 4-27: Strategy of Wenniger et al;
If, however we can use the trityl moiety as a protecting group for the terminal 
amino group in the beginning, this would eliminate 2 steps form the synthesis. It was 
also thought this would be a way in which to avoid acyl migration form occurring as the 
amino group would be protected throughout the synthesis and a deprotection step 
would be not be necessary. The modified overall synthetic strategy is shown in 
Scheme 4-13.
4.3.2.1 Protection of the hydroxyl moiety
H TBDPSiCI, pyridine H
37Ho/ \ ^ N\ ^ ' N H 2 24h, RT, 32%  ^ t B D P S O ^ ^ I I^  'NH:
Scheme 4-28: Protection with the TBDPSi group
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As mentioned previously, (4.2.3.1) the TBDPS group is a good protecting group 
for selectively protecting hydroxyl groups over amines. The reaction was carried out 
simply by adding TBDPSCI to N-(2-hydroxyethyl)ethylendiamine under N2 using dry 
pyridine as the solvent.95
TrtCI, DCM, Et3N
0°C, RT 24h H * *
NH2 ---------------------------T B D P S O ^ ^  ^^"N H Trt
63%
Scheme 4-29: Tritylation of primary amine
Selective tritylation was carried out by slow addition of a dilute solution of TrtCI 
to 38 at 0°C followed by addition of Et3N. The terminally substituted product was 
confirmed by a change in shift of the CH2NH2 protons by 0.5 ppm but no change in shift 
for the CH2NHCH2 peaks.
H
,  ^  - N .TBDPSO
4.3.2.2 Coupling to 1-carboxymethyluracil
r *
TBDPSO" ^  'NHTrt ----------------------- 52%-----------------► O.
N H1-(carboxymethyl)uracil, DCC, DhbtOH, II i 
H 0°C 1 h, RT 24h
N.
39
T B D P S O ^ ^  N ^ ^ "N H T rt
Scheme 4-30: Coupling to 1-carboxymethyluracil
Coupling to 1-carboxymethyluracil was carried out by the DCC/DhbtOH method 
described in section 4.3.1.2 and the mechanism is shown in Scheme 4-20. The pure 
product was precipitated from MeOH.
4.3.2.3 Deprotection -  removal of the TBDPS group
:   O '.'. o
NH fi NH
I TBAF, THF [| I
N ^ o  RT, 30min  ^ N ' x )
78% 40
TBDPSO' 'x /N x x ^NHTrt H O '^ v /N 's^ " "NHTrt
Scheme 4-31: Removal of the TBDPSiCI protecting group
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As described before, the TDBPSiCI group can be cleaved in mild conditions 
using HCI in MeOH or TBAF. It was thought that in this case, however, the Trt group 
might also be cleaved under the acidic conditions used previously. The method of 
using TBAF to cleave the TBDPS group was therefore employed and the product was 
obtained after purification by column chromatography.
4.4 Tritylamino phosphate dialkyl chain derivatives
It was thought that one of the branched chains of these compounds might be 
orientated is such a way in the active site of the enzyme as to interact with the 
phosphate binding site. Therefore a phosphate moiety was attached to the hydroxyl 
group of 40 to probe for interactions and to investigate as to whether this would 
increase binding affinity of the molecules.
A phosphate with protecting groups that could be cleaved selectively in the 
presence of the Trt groups was needed. It was at first thought that 2-cyanoethyl 
protected phosphates, which can be deprotected in basic conditions," would be useful 
in this case as the Trt group is stable under basic conditions. However, all literature 
methods involved purification on acidic ion exchange columns" in which the Trt group 
would almost certainly be cleaved off. This method was therefore rejected.
Benzyl protected phosphates are deprotected by hydrogenation.100 This is by 
far the simplest method of phosphate ester synthesis as purification is carried out 
simply by filtration through celite. Although the Trt group is also considerably labile 
under hydrogenation conditions, the benzyl groups are much more labile and it has 
been shown previously within the group that selective cleavage of these benzyl groups 
can be carried out in the presence of the Trt group under mild conditions.98
99 Tener, G. M. 2-cyanoethyl Phosphate and it Use in the Synthesis of Phosphate Esters. J. Am. 
Chem. Soc. 1961, 83, 159-168.
100 Yu, K. L.; Fraserreid, B. A Novel Reagent for the Synthesis of Myoinositol Phosphates - N,N- 
Diisopropyl Dibenzyl Phosphoramidite. Tetrahedron Lett. 1988, 29, 979-982.
O O n
HO'
^NH i) LiOH, MeOH, HzO
is. ii) H+ ion exchange
NH
I  NCCH20 P03H2i DCC, Pyridine
D epro t + Trt cleavage O.
NHTrt NHTrt
NC
Scheme 4-32: Use of cyanoethyl protected phosphates
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i) (BnO)2PN(/-Pr)2, Tetrazole, DCM NH NH5%  Pd/C, H2 
2h
Selective deprotection O-
NHTrtHO' O - P - O NHTrt H O -P -O
OH
NHTrt
Scheme 4-33: Use of benzyl protected phosphates
4.4.1 Synthesis of benzyl protected phosphate ester
N O
N'i
p
BnO" ^O B n . Tetrazole, DC M , R T  90min
NHTrt
ii) f-BuOOH, -40 °C  15min, R T  20min
55% O - P - O NHTrt
Scheme 4-34: Synthesis of benzyl protected phosphate ester
The synthesis was carried out by reacting 40 with A/,/V-diisopropyl dibenzyl 
phosphoramidite to form the intermediate phosphite ester by displacement of the N(i- 
Pr)2 moiety.100 The reaction was carried out in the presence of an excess of 1 -H- 
tetrazole which is thought to act as both an activator of the phosphoramidite and as a 
scavenger of the generated amine (scheme 4-33).101 A precipitate forms during the 
course of the reaction, shown to be the dialkylammonium tetrazolide salt, the formation 
of which may drive the reaction.102
Compound 40 was treated with an excess of phosphoramidite at RT in the 
presence of an excess of tetrazole. After 90 min the reaction was complete.
101 Hayakawa, Y.; Kataoka, M. Preparation of short oligonucleotides via the phosphoramidite 
method using a tetrazole promoter in a catalytic manner. J. Am. Chem. Soc. 1997, 119, 11758- 
11762.
102 Chow, C. P.; Berkman, C. E. Synthesis of N-phosphoryl amino acids via phosphoramidite 
amine-exchange. Tetrahedron Lett. 1998, 39, 7471-7474.
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Bncr, OBn
Tetrazole as amidite 
activator
H
N -N
<S*
o
I
BnCrf^OBn
NucOH
NH
BnO
P-O' NHTrt
BnO
Phosphite ester
N "N ----------N
Tetrazole as amine 
scavenger
.NH2
Dialkylammonium 
tetrazolide salt
Scheme 4-35: Mechanism of tetrazole mediated phosphate formationT02
Following the generation of this phosphite ester, oxidation to the phosphate 
ester was then carried out in situ using f-butylhydroperoxide as an oxidising agent, t- 
BuOOH was added to the solution at -40°C, which was allowed to remain stirring at this 
temperature for 15 min and a further 40 min at RT. The pure product was isolated in an 
overall 55% yield after purification by column chromatography.
4.4.2 Deprotection of the benzyl phosphate ester
Removal of the benzyl protecting groups was carried out by selective 
hydrogenation in mild conditions. 5% Pd/C in 5% w/w was sufficient to cleave the 
benzyl groups from the molecule without cleaving the Trt group.
NH
o - P - o NHTrt
5%  Pd/C (5% w/w ), H2, M eO H
H O - P - O NHTrt
Scheme 4-36: Cleavage of benzyl protecting groups from phosphate ester
The reaction was firstly attempted in a THF:H20, 50:50 mixture as solvent. 
However, no product was isolated and this was thought to be due to the insolubility of 
the starting material. The reaction was then repeated using MeOH as solvent and 
hydrogenation was successful. The catalyst was removed by filtration through celite but 
washing with DMF was necessary as the product was highly insoluble in MeOH, EtOH, 
H20, CHCI3 and acetone.
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4 Trityl-amino and TBDPSoxy uracil acetamide derivatives
4.5 Restricted rotation around the amide bond and 
variable temperature NMR
Rotation about single bonds is normally very fast in contrast to rotation about 
double bonds which is normally very low or non-existent. The C-N bond in an amide 
has partial double bond character due to delocalisation of the lone pair on the nitrogen 
into the carbonyl group.
Qb, o
r^ * ' r
o
X  S+R
r^ " V r 
2 FT_____________________R"___________________ R ___
Scheme 4-37: Delocalization in an amide group 
Often, slow rotation around the amide bond can mean that two isomers, or 
more specifically rotamers, cis and trans exist. Both of these rotamers can often be 
seen by NMR spectroscopy and the ratio in which they exist can be measured from the 
integration of the relevant peaks. Normally, where R are large substituents, the trans 
conformation would be the more stable. The rate at which the two isomers interchange, 
however depends on the energy of activation (Ea) of their rotation.
R groups cis
R groups trans
180°90°
Figure 4-6: Energy profile diagram of rotation about amide bond
The energy of activation is the energy which is required to overcome the barrier 
to rotation. Not only does this depend on the R groups, but according to the Arrhenius 
equation, the rate at which rotation occurs also depends on temperature.
k - A e
-£a'|
~ R T  J
Equation 1 : (k = rate coefficient, A = pre-exponential factor, Ea = activation energy, 
R = 8.314J 1C1 mof1, T = temperature in Kelvin)
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Increasing the temperature of the system can supply the molecules with 
sufficient energy to overcome the barrier of rotation. This is the basis for variable 
temperature NMR. Carrying out NMR experiment at a higher temperature will supply 
energy to the system such that free rotation about the amide bond becomes easier. 
The two isomers interconvert more rapidly and the structures are averaged out. The 
result is that the NMR peaks converge and the splitting in reduced.
Peak splitting due to restricted rotation around the amide bond was quite 
evident in some of the compounds synthesised. The effect was especially pronounced 
in compounds 39 and 40. With compound 39 all peaks were evidently split and the 
presence of two isomers if not two compounds was obvious. From integration of the 
peaks it was calculated that at RT the isomers existed in a ratio of 2:3.
NH
N ^ O
O
NH
( A o
S'O, 5' CX
TBDPSO'
_ . N . _  
~  5+ ^  
Rotamer 1
NHTrt TrtHN' 'OTBDPS
Rotamer 2
Scheme 4-38: 2 possible rotamers of compound 39
1°
■ i l l  i  .1 ll
1 i  n i  i i  ■V ' V, v * L J  < J J U “ u ^  U L /J  W j ^ J j v v *.__ a J  '
Figure 4-7: 1H-NMR of compound 39
After desilylation, removal of the bulky protecting group probably reduced the 
barrier to rotation significantly as the peak splitting of compound 40 was not as 
noticeable but was still present. To prove that the peak splitting was due to the 
presence of two isomers and not due two different compounds being formed, a variable 
temperature NMR experiment was carried out on compound 40.
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The experiment was carried out in CD3OD at RT and then at 40°C. In the event 
of unrestricted rotation, the protons in position ‘a ’ would be expected to resonate as a 
singlet (e.g compound 1). However, in this case, two singlets were observed. On 
heating, the peaks converged and the splitting of N-1(CH2) (a, a ’ Scheme 4-39) 
reduced from 0.04ppm to 0.01 ppm. The protons in position ‘b ’ would be expected to 
resonate as 2 sets of triplets in the case of unrestricted rotation. In this case, four sets 
of triplets were observed. Once again, however, these CH2 started to converge on 
application of heat to the sample. This proved that peak splitting was due to restricted 
rotation around the amide bond.
o
An t  ( jr
N " X )  N ^ O
8V a 8V a'
H O  N H Trt T rtH N  O Ho b  O b
Rotamer 1 Rotamer 2
Scheme 4-39: 2 possible rotamers of compound 40
Figure 4-8: 1H-NMR of 40. Top. Full spectrum of 40 at RT (blue) and at 40°C(black). Bottom: 
Expansion of CH2 multiplets at RT (blue) and at 40°C (black). Experiments were carried out in
MeOD
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Biological results: P. falciparum
4.6 Biological results: Trimeric dUTPases and 
falciparum parasites
As the design of these compounds was based on lead inhibitors of the P. 
falciparum  dUTPase, they were tested on this (trimeric) form of the enzyme initially. 
They were also tested against the human dUTPase enzyme to determine selectivity. 
For assay procedures see appendix 1.
Figure 4-9: Mono-alkyl chain uracil acetamide derivatives
Compound Enzyme assay Kj(pM) In vitro assay IC50(mM)
P. falc Human S la P. falciparum ToxicityD
Amino mono-alkyl chain derivatives
17 37.3 >1mM >26 4.2 53.0
18 23.1 >1mM >43 2.5 102.2
19 >1mM >1mM >1 2.9 42.7
2 >1mM >1mM >1 2.0 1.1
3 >1mM >1mM >1 2.3 8.8
iOxy mono-alkyl chain derivatives
8 >1mM >1mM >1 4.6 88.9
9 >1mM >1mM >1 3.7 33.4
4 >1mM >1mM >1 >83.0 >373
5 >1mM >1mM >1 1.2 6.3
6 >1mM >1mM >1 1.4 4.1
11 >1mM
_
>1mM >1 1.0 4.0
Table 4-2: Biological results of mono-alkyl chain derivatives against the trimeric dUTPase and 
in vitro results against malaria parasites, a) Sl=selectivity 
index[Kj(humandUTPase)/Ki(PfdUTPase)] b) Toxicity tests were carried out L6 cells
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Figure 4-10: Di-alkyl chain uracil acetamide derivatives
Compound Enzyme assay Kj(pM) In v itro  assay IC50(pM)
P. fate Human S Ia P. falciparum ToxicityD
Diamino di-alkyl chain derivatives
__ I
27 >1mM >1mM >1 >9 >172.0
28 >1mM >1mM >1 >19.6 >352.6
35 >1mM >1mM >1 4.48 52.7
.
36 >1mM >1mM >1 0.4 >121.64
29 >1mM >1mM >1 15.4 >317.7
31 >1mM >1mM >1 3.9 76.7
31b >1mM >1mM >1 0.5 43.2
33 >1mM >1mM >1 0.3 >117.2
Oxy amino di-alkyl chain derivatives
40 >1mM >1mM >1 5.6 nd
41 >1mM >1mM >1 nd nd
42 >1mM >1mM >1 nd nd
Table 4-3: Biological results of di-alkyl chain derivatives against the trimeric dUTPase and in 
vitro results against malaria parasites, a) Sl=selectivity index 
[Ki(humandUTPase)/Ki(PfdUTPase)] b) Toxicity tests were carried out on L6 cells
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4.6.1 Results and discussion
■  Trt amino
■  Acyclic analogues 
B No uracil ring
1000
Toxicity
Figure 4-11: Inhibitory activity of Trt-amino uracil acetamides on PfdUTPase and on P. 
falciparum parasites compared with their acyclic analogues
Figure 4-12: Acyclic analogues 43 and 44
Two of the Trt-amino uracil acetamide compounds 17 and 18 exhibited weak 
but selective inhibition of the PfdUTPase enzyme (Kj = 37.3, 23.1 pM respectively). 
However, the activity of these compounds against the enzyme was somewhat 
diminished in comparison with their acyclic analogues 43 and 44 (Kj = 4.29, 1.84 pM 
respectively). It would therefore seem that introduction of an amide bond is 
unfavourable for the inhibitory action of these nucleoside derivatives against the 
PfdUTPase.
Despite their lack of activity as inhibitors of the dUTPase enzyme, some of 
these compounds show quite potent anti-parasitic activity in vitro. Compounds 17, 18 
and 19 exhibit inhibition of parasite growth at concentrations similar or equivalent to 
their acyclic analogues (IC50 = 4.2, 2.5, 2.9 pM compared to 2.2 and 1.1 pM). These 
compounds may, therefore be exerting their effect on a different target that has not yet 
been identified. Compounds 2 and 3 that do not contain the uracil ring inhibit parasite 
growth, however they also inhibit the growth of mammalian cells and are therefore 
more than likely generally toxic.
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m TBDPSi
■  Acyclic analogues 
□  H
■  No uracil ring
1000
Toxicity
Figure 4-13: Inhibitory activity of TBDPS-oxy uracil acetamides on PfdUTPase and on P. 
falciparum parasites compared with their acyclic analogues
Figure 4-14: Acyclic analogues 45 and 46
For the TBDPS-oxy uracil acetamide derivatives, dUTPase inhibition is 
completely lost and they show no enzyme inhibition at concentrations greater than 
1mM. This is in contrast to the acyclic analogue 45 (Kj = 8.74 pM), showing that the 
introduction of an amide bond is detrimental to PfdUTPase enzyme inhibition.
Once more, however, the compounds show inhibition of parasite growth at 
concentrations sim ilar to or lower than their acyclic analogues (IC50 = 4.6 and 3.7 pM 
compared to 3.9pM). For compounds 8 and 9, the selectivity over mammalian cell 
growth inhibition is retained showing that the compounds are not generally toxic. This is 
further proof that these compounds may be exerting their activity by means of a 
different target to the dUTPase enzyme. However, as seen by the loss of activity of 
compound 11 (IC50 = 83 pM), the presence of the uracil ring is still required for in vitro 
activity suggesting that the target may still be a uracil binding protein.
A sim ilar phenomenon is observed with the di-alkyl chain derivatives in that they 
show no inhibition of the dUTPase enzymes but they are slectively active in vitro. In 
fact, they are ten fold more potent than their mono-alkyl chain equivalents in vitro but 
only when the term inal amino groups are protected by Trt or CbZ groups.
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Figure 4-15: Inhibitory activity of the branched chain uracil acetamide derivatives on 
PfdUTPase and P. falciparum parasites
The most potent of the di-alkyl chain derivatives are those with two Trt groups 
attached (36, IC50 = 0.4pM and 33, IC50 = 0.4pM), followed by compound 31b (IC50 = 
0.5pM) which has one Trt group and one CbZ group attached. The loss of one lipophilic 
protecting group results in a ten fold decrease in activity (35, IC50 = 4.48pM, 31, IC50 = 
3.9pM and 40 IC5o = 5.6 pM) and the loss of both lipophilic groups results in at least a 
further ten fold reduction in activity in vitro (28, IC50 = >19.6pM and 29, IC50 = 15.4 pM). 
Interestingly, compounds 27 (IC50 = >9pM) which has two CbZ groups is also quite 
inactive in vitro, therefore, at least one Trt group is required for in vitro activity.
Overall, the addition of the second alkyl chain to the uracil acetamide 
compounds results in a ten fold increase in in vitro activity, only if the second lipophilic 
group is attached. The extra chain itself does not bare much effect on the activity of the 
compounds. A correlation between lipophillicity and anti parasitic activity can be seen. 
It would be reasonable to say that the presence of the Trt groups aids the transport of 
the compounds across the membrane of the parasite. However, as the target of these 
compounds is not known, the effect of the increased potency due to the extra Trt group 
can not be as yet attributed with certainty to membrane permeability or to a specific 
effect on the target within the parasite.
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4.7 Biological results: Dimeric dUTPases and
trypanosome parasites
The uracil acetamide compounds were also tested fo r anti-trypanosome activity. 
The inhibition of growth of T. cruzi, T. brucei and L. donovani was measured. For 
procedures see appendix 1.
Compound L. donovani axen. 
(amastigote form)
IC50|jM
T. brucei rhod. 
(blood stream 
trypomastigotes) 
IC50pM
T. cruzi 
(blood stream 
trypomastigotes) 
ICsopM
Toxicity 
(L6  cells)
IC50pM
Mono-alkyl chain derivatives
17 19.6 8.8 42.0 53.0
18 30.9 18.4 23.5 102.2
19 29.6 1.5 29.6 42.7
2 26.5 0.5 6.4 1.1
3 26.2 0.5 2.0 8.8
8 >64 16.3 37.4 88.9
9 15.6 6.0 16.9 33.4
4 13.4 0.7
CMO 6.3
5 25.5 0.6 5.7 4.1
6 12.8 0.4 4.6 4.0
11 >124 26.9 >124 >373
Di-a kyl chain derivatives
27 Nd 118.6 >57 >172.0
28 Nd 199.3 >117.5 >352.6
35 Nd 16.8 36.8 52.7
36 Nd 20.8 >40.6 >121.6
29 Nd 147.3 >105.9 >317.6
31 Nd 45.4 >57.1 76.7
31b Nd 24.8 45.5 43.2
33 Nd 19.0 39.1 >117.2
40 Nd 83.2 60.2 99.5
41 Nd 18.3 Nd 21.0
42 Nd 0.3 Nd >155.6
Table 4-4: In vitro activities of the uracil acetamide compounds against trypanosome parasites
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4.7.1 Results and discussion
Compounds 2, 3, 4, 5 and 6 (IC50 = 0.5, 0.5, 0.7, 0.6 and 0.4 pM respectively) 
seem to inhibit the growth, in particular of the 7. brucei parasite. These compounds do 
not contain the uracil moiety. Their selectivity over mammalian cells, however is still 
quite low and they are therefore most probably too generally toxic to pursue further.
The phosphate compound 42 (IC50 = 0.3 pM) exhibits promising activity against 
the 7. brucei parasites. As this is an unprotected phosphate, it is surprising that this 
compound can cross the membrane of the parasite as it would normally be charged 
under physiological conditions. This compound may be acting on a membrane bound 
protein on the parasite, its activity against the dUTPase enzyme has not yet been 
determined. The benzyl ester equivalent, 41 (IC50 = 18.3 pM) is not significantly active, 
however, neither is the free hydroxyl compound 40 (IC50 = 83.2 pM). Therefore, the 
phosphate moiety plays a significant role in the activity of this compound.
4.8 General discussion
A number of chemical properties of the uracil acetamide compounds were 
explored in more detail to investigate the observed activity, or lack thereof of these 
compounds and to attempt to ascertain a reason why these compounds may not bind 
in the active site of the PfdUTPase as efficiently as their acyclic counterparts.
Conformational effects
The conformational effect of the insertion of an amide bond was firstly 
investigated. Conformational analyses of uracil acetamide 18 and the acyclic analogue 
44 were first simply carried out in vacuo using Moloc.103 Moloc is a molecular modelling 
package obtained from Gerber Molecular Design. It uses the MAB force field to 
calculate descriptions of molecular geometries and energies which is modelled by the 
following expression:
E = Eb+ Ev + Et + E p +  E 14 +  E|n +  E bb
Where:
Eb= bond stretching energy, Ev= valence angle bending energy
Et = dihedral angle distortion energy, Ep = pyrimidality deformation energy
E14 + Ein = dispersion interaction energies, Ebb = hydrogen bonding energy
103 Gerber, P. R.; Muller, K. MAB, A Generally Applicable Molecular-Force Field for Structure 
Modeling in Medicinal Chemistry. J. Comput.-Aided Mol. Des. 1995, 9, 251-268.
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The results showed that overall, the molecules could adopt a sim ilar conformation in 
vacuo. The uracil ring, however was turned in the opposite direction in compound 18. 
This was probably due to the fact that if the conformation was as in 44, then there is 
the possibility of an unfavourable interaction between the 0 -2  of the uracil ring and the 
carbonyl oxygen of the amide bond.
Figure 4-16: Superimposition of lowest energy conformation of compound 44 (lime) and 
compound 18 (pink) as calculated in vacuo using Moloc
Docking studies were attempted on the compounds. Previous attempts to dock 
compound 18 into the active site of the enzyme using the program FlexX were 
unsuccessful. The docking algorithm produced no results suggesting that when the 
protein is not flexible, the compounds do not in fact fit into the active site.
Docking studies were then attempted using the program GOLD. GOLD allows 
for more protein flexibility than FlexX. Uracil acetamide compound 18 and the acyclic 
analogue 44 were docked into the active site. The best ranked conformations 
according to Goldscore were visualised and superimposed in the active site using VMD 
1.8.4 (Figure 4-17). Both compounds superimposed well over each other, however they 
did not superimpose over the crystal structure ligand. Rather, both compounds docked 
by GOLD in different positions in the active site to the crystal structure, rendering the 
results quite inconclusive as regards protein -  ligand interaction.
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Figure 4-17: Docking of compounds 18 (purple) and 44(cyan) into PfdUTPase active site by 
GOLD. Also shown is the reference molecule WSP869 (yellow)
Following the lack of success with automated docking procedures, compound 
18 and 44 were placed manually into the active site of the enzyme. This was carried 
out using Sybyl 7.2. The uracil rings of compounds 18 and 44 were superimposed over 
the uracil ring of reference molecule W SP869 (Figure 2-26 and 2-25) and the active 
site later added. The placement of the compounds in the active site could then be 
visualised.
Figure 4-18: Manual docking of compounds 18 (purple) and 44 (cyan) in active site of 
PfdUTPase superimposed over reference molecule WSP869 (yellow)
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Finally, compound 18 was minimised in the binding pocket using the MAB force 
field in Moloc. The purpose of this force field calculation was to investigate any large 
conformational change resulting from an undesired interaction between the ligand and 
the protein. However, no large change was observed and the compound could be 
visualised within the active site of the PfdUTPase in a binding mode similar to the 
crystal structure reference molecule.
I  - ,  ’ H
/
/
/  *
Figure 4-19: Compound 18 in active site of PfdUTPase after Moloc minimization
Figure 4-20: Possible interactions of compound 18 in PfdUTPase active site
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When the uracil ring of compound 18 is bound in the correct pocket, the 
interactions that could be postulated are shown in Figure 4-20 and 4-21. It is possible 
that there might be some repulsive interaction between the carbonyl oxygen of the 
amide bond and the backbone oxygen of Glu115 or the side chain phenol of Tyr112 
(Figure 4-21). The NH of the amide bond of compounds 18 was seen to lie very close 
to the OH of Ser92. Although there could be a hydrogen bond between the NH and OH 
of Ser92, there could also be a steric clash between them. The trityl moiety of the 
compound 18, however, seems to be in a favourable orientation to form a TT-stacking 
interaction with Phe46.
However, the carbonyl of the side chain and the 0 -2  of the uracil ring are in 
close proximity which may also give rise to a repulsive interaction in the bound 
conformation of compound 18. This could play a factor in decreased binding of the 
uracil acetamide compounds. As this conformation would not be one of the low energy 
conformations of the molecule in solution, the compounds would have to overcome an 
energy barrier to adopt it and this may be one reason for their low affinity for the 
enzyme. In fact, the energy difference between the two conformations as calculated 
using the Tripos force field is 7.5kcal/mol.
Glu115
Figure 4-21: Possible repulsive interactions to the carbonyl oxygen of the amide bond on uracil 
acetamide compounds in the PfdUTPase active site
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pKa calculations
Using ACD labs 7.0 /pKaDB, the pKa values of som e of the compounds were 
evaluated and compared to that of the analogues in which the am ide bond was absent. 
The most noticeable change was the pKb of the N-3 o f the uracil ring which was 
reduced from approximately 9.2 to 8.5. Although, the localised die lectric constant of the 
active site of the protein is not known, it can be estimated this difference would lead to 
a ten fold increase in the concentration of the deionised species of the uracil 
acetamides over the aliphatic derivatives. It has been shown in the crystal structure of 
the PfdUTPase that the N-3 of the uracil ring hydrogen bonds to the main chain CO of 
Ile117 and that this is an important interaction for maintaining selectivity over cytosine 
in which the N-3 is not a HBD. The presence of the deionised species would therefore 
result in an unfavourable electrostatic interaction with this residue and therefore result 
in decreased binding affinity. The presence of the electron withdrawing amide bond, or 
most probably any electron withdrawing group next to the N-1 of the uracil ring could 
therefore apparently be unfavourable as it reduces the pKb of the N-3 by electron 
delocalisation, though it is unlikely that this is the main contributing factor to the loss in 
activity of the uracil acetamides.
Ile117 Ile117
. y -  s
n -H H bond |j N . e|ectrostatic repulsion
’N ^ O , . ......................................................................................
r R = alkyl chain (electron donating), Kb = 10'9 2
R = CH2amide (electron withdrawing), Kb = 10'8 51
Figure 4-22: pKb of N-3 of the uracil ring and effect of electron donating or electron withdrawing
group to the N-1 position
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LogD calculations
The logD values of some of the uracil acetamide compounds were calculated 
using ACD labs 7.0/logD software and in the case of the single chain derivatives were 
compared to their aliphatic analogues. The results are shown in Table 4.5. for the 
mono chain derivatives, the LogD values are decreased quite significantly compared to 
the aliphatic chain derivatives. For general drug design, this is advantageous as drug­
like molecules should generally have a LogD value of less than 5 to aid their oral 
bioavailability.104
The LogD values of the di-alkyl chain derivatives 33 and 34, however are quite 
high, due to the presence of the two large lipophilic trityl groups. Although the LogD 
values do not seem to correlate with enzyme inhibition, there seems to be a 
relationship between lipophilicity and inhibition of parasite growth. This could be due to 
increased membrane permeability of the compounds. Once inside the cell, however, 
the mechanism by which the compounds exert their activity is not yet known.
Compounds 
(aliphatic analogues)
Ki (pM) IC50(MM) LogD calculated at pH7
17 37.3 4.2 2.89
(43) (4.3) (2.2) (4.28)
18 23.1 2.5 3.10
(44) (1.8) (1.1) (4.78)
8 >1mM 4.6 1.33
(45) (8.7) (3.9) (2.96)
33 >1mM 0.3 8.67
36 >1mM 0.4 9.57
Table 4-5: Calculated LogD values for selected compounds at pH7
104 Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development settings. 
Advanced Drug Delivery Reviews 1997, 23, 3-25.
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4.9 Conclusions
In this part of the project, series of mono alkyl chain and diaikyl chain tritylamino 
and hydroxyl derivatised uracil acetamides were successfully synthesised. Difficulties 
included selective protection and deprotection of hydroxyl functions over amines and of 
primary amines over secondary amines, effective amide bond formation and 
elucidation of unexpected structures.
The biological assays of these uracil acetamide compounds show that these 
compounds are not potent inhibitors of the dUTPase enzymes. Therefore, introduction 
of an amide bond at the p-C to the N-1 of the uracil ring results in a loss of activity 
against the PfdUTPase enzyme. This may be due to the energy barrier which the low 
energy conformation of the uracil acetamide compounds must overcome to adopt the 
required binding conformation. It has also been shown that the introduction of an 
electron withdrawing group at the N-1 position of the uracil ring has the effect of 
lowering the pKb of the N-3 which also may reduce the ability of these compounds to 
bind in the active site of the PfdUTPase.
The uracil acetamide compounds, however, retain good activity in vitro. Their 
mode of action has not yet been ascertained, however, their does seem to be a 
correlation between lipophilicity and anti-plasmodial activity.
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5 Acyclic uridine analogues
5.1 Acyclic uridine analogues
The elucidation of the crystal structure of the PfdUTPase enzyme with a 
previously synthesised novel inhibitor bound in the active site was published in 2005.57 
This provided a foundation for the use of structure based design approaches to the 
design of inhibitors of the PfdUTPase enzyme. Previously, inhibitor design was mainly 
analogue based. The use of the program GRID105 to probe for interactions in the 
PfdUTPase active site was therefore employed. Potential inhibitors were then docked 
and modelled in the active site using FlexX and subsequently synthesised if possible.
Figure 5-1: Previously synthesised inhibitor WSP869 in the active site of the PfdUTPase
W SP869 was a uridine analogue, however, acyclic nucleoside analogues, 
previously synthesised by the group also showed good and selective inhibition of the 
PfdUTPase enzym e.75 The prelim inary scaffold for the set of uridine analogues 
discussed in this chapter was based upon these acyclic nucleoside analogues.
WSP 869 (reference molecule)
O O
W S P1328  
Kj=2.15 (S l=260) 
IC S0= 1 .15 (T o x= 32 .6 )
W SP1321  
Kj=0.9 (S l=23.7) 
IC50=1.85 (To x=57.1)
W SP1322  
Kj=23.1 (S l=>43.2) 
IC50=0.64 (To x=18.4)
Figure 5-2: Some of the previously synthesised acyclic PfdUTPase inhibitors
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5.2 GRID calculations on P. falciparum dUTPase 
enzyme
The program GRID is a computational procedure for determining energetically 
favourable binding sites on molecules of known structure.105 GRID has been applied to 
structure based design106 and has also been used to understand structural differences 
relating to enzyme selectivity.107
GRID computes the interaction of a probe or probes with a protein of known 
structure at sample positions throughout and around the macromolecule, giving an 
array of energy values. Energetically favourable binding sites for each probe are shown 
by contours mapped on to the surface of the protein.
For the purpose of this study, GRID was used to probe the active site of the P. 
falciparum dUTPase enzyme for energetically favourable interactions. Docking of the 
previously synthesised inhibitor WSP1328 (Figure 5-2) and subsequent 
superimposition of this molecule into the GRID calculated structure, revealed several 
interesting implications. This then allowed for determination of some possible 
advantageous modifications that could be made to the previously synthesised acyclic 
inhibitors. These modifications would then generate new lead compounds that would, 
hopefully, have increased activity against the enzyme by interacting with the GRID 
proposed energetically favourable binding sites.
O
NH
X = N,
Y = t-Bu, Ph
Figure 5-3: Proposed modified inhibitors (X = N, O)
105 Goodford, P. J. A Computational-Procedure for Determining Energetically Favorable Binding- 
Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857.
106 von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; 
Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, 
J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational Design of Potent 
Sialidase-Based Inhibitors of Influenza-Virus Replication. Nature 1993, 363, 418-423.
107 Kastenholz, M. A.; Pastor, M.; Cruciani, G.; Haaksma, E. E. J.; Fox, T. GRID/CPCA: A new 
computational tool to design selective ligands. J. Med. Chem. 2000, 43, 3033-3044.
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The PDB file was loaded and the area over which the calculations were to be 
carried out was defined manually. This is possible in GRID by using the ‘grid box’ or 
‘cage’ which is an interactive 3D cube that can be visualised in Gview and toggled 
around the area in which the calculations are to take place.
Several single atom and multi atom probes (Table 5-1) were used and their 
subsequent binding pockets shown at a given energy level.
Probe
name
Description Energy
(kcal)
Probe name Description Energy
(kcal)
C3 Methyl CH3 -2.47 N: sp3 N with lone pair -5.93
N:# sp N with lone pair -7.49 N:= sp2 N with lone pair -7.90
[
N1 Neutral flat NH e.g. 
amide
-6.66 N1 + sp3 amine NH cation -7.49
N1: sp3 NH with lone pair -7.49 NH= sp2 NH with lone pair -7.90
N2 Neutral flat NH2 e.g. 
amide
-7.93 N1 = sp2 amine NH cation -7.90
N2= sp2 amine NH2 cation -7.93 N2: sp3NH2 with lone pair -6.15
01 Alkyl hydroxy OH -5.40 OH Phenyl or carboxy OH -5.42
0- sp2 phenolate oxygen -4.08 0 sp2 carbonyl oxygen -4.01
0:: sp2 carboxy oxygen 
atom
-4.36 0= 0  of sulphate or 
sulphonamide
-3.93
OES sp3 ester oxygen atom -1.33 OC2 Ether or furan oxygen -2.61
OS 0  of sulphone or 
sulphoxide
-4.50 ON Oxygen of nitro group -4.50
P04H P04H phosphate 
anion
-6.77 S1 Neutral SH group -5.53
F Organic fluorine atom -2.45 Cl Organic chlorine atom -3.80
Br Organic bromine atom -5.13 I Organic iodine atom -6.63
BOTH The amphipathic 
probe
-0.39 DRY The hydrophobic 
probe
-0.50
COO- Aliphatic anioninc 
carboxy group
-7.88 AR.COO­ Aromatic anioninc 
carboxy group
-7/12
CONH2 Aliphatic neutral 
amide group
-7.53 AR.CONH2 Aromatic neutral 
amide group
-7.30
CONHR Aliphatic neutral 
amide group
-7.75 AR.CONHR Aromatic neutral 
amide group
-7.30
AMIDINE Aliphatic cationic 
amidine group
-10.0 AR.AMIDINE Aromatic cationic 
amidine group
-10.08
Table 5-1: Tables of probes used and their equivalent symbols and energies at which contours
were shown
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Nitrogen probes
In the case of the amino probes, where the nitrogen could potentially act as a 
hydrogen bond acceptor (HBA) and a hydrogen bond donor (HBD) such as in Figure 5- 
4, a large contour of binding potential could be seen where the end of the branch chain 
would be thought to sit.
Figure 5-4: GRID calculations for N1: probe at an energy of-7.5kcal. (Side chain highlighted in 
pink bubble and interaction area highlighted in blue bubble)
This was also true for amino probes in which the nitrogen could potentially act 
as only a hydrogen bond donor as shown in Figure 5-5.
Figure 5-5: GRID calculations for N1= probe at an energy of -7.9kcal. (Side chain highlighted in 
pink bubble and interaction area highlighted in blue bubble)
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However, when the nitrogen of the amino probe had a lone pair but no 
hydrogen, i.e could potentially act solely as a hydrogen bond acceptor and not as a 
donor, the same contour could be seen but was greatly reduced in surface area and 
energy.
Figure 5-6: GRID calculations for N: probe at an energy of-5.9kcal. (Side chain highlighted in 
pink bubble and interaction area highlighted in blue bubble)
The assumption could therefore be made that an amino group that could act as 
a hydrogen bond donor, such as a primary or secondary amine or amide, at the end of 
the branch chain could lead to possible interactions between the molecule and active 
site. The larger, multi-atom amidine probes also seemed to bind in this region 
favourably and therefore would also be well tolerated.
Figure 5-7: GRID calculations for the AMIDINE probe at an energy of -10.0kcal. (Side chain 
highlighted in pink bubble and interaction area highlighted in blue bubble)
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Oxygen probes
The carbonyl oxygen probes showed a banana shape favourable binding 
contour approximately 2.0 A  distance from C-10 and C -11 of the inhibitor.
Figure 5-8: GRID calculations for O probe at an energy of -4.01 kcal. (Side chain highlighted in 
pink bubble and interaction area highlighted in orange bubble)
This is due to the presence of the Ser92 residue of the protein, whose side 
chain could act as a HBD. These results would suggest that the presence of a carbonyl 
oxygen that could act as a HBA on either C-10 or C-11 of W SP1328 would lead to an 
extra hydrogen bond within the active site providing the conformation of the molecule 
would not change significantly with this modification.
Other probes
Other calculations were also carried such as halogen atoms, amphipathic, 
hydrophobic, phosphate groups and multi atom probes. SH probes (Figure 5-9) and 
other HBD donating probes showed similar results to those of the amino probes. The 
phosphate probes showed a large contour in what would normally be the phosphate 
binding region of the active site (Figure 5-10) and the hydrophobic probes showed a 
contour around where the trityl moiety of the inhibitors are thought to bind (Figure 5- 
11). The halogen probes showed that it could be possible to replace some of the 
hydrogens on the molecule if necessary (Figure 5-12) and the multi atom probes 
suggested that quite a large group could tolerated at G (F igure 5-14).
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Figure 5-9: SH probe energy -5.5kcal
Figure 5-11: DRY probe energy -0.5kcal
Figure 5-10: P04H probe energy -6.8kcal
Figure 5-12: Cl probe energy -3.8kcal
Figure 5-13: C3 probe energy -2.5kcal Figure 5-14: CONHR probe energy -7.8kcal
5 Acyclic uridine analogues
x = c h 2, CO
Y =  N, O 
Z = t-Bu, Ph
G l G = C 02H, CONF^Rz
Figure 5-15: Proposed modified compounds
In summary, the main points noted from The GRID calculations are as follows:
1 A carbonyl oxygen attached to position 10 or 11 in the molecules could 
hydrogen bond to the side chain of Ser92 in the active site and therefore would have a 
favourable interaction.
2 The modified group G (Figure 5-15) should retain good hydrogen bond donating
ability. This is probably due to Asp109 whose negatively charged side chain could act
as a hydrogen bond acceptor. There does not seem to be great restriction on the size 
of G, however, the molecules are already of high molecular weight, therefore a small 
substitution such as an amine, amide or am idine would be ideal.
3 The molecules are currently synthesised as a mixture of enantiomers. O f the
two enantiomers, however, the S may be more active. This is due to the presence of 
Tyr 112 which is 3.8 A from the chiral carbon and may sterically hinder the side chain 
of the R enantiom er from sitting in the active site.
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5.3 Docking of proposed compounds into PfdUTPase
Some compounds with the general structure of the proposed compounds 
shown in Figure 5-15 were docked into the active site of the PfdUTPase using FlexX. 
FlexX is a docking program that takes into account the flexibility for the ligand but not 
that of the molecule108 and is described in more detail in Chapter 6.
The compounds shown in Figure 5-17 were drawn and minimised using Sybyl 
6.9.1. The active site of the protein was defined as being 8A around the reference 
molecule (inhibitor bound in crystal structure PDB entry 1VYQ) and the compounds 
were docked using FlexX.
O L
WSP 869 (reference molecule)
Figure 5-17: Branched acyclic derivatives which were docked into the active site of PfdUTPase
108 Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A Fast Flexible Docking Method using an 
Incremental Construction Algorithm. J. Mol. Biol. 1996, 261, 470-489.
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The results for each compound docked were listed in order of increasing energy
which was calculated by FlexX as described in Chapter 6.
Compound Number of conformations 
generated
Energy of highest scoring conformation 
(kcal mol'1)
S R S R
47 30 No solution -59 No solution
48 30 8 -62 -58
49 30 21 -59 -58
50 30 23 -62 -61
51 24 30 -54 - 54
52 27 1 -57 -38
53 30 25 -65 -70
54 30 23 -65 -54
55 4 4 -75 -62
56 30 30 -60 -55
Table 5-2: Results of compounds 47-56 docked into the active site of the PfdUTPase
The best results were superimposed in the active site of the molecule using
Visual Molecular Dynamics (VMD) 1.8.4 software (Figure 5-18).
Figure 5-18: Compounds 47 (blue), 48 (red), 49 (orange), 50 (yellow), 51 (green), 52 (pink), 53 
(cyan), 54 (purple), 55 (lime), 56 (mauve). All are shown in S configuration
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The R  and S enantiomers of each compound were drawn, minimised and 
docked separately in order to investigate the effect of the stereochemistry of the 
compounds. In agreement with the GRID calculations, the S enantiomers docked much 
more successfully and with better superimposition over the reference molecules than 
the R enantiomers. For compound 47, the R  enantiomer did not dock at all. In 
compounds 48 -  55 the Trt moiety of the R enantiomer is displaced. The amide 
functionality superimposes over the sugar and alkyl chain of the reference molecule 
and the Trt moiety moves towards the phosphate binding region of the active site. 
(Figure 5-19 -  5-21) in the R enantiomer solutions.
rfrityl binding 
' & ■  region
binding region
Phosphate 
binding region
Figure 5-19: S enantiomer of 49 and reference molecule (yellow) in the PfdUTPase active site
Figure 5-20: R  enetiomer of 49 and reference molecule (yellow) in the PfdUTPase active site
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\
Figure 5-21: R - 49 (blue), S - 49 (red) and reference molecule wsp 869 (yellow) superimposed
using Molsoft ICM-Browser-pro
The size of the substituents at position 11 (G in Figure 5-15) also effects the 
way in which the com pounds dock into the active site. All of the conformations 
generated from com pounds 47 and 48 and more than half of the conformations 
generated from compounds 49, 50 and 51 dock with good superimposition over the 
reference molecule and in the correct orientation in the active site. As the substituents 
get larger, however, trityl d isplacem ent becomes more common. For compounds 52 
and 54, only two of the conformations dock with the correct orientation, for compound 
53, only four of the conform ations dock in the correct orientation and for compound 55, 
only one of the four generated conformations dock in the correct orientation. In all of 
the remaining conformations, one, two or all of the phenyl rings of the trityl moiety are 
displaced to accom modate the bulky substituents present. Therefore, when G = 
CONHR1R2, Ri and R2= H or Me is well tolerated (Figure 5-22), R1 and R2= Et, amidine 
or Me-amidine is reasonably tolerated (Figure 5-23) and Ri and R2 = di-Me-am idine is 
poorly tolerated (Figure 5-24).
Trityl binding Uracil
binding regionregion
Phosphate 
binding region
Figure 5-22: Compound 50 in active site. Ri = H, R2 = Me. G well tolerated. 30 conformations
generated. Ref. molecule shown in yellow
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Docking studies on the PfdUTPase active site
Trityl binding 
region
Uracil 
binding region
Phosphate 
binding region
Figure 5-23: Compound 52 in active site. R, = R2 = Et. G reasonably tolerated. Uracil ring 
slightly displaced, 27 conformations generated. Ref. molecule shown in yellow.
Figure 5-24: Compound 55 in active site. G = di-methylamidine. G not well tolerated. Trityl 
displaced and only 4 conformations generated. Ref. molecule shown in yellow
Compound 56, in which there is a Trt-amide moiety, also docks with good 
superimposition into the active site and therefore this modification may be well 
tolerated within this group of compounds. The carbonyl oxygen points toward Ser 92, 
the residue with which it might form a hydrogen bond (Figure 5-25).
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Figure 5-25: Compound 56 and reference molecule (yellow) in PfdUTPase active site Ser 92
shown in green
5.4 Modifications at position 11
The synthesis of these compounds started from the branched, acyclic uridine 
analogues 57 and 72 kindly provided by our partner, Medivir. As it was previously 
shown that compounds containing the TBDPS group were equipotent against the 
enzyme as compounds with the Trt moiety, compound 57 was used to synthesise 
TBDPSO derivatives. TrtNH derivatives were synthesised from intermediate 72.
OH
R = TBDPS or TBDMS
Figure 5-26: Intermediates 57 and 72 provided by Medivir
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5.4.1 TBDPS-0 derivatives
The overall synthetic strategy for the TBDPS-0 derivatives is shown in Scheme 
5-1. The first step required the oxidation of 57 to an acid, either through a two step 
oxidation via the aldehyde or by direct oxidation to the acid. Subsequent amide 
formation could then be achieved using suitable coupling reagents. Alternatively, 
oxidative amidation of aldehydes by a radical mechanism involving N- 
bromosuccinimide (NBS) and azobisisobutylonitrile (AIBN) as a radical initiator to form 
amides directly has also been documented.109, 110 This methodology was also 
investigated.
Ox. ' Route 2Route 1
NHNHNH
OH N
Ox. Ox.
HO
OTBDXSOTBDXSOTBDXS 
X = Ph, Me
Coupling reagent, 
HNR1R2
AIBN, NBS, N HR ^;
NHNH
OTBDXS OTBDXS
Scheme 5-1: Synthetic strategies for the synthesis of the branched TBDPS-0 derivatives
109 Marko, I. E.; Mekhalfia, A. Radical Mediated Oxidations in Organic-Chemistry .3. An Efficient 
and Versatile Transformation of Aldehydes into Amides. Tetrahedron Lett. 1990. 31, 7237-7240.
110 Fan, C. A.; Tu, Y. Q.; Song, Z. L.; Zhang, E.; Shi, L.; Wang, M.; Wang, B. M.; Zhang, S. Y. 
An efficient total synthesis of (+/-)-lycoramine. Org. Lett. 2004, 6, 4691-4694.
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5.4.1.1 Oxidation of the primary alcohol at position 11
Various methods of oxidation of intermediate 57 to e ither the aldehyde or the 
acid (Scheme 5-2) were attempted as shown in Table 5-3. The oxidation procedure 
was not trivial and problems were encountered with many of the standard oxidation 
procedures as described below.
Method Desired
product
Result
PDC/DMF111' 11* Acid Bromocresol green staining showed acid on TLC. 
Product could not be isolated from chromium salts.
PCC/DCM113 Aldehyde Product could be seen by TLC but could not be 
isolated from chromium salts.
Cr03, H5I0 6, wet ACN114’115 Acid Silanol group did not withstand conditions
Swern116’117 Aldehyde Decomposition of product occurred. Uracil base 
and a,p-unsaturated aldehyde were isolated.
TPAP, NMO, DCM118’m  120 Aldehyde 30% - 40% yield
BAIB, TEMPO, ACN/H20 121 Acid 85% yield
Table 5-3: Attempted procedures for oxidation at position 11
111 Corey, E. J.; Schmidt, G. Useful Procedures for the Oxidation of Alcohols Involving 
Pyridinium Dichromate in Aprotic Media. Tetrahedron Lett. 1979, 399-402.
11 Czernecki, S.; Georgoulis, C.; Stevens, C. L.; Vijayakumaran, K. Pyridinium Dichromate 
Oxidation - Modifications Enhancing Its Synthetic Utility. Tetrahedron Lett. 1985, 26, 1699-1702.
113 Corey, E. J.; Suggs, J. W. Pyridinium Chlorochromate - Efficient Reagent for Oxidation of 
Primary and Secondary Alcohols to Carbonyl-Compounds. Tetrahedron Lett. 1975, 2647-2650.
114 Zhao, M. Z.; Li, J.; Song, Z. G.; Desmond, R.; Tschaen, D. M.; Grabowski, E. J. J.; Reider, P. 
J. A novel chromium trioxide catalyzed oxidation of primary alcohols to the carboxylic acids. 
Tetrahedron Lett. 1998, 39, 5323-5326.
115 Yamazaki, S. Chromium(VI) oxide-catalyzed benzylic oxidation with periodic acid. Organic 
Letters 1999, 1, 2129-2132.
116 Omura, K.; Swern, D. Oxidation of Alcohols by Activated Dimethyl-Sulfoxide - Preparative, 
Steric and Mechanistic Study. Tetrahedron 1978, 34, 1651-1660.
117 Mancuso, A. J.; Huang, S. L.; Swern, D. Oxidation of Long-Chain and Related Alcohols to 
Carbonyls by Dimethyl-Sulfoxide Activated by Oxalyl Chloride. J. Org. Chem. 1978, 43, 2480- 
2482.
118 Griffith, W. P.; Ley, S. V. TPAP: Tetra-n-propylammonium perruthenate, a mild and 
convenient oxidant for alcohols. Aldrichimica Acta 1990, 23, 13-19.
119 Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. Tetrapropylammonium Perruthenate, 
Pr4n+Ruo4-, Tpap - a Catalytic Oxidant for Organic-Synthesis. Synthesis-Stuttgart 1994, 639- 
666 .
120 Sharpless, K. B.; Akashi, K.; Oshima, K. Ruthenium Catalyzed Oxidation of Alcohols to 
Aldehydes and Ketones by Amine-N-Oxides. Tetrahedron Lett. 1976, 2503-2506.
121 DeMico, A.; Margarita, R.; Parlanti, L.; Vescovi, A.; Piancatelli, G. A versatile and highly 
selective hypervalent iodine (lll)/2,2,6,6-tetramethyl-1-piperidinyloxyl-mediated oxidation of 
alcohols to carbonyl compounds. J. Org. Chem. 1997, 62, 6974-6977.
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NH
TBDXSO-
or
59
NHNH
Ox. ^  TBDXSOTBDXSO
X = Ph, Me HO
58
OH
57
Scheme 5-2: Oxidation of 57
PDC in DMF
NHNH
PDC, DM 18hr TBDMSOTBDMSO
HO
58
OH
Scheme 5-3: Oxidation of 57 using PDC in DMF
Initially, direct oxidation of 57 to the acid was attempted using the widely known 
pyridinium dichromate (PDC)/DMF methodology111 following the procedure of Xing et 
al;122 The TBDMS alcohol was used. The reaction was left stirring overnight and the 
presence of an acid could be seen by TLC using bromocresol green staining. The 
carboxylate was extracted into a saturated NaHC03 solution which was then acidified 
to pH 2 and an extraction with diethyl ether was then carried out. However, 
bromocresol green staining showed that the acid remained in the aqueous layer with 
the PDC. The product could not be separated from the PDC by washing with ether, 
ethyl acetate, DCM or MeOH. The product could not be identified by NMR, as no peaks 
were observed in the processed spectra. This was probably due to the interference of 
the paramagnetic chromium species with accurate shimming.
122 Xing, X. C.; Fichera, A.; Kumar, K. Simple and efficient method for the resolution of all four 
diastereomers of 4,4,4-trifluorovaline and 5,5,5-trifluoroleucine (vol 67, pg 1722, 2002). J. Org. 
Chem. 2002, 67, 8290-8290.
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PCC in DCM
In order to facilitate the separation of the product from the oxidising species, the 
use of the more hydrophilic, but stronger oxidising agent, pyridinium chlorochromate 
(PCC) was employed.113
PCC PDC
Figure 5-27: Structures of PCC and PDC
The reaction was carried out in dry DCM in order to obtain the aldehyde 
species. Again, the TBDMS protected alcohol was used. The reaction was left stirring 
overnight and formation of a new spot on TLC was observed. However, after filtration 
of the PCC through celite and subsequent washing with DCM, only tert-butyl silanol 
was recovered. The TBDMS group was cleaved under these conditions, probably due 
to the weakly acidic nature of PCC.111
NHNH
PCC, DCI 18hr TBDMSO.TBDMSO
57
OH
Scheme 5-4: Oxidation of 57 using PCC in DCM
Cr3Ot HsIOe, wet acetonitrile
In both cases where stoichiometric amounts of chromium oxidising agents were 
used, the product could not be separated from the oxidising species. It was thought, 
therefore that the product was forming a complex with the chromium species present in 
the reaction mixture and could not be isolated as a result. The method of oxidation of 
primary alcohols to carboxylic acids reported by Zhao et a/;114 seemed attractive as 
only a catalytic amount of chromium species is required in the presence of periodic 
acid as the stoichiometric oxidant. Reactions were also reported to go to completion in 
less than 1h.114115 In this case the TBDPS protected intermediate 57 was used in order 
to increase the lipophilicity and therefore ease of purification of the compound. It was 
also thought the TBDPS group may be more stable to cleavage. The reaction was 
carried out according to the procedure of Zhao et a/;114 and DCM was added to form a
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precipitate. The precipitate was removed and identified by 1H NMR as starting material 
in which the TBDPS group had been cleaved. The filtrate was starting material and the 
silanol by-product. The TBDPS protecting group was cleaved under the reaction 
conditions.
NH
H5I0 6i C r03, w^t ACN 
30 min 0°^ in RT TBDPSOTBDPSO.
HO
58
OH
Scheme 5-5: Oxidation of 57 using chromium trioxide and periodic acid
Swern oxidation
The oxidation of 57 was then attempted using the Swern procedure116,117 which 
seemed attractive as it excluded the use of metal complex oxidising agents and was 
carried out in non-acidic conditions.
O O
NH i) DMSO, (COCI)2, NEt3l- 70°C
O
Si-O.
OH
NH
Si-O
Scheme 5-6: Oxidation of 57 via the Swern procedure
The procedure was carried out according to Bundy et a/;123 However, following 
purification by column chromatography 59 was isolated in very low yield. The main 
product isolated, which was identified by NMR and a peak at 214 by mass 
spectrometry, was the a,p-unsaturated aldehyde 60 and uracil. The loss of pyrimidine 
base from nucleoside analogues under the oxidisng conditions of Nal04 and RuCI3 has 
been reported in the literature.124 In this case, loss of nucleoside base probably 
occurred through an elimination, similar to a reverse Michael addition reaction to
123 Bundy, G. L.; Banitt, L. S.; Dobrowolski, P. J.; Palmer, J. R.; Schwartz, T. M.; Zimmermann, 
D. C.; Lipton, M. F.; Mauragis, M. A.; Veley, M. F.; Appell, R. B.; Clouse, R. C.; Daugs, E. D. 
Synthesis of 2,4-di-1-pyrrolidinyl-9H-pyrimido 4,5-b indoles, including antiasthma clinical 
candidate PNU-142731A. Org. Process Res. Dev. 2001, 5, 144-151.
124 Singh, A. K.; Varma, R. S. Ruthenium Tetraoxide - a Mild Reagent for the Oxidation of 2',3'- 
O-lsopropylidene Purine Nucleosides. Tetrahedron Lett. 1992, 33, 2307-2310.
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release uracil and compound 60. This was probably due to the acidic nature o f the 
hydrogen atom at position 8 and the fact that uracil is a good leaving group. The 
reaction may have proceeded through a base catalysed mechanism. Et3N or the 
sulphur ylide interm ediate produced during the reaction may have had the required 
basicity to abstract this proton and cause the elim ination reaction to occur. In any case, 
compound 59 was not stable under the Swern oxidation conditions.
Scheme 5-7: Proposed mechanism for the elimination reaction under Swern conditions 
TPAP, NMO
Ruthenium catalysed oxidation of alcohols to aldehydes and ketones by amine- 
A/-oxides is a mild, effective and well docum ented oxidation procedure.120 The 
tetrahedral perruthenate ion [R u (V II)04]' is a m ilder oxidant than ruthenium tetroxide 
[R u(V III)0 4]. Particularly effective is the tetrapropylam m onium  salt of th is species as it 
is soluble in many organic solvents. Catalytic tetrapropylam m onium  perruthenate 
(TPAP) and A/-methylmorpholine-A/-oxide (NMO) is a w idely used procedure fo r the 
oxidation of alcohols to aldehydes. Many functionalities, including the TBDPS 
protecting group, are stable under these conditions and TPAP operates at room 
tem perature and is devoid o f obnoxious or explosive side products.118,119
TPAP is an overall three electron oxidant and a postulated reaction sequence 
for [R u(VII)0 4]' is the following:
O
Elimination reaction
Acidic hydrogen
Ru(VII) + 2e' Ru(V)
2Ru(V)
^  Ru(IV)
Scheme 5-8: Mechanism of TPAP catalysed oxidation
Ru(VI) + Ru(IV)
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This procedure was therefore attempted according to the conditions used by 
Marcos et a/;125 The removal of water of crystallisation of the NMO and also the water 
formed during the reaction was obligatory to maintain good catalytic turnovers and this 
was best achieved by adding 3A molecular sieves. The exclusion of water is also the 
main determining factor in preventing further oxidation to carboxylic acids.119
After stirring the reaction for 5h at RT, the desired aldehyde product 59 was 
isolated in 30% yield. This yield could not be improved by increasing the reaction time 
to overnight or by increasing the mol% of catalyst from 0.05% to 0.10%.There was no 
evidence from NMR or mass spectrometry that elimination had taken place.
TEMPO, BAIB
In an effort to increase the yield of the first step of the synthesis of these 
compounds, a final oxidation procedure using a hypervalent iodine method was 
attempted. This procedure which utilised [bis(acetoxy)-iodo]benzene (BAIB) in excess 
and a catalytic amount of 2,2,6,6,-tetramethylpiperidine-l-oxyl (TEMPO) was originally 
reported by De Mico et al;121 to oxidise alcohols to aldehydes and ketones. The 
procedure was then modified by Epp et a/;126 to prepare nucleoside-5’-carboxylic acids 
in the presence of high concentrations of water.
The advantages to this method included fast reaction times, ease of purification 
of the final carboxylic acid, stability of various protecting groups (including the TBDMS 
group), and the absence of inorganic salts. The side products of the reaction are 
iodobenzene, which can be removed in an ether wash, and acetic acid which can be 
removed under vacuum. The fact that the nucleoside derivatives had already been 
shown to be stable under these conditions was also promising.
The reaction was carried out in a 1:1 mixture of ACN/H20  and left stirring for 3 
h. The desired acid was isolated in 85% yield after trituration from diethyl ether.
125 Marcos, I. S.; Garcia, N.; Sexmero, A. J.; Basabe, P.; Diez, D.; Urones, J. G. Synthesis of 
(+J-agelasine C. A structural revision. Tetrahedron 2005, 61, 11672-11678.
2 Epp, J. B.; Widlanski, T. S. Facile preparation of nucleoside-5 '-carboxylic acids. J. Org. 
Chem. 1999, 64, 293-295.
O O
TPAP, NMO, DCM, RT, 5
30%
Scheme 5-9: Oxidation of 57 to aldehyde 59 using TPAP and NMO
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The pure product was identified by NMR and mass spectrometry.
o  0
A NH
TBDPSO
NH
11 TEMPO, BAIB, wet ACN, 3hr
N ^ O  ----------------------------------------- ►
T B D P S O ^ / \ J  85%
57
Scheme 5-10: Oxidation of 57 to acid 58 using TEMPO and BAIB 
The mechanism of the reaction is as follows:
Phl(OAc)2 + nROH — ^  Phl(OAc)2 . n(RO)n + nAcOH ^ Phl(OR)2n + 2AcOH
OH
-►
C
u  u OH
OH
BAIB
i
O
TEMPO
Scheme 5-11: Mechansim of oxidation by TEMPO and BAIB121, 127
After a ligand exchange around the iodine of BAIB, the generated acetic acid 
catalyses the disproportionation of TEMPO to the hydroxylamine and oxoammonium 
salt. The oxoammonium salt is the species responsible for the oxidation of the alcohols 
while being, itself, reduced to hydroxylamine. The role of BAIB is to regenerate 
TEMPO.
1 ?7 de Souza, M. V. N. The use of TEMPO (2,2,6,6-tetramethylpiperidine-N-oxyl) for the 
oxidation of primary and secondary alcohols. Quim. Nova 2004, 27, 287-292.
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5.4.1.2 Amide coupling to carboxylic acid 58
Coupling of various substituted amines to the carboxylic acid moiety of 58 was 
then attempted (Route 2, Scheme 5-1). Initially, two methods were tried. The first was 
using the DCC, DhbtOH method as described in section 4.3.1.2 and the second was 
using EDC as a coupling reagent as described in section 4.2.3.2. In the case where the 
hydrochloric salt of the amine was used, Et3N was used as the neutralising base. For 
the initial, trial reaction, more success was achieved with the former methodology.
NH
DhbtOH, Et3N, DMF, DCC 
0°C 1 h, RT 16h
TBDPSO
80%
NH
TBDPSO.
Scheme 5-12: Amide coupling to acid 58 using DCC and DhbtOH
NH
TBDPSO.
EDC, DMF, Et3N 
2d RT
7%
Scheme 5-13: Amide coupling to acid 58 using EDC
TBDPSO
62 o
Using DCC as a coupling reagent in the presence of DhbtOH as an addititive, it 
seemed that higher yields could be obtained. This methodology was therefore used to 
synthesise a small library of amides in a parallel fashion, using a Radley’s low 
temperature carousel. Eight reactions were carried out simultaneously, varying the 
amine used. In cases were the hydrochloric salt of the amine was used, Et3N was used 
as the neutralizing base. The acid, amine and DhbtOH were placed in the carousel 
reaction tubes with 2-3mL DMF and cooled to 0°C while stirring. The Et3N was then 
added if necessary, followed by DCC. The reactions were stirred at 0°C for 1 h and then 
at RT overnight. The precipitates which formed during the reactions were filtered off 
and identified to be the side product DCU. The solvent was evaporated under reduced 
pressure. In some cases, more DCU was removed by precipitation from acetone. The 
products were purified by column chromatography.
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Compounds 64, 65 and 67 were isolated in varying yields (Scheme 5-14). 
These compounds were characterised by 1H and 13C NMR, low resolution and high 
resolution mass spectrometry.
Unfortunately, products 62, 63, 66, 68 and 69 could not be isolated. In all cases, 
a product that seemed to be the starting alcohol 57 by NMR, was isolated. No peaks 
corresponding to the amine substituents could be seen and there was no carbonyl 
peak in the 13C spectra at 172 ppm, which had been present in the starting material. 
The integration of the peaks in the 3.5-3.9 ppm region of the 1H NMR spectra was 
between 5 and 6. This would correspond to protons attached to carbon 7, 10 and 11 for 
the alcohol 57, but should only integrate to 4 for the carbonyl compounds, 
corresponding to the protons at positions 7 and 10. The proton attached to carbon 8 
usually resonates at approximately 2 ppm and moves downfield to approximately 3 
ppm in the carbonyl compounds. This peak appeared at 2.2 ppm in this case. Neither 
the alcohol 57 nor the products 62, 63, 66, 68, and 69 could be seen by mass 
spectrometry.
Therefore 3 compounds (62, 65, 67) were successfully synthesised and isolated 
in sufficient quantity to submit for biological evaluation. However, there was no 
conclusive evidence for the formation of compounds 62, 63, 66, 68 and 69 and these 
compounds were not submitted for biological evaluation.
O O
TBDPSO. + RR'NH
DhbtOH, Et3N, 
DMF, DCC,
0° 1 hr, RT 16hr 
 ► TBDPSO
R
R=H, R -M e  
R=R-M e*
R=H, R -E t*
R=R-Et*
Piperazine 
N-Z-piperazine 
R=H, R-N-Z-diaminoethane* 
R=H, R-N-Z-diaminopropane
62:R=H, R-M e*, 0%
63:R=R'=Me*, 0%
64:R=H, R -  Et*, 16%
65:R=R-Et*, 38%
66:Piperazine, 0%
67:N-Z-piperazine, 81%
68:R=H, R-N-Z-diaminoethane*, 0% 
69:R=H, R-N-Z-diaminopropane*, 0%
Scheme 5-14: Synthesis of amides 62-69 hydrochloride salt used
- 112 -
Modifications at position 11
in h  id
VO oo o  if> ro n
CNJ 00 P*
go ch invo ro co O  O') t o  t o  '
TBDPSO
OH
8.0 7.8 7.0 6.5 6.0 5.5 5.0 4.5 2.04.0 3.5 3.0 2.5 1.5 1.0 ppm
Figure 5-28: NMR of compound isolated from purification of compounds 62, 63, 66, 68 and 69 
and possible correlation to protons of alcohol 57
5.4.1.3 Deprotection of aldehyde 59
Although the amide coupling procedure described above was in some instances 
a success, some exploration into the synthesis of amides via route 1 (Scheme 5-1) was 
carried out. This procedure involved synthesis of amides directly from aldehyde 59 
through oxidative amidation carried out via a radical mechanism.
In this case, the TBDPS protecting group had first to be replaced by the Trt 
group as it is quite labile under the AIBN/NBS conditions required for amide synthesis. 
The Trt group is more stable under these conditions.128
O O
NH
TBAF (1M in THF), 4h, RT
72%
"Si
NH
OH
Scheme 5-15: Removal of the TBDPS group with TBAF
128 Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis; 3rd ed.; John Wiley &
Sons, 1999.
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Deprotection of aldehyde 59 was therefore carried out using the TBAF method. 
Compound 59 was stirred in a 1M solution of TBAF in THF until the disappearance of 
starting material was observed by TLC. Following column chromatography, the product 
was isolated. The presence of TBAF could be seen by 1H NMR and mass spectrometry 
and proved difficult to remove. The product could therefore have been isolated as the 
TBAF salt. The following tritylation step was carried out in any case.
5.4.1.4 Tritylation of alcohol 70
NHNH
TrtCI, MW, 160°, 2 x15m in
 *  ►
OH
70
Scheme 5-16: Unsuccessful tritylation of compound 70
Compound 70 and TrtCI were dissolved in pyridine and exposed to microwave 
radiation at 160°C twice for 15min each time. However, though new spots were seen 
by TLC, after column chromatography only starting materials were isolated. No 
tritylated product was obtained. It was probable that the starting compound 70 was 
unreactive due to inter or intra molecular interaction between the alcohol and the 
aldehyde. Especially, in basic media, an intramolecular cyclisation to form a five 
membered ring could be envisaged, followed by oxidation in the MW reactor due to the 
presence of gas in the solvent.
O
NH
Figure 5-29: Possible cyclised product of aldehyde 70
Due to lack of starting material and time constraints this method was therefore 
abandoned.
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5.4.2 Triphenylmethylamino derivatives
Triphenylmethylamino derivatives were then synthesised from intermediate 72 
(Figure 5-26) provided by Medivir as it was previously established that replacement of 
the TBDPS-O group with a Trt amino group increased the stability of the compounds in 
liver microsomes.74 The overall synthetic strategy was as follows:
Tritylation
Oxidation
Azide reduction
( \ B Z-deprotection
NHTrt
Amide coupling
0 NH
NHTrt o
77-81
NHTrt NHTrt
Scheme 5-17: Overall synthetic strategy for branched acyclic Trt amino nucleoside derivatives
5.4.2.1 Reduction of azide 72
Reduction of azides to amines can be carried out using various methods. The 
most common are hydrogenation using Pt or Pd catalysts or reduction using lithium 
aluminium hydride or sodium borohydride.129 Previously, in the group the reduction of 
azides in uridine derivatives by catalytic hydrogenation was attempted. 5% Pd/C was 
utilized. However, this resulted in reduction of the uracil ring and none of the desired 
amine was isolated.98 The Staudinger reaction is an alternative, mild and selective 
route to convert azides to amines using triphenylphosphine and ammonium 
hydroxide.129
129 Scriven, E. F. V.; Turnbull, K. Azides - Their Preparation and Synthetic Uses. Chem. Rev. 
1988, 88, 297-368.
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This method has also been used on nucleoside derivatives effectively130 and 
was therefore the method of choice in this case. The mechanism of the reaction is as 
follows:
PPh3 + N = ^ -N -R  
i ii
Ph3P—N = N -N —R 
iii
N=N
Ph3P—N -R  
6+  8-  
iv
Ph3P—N—R 
v
OH H2N -R  + 0=P P h3 
vi vii
Ns
Scheme 5-18: Mechansim of the Staudinger reaction 131
The lone pair of electrons on the phosphine i attack the terminal nitrogen atom 
of the azide ii to yield the linear triamine phosphazide intermediate iii. This 
intermediate undergoes intramolecular rearrangement via a four membered transition 
state iv to yield the iminophosphorane v with loss of N2. The iminophosphorane then 
undergoes hydrolysis to release the desired amine vi and triphenylphosphine oxide 
vii.131
NH
N ^ O  j) ph3p, Pyridine, RT 1.5hr 
ii) NH4OH, 50°C 3d 
 *
N3 37% ^  NH2
72
Scheme 5-19: Reduction of azide 72 to amine 73 under Staudinger conditions
The reaction was carried out according to Vanheusden et a/;130 However, 
hydrolysis of the iminophosphirane intermediate proved difficult. The intermediate v 
was probably stabilised due to interaction of the phenyl rings with the CbZ protecting 
group in place. Longer reaction times and heating was required. After purification by 
column chromatography, the pure amine 73 was isolated in 37% yield.
130 Vanheusden, V.; Munier-Lehmann, H.; Froeyen, M.; Dugue, L.; Heyerick, A.; De Keukeleire, 
D.; Pochet, S.; Busson, R.; Herdewijn, P.; Van Calenbergh, S. 3 '-C-branched-chain-substituted 
nucleosides and nucleotides as potent inhibitors of Mycobacterium tuberculosis thymidine 
monophosphate kinase. J. Med. Chem. 2003, 46, 3811-3821.
131 Lin, F. L.; Hoyt, H. M.; van Halbeek, H.; Bergman, R. G.; Bertozzi, C. R. Mechanistic 
investigation of the Staudinger ligation. J. Am. Chem. Soc. 2005, 127, 2686-2695.
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5.4.2.2 Tritylation of amine 73
o
NH TrtCI, Pyridinei) MW 120°C 15min
ii) MW 140°C 20min
iii) DMAP 160°C 2 x 15min 
 ►
100%
NHTrt
Scheme 5-20: Tritylation of amine 74
The next step of the synthesis was tritylation of the amino group. This was 
carried out in the microwave reactor in pyridine solvent. After exposure of the TrtCI and 
amine 73, dissolved in pyridine, to MW radiation at 120°C for 15min and then at 140°C 
for a further 20min, starting material could still be seen by TLC. A catalytic amount of 
DMAP was added to the reaction mixture which was then exposed to microwave 
radiation for a further 15min at 160°C and the reaction went to completion. In fact, the 
optimal conditions found were DMAP, TrtrCI and amine dissolved in pyridine and 
exposed to MW radiation twice at 160°C for 15min. By TLC it could be seen that the 
reaction had gone to completion. After purification by column chromatography the 
tritylated compound was isolated in 100% yield.
5.4.2.3 Deprotection -  cleavage of the benzyl carbonate protecting group
Cleavage of the benzyl carbonate protecting group can be carried out by 
hydrogenolysis. This had to be carried out selectively in the presence of the Trt moiety 
which is also labile by hydrogenolysis.
O
NH
NHTrt74
H2, Pd/C, RT 3d 
53%
NHTrt
Scheme 5-21: Cleavage of the benzyl carbonate protecting group by hydrogenolysis
The reaction was carried out using 5% Pd/C catalyst and hydrogen filled 
balloons. After stirring for 2d at RT, starting material could still be seen by TLC. Fresh 
catalyst was added and the mixture was stirred again overnight after which time the 
catalyst was filtered off through celite. After purification by column chromatography the 
desired product was isolated in 53% yield.
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5.4.2.4 Oxidation of alcohol 75
o o
HO
A .
NHTrt
NH
°  BAIB, TEMPO, ACN:H20
HO
NHTrt
Scheme 5-22: Oxidation of alcohol 75 to acid 76
The oxidation of alcohol 75 was carried out according to the BAIB, TEMPO 
procedure described in section 5.4.1.1. Formation of a new spot which stained with 
bromocresol green could be seen by TLC. However, this ran very close to BAIB which 
also stained with bromocresol green. The product, was slightly more lipophillic than the 
previous acid 58 and as a result, purification by column chromatography was 
necessary.
Analysis of the isolated product by electrospray mass spectrometry was 
complicated. Traces of the peak at 469 for compound 76 could be seen in negative 
mode. The fragment 77, with molecular weight 227, due to loss of the trityl group, was 
the main peak in negative mode, supporting evidence that acid 76 had been made. The 
presence of the trityl peaks in the 1H NMR, however, was proof that the trityl group was 
not cleaved in the main product and that 77 was a product of fragmentation during the 
electrospray process. In positive ion electrospray mass spectrometry, the Trt cation 
was the overwhelming main peak, however traces of the cyclised product 78 could also 
be seen. This product, however, may have formed during the electrospray process.
In the 1H NMR spectrum of the purified product in CDCI3, a broad peak could be 
seen at 9.39 ppm which corresponded to the acidic OH. The characteristic carbonyl 
peak at 172 ppm in the 13C spectrum could also be seen. Despite the presence of 
some contaminant peaks in the 1H NMR spectrum which could not be identified, 
compound 76 was used to carry out the next step in the synthesis.
O O
Figure 5-30: Fragments seen in electrospray mass spectrometry
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5.4.2.5 Amide coupling to carboxylic acid 76
Amide bond formation was carried out in a parallel synthesis fashion in the 
Radley’s low temperature carousel using DCC as a coupling reagent and DhbtOH as
an additive as described in section 5.4.1.2.
„  _  ,
N
NH
X
DhbtOH, Et3N, 
DMF, DCC,
0° 1 hr, RT 16hr
T r t H N ^ ^ J
NH
N ^ O
76 C T "O H O N
R=R'=H 
R=R-Me*
Piperazine 79:R=R,=H*,10% r
R=H, R-N-Z-diaminopropane* 80:R=R'=Me*, 0% 
p-alanine 81:Piperazine, 0%
82:R=H, R-N-Z-diaminopropane*, 0% 
83: p-alanine, 0%
Scheme 5-23: Amide coupling to carboxylic acid 76 *HCI salt used
Disappointingly, only amide 79 was isolated. Although, from the reaction 
utilising piperazine, some of compound 84 shown below was also isolated.
O.
y Y  r y
o
84
Figure 5-31: Compound 84
For amide 82, only starting material was isolated after column chromatography. 
Some of the amide 80 could be detected by mass spectrometry in one of the isolated 
fractions, but subsequent column chromatography resulted in isolation of unidentifiable 
products and DCC. This was likewise with amides 81 and 83. Initially, peaks 
corresponding to the molecular weights of the products could be seen by mass 
spectrometry but subsequent column chromatography on silica resulted in isolation of 
unidentifiable side products. It was therefore thought that these compounds are 
unstable to purification by column chromatography on silica gel. Alternatively, the 
starting material 76 was decomposing under these conditions. It is possible that 
intramolecular amide bond formation was taking place instead, to give compound 78.
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5.5 Modifications at position 10
As suggested by the GRID calculations carried out, described in section 5.2, a 
modification in which a carbonyl oxygen was attached to C-10 of this class of branched 
acyclic inhibitors, may also be advantageous to the binding of the inhibitors in the 
PfdUTPase active site as it may also interact with Ser92 (Figure 5-16 and 5-25). The 
Trt-amide compound 56 docked well into the active site using FlexX. The attempted 
synthesis of this compound was therefore carried out from intermediate 57 supplied by 
Medivir.
O
NH
OH
56
Figure 5-32: Trt-amide compound 56
The overall synthetic strategy was as follows:
Protection Deprotection
Amide coupling
Deprotection
Scheme 5-24: Overall synthetic strategy for Trt-amide derivative 56
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5.5.1 Orthogonal protection of compound 57
The initial challenge in the synthesis of compound 56 was to find a protecting 
group for the free hydroxyl moiety of compound 57 that was orthogonal to the TBDMS 
group. Benzyl ethers seemed suitable as they are stable to the acidic or TBAF 
conditions required to cleave the TBDMS group.128 Substituted benzyl ethers are more 
readily cleaved under oxidative conditions using DDQ132, 133 than their unsubstituted 
counterparts, a procedure to which other functionalities in the molecule should be 
stable.
The 4-methoxyphenylmethyl (4-MPM) protecting group was used in this case. 
Alcohol 57 was protected using NaH and 4-MPMCI.134 The procedure was carried out 
according to Ueda et a/.135
O M e
S i-O .
O H
7.6 7.0 6.6 6.0 6.6 5.0 4.6 4.0 3.6 3.0 2.6 2.0 1.6 1.0 0.6 ppm
Figure 5-33:1H-NMR of 4-MPM protected compound 85
132 Horita, K.; Yoshioka, T.; Tanaka, T.; Oikawa, Y.; Yonemitsu, O. On the Selectivity of 
Deprotection of Benzyl, Mpm (4-Methoxybenzyl) and Dmpm (3,4-Dimethoxybenzyl) Protecting 
Groups for Hydroxy Functions. Tetrahedron 1986. 42, 3021-3028.
133 Oikawa, Y.; Yoshioka, T.; Yonemitsu, O. Specific Removal of Ortho-Methoxybenzyl 
Protection by Ddq Oxidation. Tetrahedron Lett. 1982, 23, 885-888.
134 Marco, J. L.; Huesorodriguez, J. A. Synthesis of Optically Pure 1-(3-Furyl)-1,2- 
Dihydroxyethane Derivatives. Tetrahedron Lett. 1988, 29, 2459-2462.
135 Ueda, T.; Feng, F.; Sadamoto, R.; Niikura, K.; Monde, K.; Nishimura, S. I. Synthesis of 4- 
fluorinated UDP-MurNAc pentapeptide as an inhibitor of bacterial growth. Org. Lett. 2004, 6, 
1753-1756.
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The 1H-NMR of the crude product in CDCI3 however, showed the presence of a 
broad OH peak at 2.71 ppm and the absence of the uracil N(3)H, normally resonating 
at 8 ppm. This was suggestive of the fact that the 4-MPM group was actually attached 
to the N-3 of the uracil ring and not the hydroxyl function.
NHNH
Si-O.Si-O
57 i) 0°C, NaH
ii) TBAI, 4MPCI, 40°C 2dOH
OMe
OMe
Si-O
85
OH
Scheme 5-25: 4-MPM protection of alcohol 57
In fact, calculation of the expected pKa values of the heteroatoms of molecule 
57 using ACD/pKa DB version 7.07 showed that the expected pKg of N(3)H was 9.5 
while that of the OH was 14.5. It was therefore most likely that the NaH deprotonated 
the N-3 of the uracil ring instead of the alcohol, resulting in 4-MPMCI reaction at the N- 
3 position and attachment of the protecting group here and not at the desired position.
Protection of the N-3 of the uracil ring using the benzoyl (Bz) group which can 
subsequently be cleaved in the presence in MeNH2 in EtOH is possible. The 
benzoylation procedure was carried out using BzCI in ACN and pyridine according to a 
modified procedure of Kumar et a/;136 in an effort to initially protect the N-3 position. 
The reaction, however, was low yielding and purification difficult. This method was 
therefore abandoned and an alternative protecting group strategy sought.
NH
BnCI, ACN, pyridine, RT 16h
<30%
Scheme 5-26: Attempted benzoyl protection at N-3
136 Kumar, T. S.; Madsen, A. S.; Wengel, J.; Hrdlicka, P. J. Synthesis and hybridization studies 
of 2 '-amino-alpha-L-LNA and tetracyclic "locked LNA". J. Org. Chem. 2006, 71, 4188-4201.
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The second attempt at orthogonal protection of the alcohol 57 involved the use 
of the tetrahydropyranyl (THP) protecting group as this can be cleaved under mild 
conditions in which the Trt group should be stable.128 It is also stable to the oxidation 
conditions of BAIB and TEMPO.126 However, it does limit the deprotection step of the 
TBDMS group to the use of TBAF, as under acidic conditions, the THP group would be 
cleaved. Another disadvantage of THP as a protecting group is the formation of 
diastereoisomers as THP contains a chiral centre.
The THP ether of compound 57 was prepared according to the procedure of 
Takayama et a/;137 initially. However, the isolated yield could be improved and the 
reaction time lowered by using microwave radiation. After exposure to microwave 
radiation at 100°C for only 15min, no starting material could be seen by TLC and the 
desired THP ether was isolated in quantitative yield.
O
A mh
I  DHP, DCM, TsOH,
N °  MW 100°C 15min 
TBDXSCL J   '
v  y  100%
57 OH 87: R = Me
Scheme 5-27; THP protection of alcohol 57 * = chiral centre
The presence of two chiral centres now meant that the product existed as four 
stereoisomers. This complicated the NMR spectra of the product as the different 
diastereoisomers resonate at different frequencies. Nearly all peaks were therefore 
solved as complicated multiplets.
i  i i i
V V V
T U T  
N // in n s\ / \ l ^ i i H l i H i S U i U
»1Q fO  
1. 13
mo -ro
Figure 5-34: C NMR of 87. Peaks are multiplets
137 Takayama, H.; Fujiwara, R.; Kasai, Y.; Kitajima, M.; Aimi, N. First asymmetric total synthesis 
of Us-7 and-8, novel D-seco corynanthe-type oxindole alkaloids from Uncaria attenuata: 
Structure revision of Us-7 and determination of absolute stereochemistry. Organic Letters 2003,
5, 2967-2970.
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O  00
18 17
Si-O .
10
ppm
9, 13, 14, 1514
15
ppm
7 ,1 0 ,11 ,16
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 6.5 5.0 4.5 4.0 3.6 3.0 2.6 2.0 1.5 1.0 0.5 ppm
V V I 1s
Figure 5-35: 1H NMR of 87 in CDCI3 showing CH and CH2 multiplets due to diastereoisomers
5.5.2 Deprotection of compound 87
o
NH
Si-O.
87: R = Me 
88: R = Ph
TBAF, THF, RT 3h 
93%
Scheme 5-28: Deprotection of the silyl group from compound 87 or 88
The removal o f the TBDMS group of compound 87 and 88 was carried out 
using the TBAF method described in section 5.4.1.3 and follow ing purification by 
column chromatography, the desired product was isolated in 93% yield.
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5.5.3 Oxidation of alcohol 88
o o
NH
BAIB, TEMPO, H20:ACN, RT 8hrHO.
100%
NH
HO.
Scheme 5-29: Oxidation of alcohol 89
The oxidation of alcohol 89 was carried out using BAIB and TEMPO in wet ACN 
as described in section 5.4.1.1. The product was isolated by trituration from diethyl 
ether as a sticky gum. The product could not be seen by electrospray mass 
spectrometry. However, the 1H NMR peaks of the hydrogens attached to position 10 
had disappeared and the characteristic broad OH peak from the carboxylic acid could 
be seen at 9 ppm. The carbonyl peak of the carboxylic acid at 171.4 ppm was also 
clearly visible in the 13C NMR. The reaction was therefore deemed successful.
O
6
9
8 7
12
13
15
OH
y \
"H— r———i ■ ■ ■ " i '
10.0 9.6 9.0 8.5
J IL
i-< o  ^  
o  cm cx> ro 
r -  m ro cm
co ro ro co CM CM CM
9, 13, 14,15
12 7,11,16
J j
•-"T-*— — ~T ' " I "   I ■ | ■ . ■ . ! | .............., | | , ............... ^ ........ ^ .p . ■ . ■■ ,■ ■ .■
8J) 7.5 7.0 6.5 6.0 6.6 6.0 4.6 4.0 3.6 3.0 2^ 2.0 1.6 1.0 ppm
! •  1 lFigure 5-36: 'H NMR of acid 90
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5.5.4 Amide coupling
NHNH
H
NTrtNH2, DCc\DJa6tOH, DMFHO.
90
Scheme 5-30: Amide coupling to acid 90
The next step of the synthesis then involved the coupling of acid 90 to 
triphenylmethylamine and formation of the trityl amide 91 which in the final step needed 
to be deprotected to give the final compound 56.
The amide coupling was attempted using the previously described method of 
DCC as a coupling reagent and DhbtOH as an additive. The crude product was purified 
by column chromatography but the product 91 could not be detected in any of the 
fractions by mass spectrometry or NMR. The starting tritylamine, DCU and DhbtOH 
were isolated and the final fraction collected seemed to be the starting acid 90 but 
some undentifiable contaminant peaks were present in the 0.5-2.0 ppm region of the 1H 
NMR spectrum.
It is probable the triphenylmethylamine is too sterically hindered by the three 
phenyl rings to act as a nucleophile and attack the intermediate formed in the coupling 
reaction, preventing the reaction from being successful.
5.6 Single chain derivatives
An effort was made to identify some chemistry that might be used successfully 
in the synthesis of trityl amide derivatives. As the amide coupling procedure was 
unsuccessful, it was thought that this might be achievable through the previously 
discussed AIBN, NBS method. However, due to the limited availability of the starting 
material 57 provided by Medivir, the chemistry was first attempted on more easily 
synthesised single chain derivatives. The comparison of the activity of unbranched 
chain derivatives against the enzyme to the activity of the branched chain derivatives 
would also be interesting for further SAR investigations.
The overall synthetic strategy for the single chain derivatives was as follows:
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NH NH
NaOMe, MeOH 
RT 16h
N TPAP, NMO, DCM
I RT 16h
25% 50%
OH O
i) NBS, radical initiator,
CCI3, 95°C, 12min
ii) 0°C, TrtNH3, 10min 
 ►
0%
Scheme 5-31: Overall synthetic strategy for single chain trityl amide
The synthesis of 95 was carried out according to the procedure of Ng 
a/;74 from uracil and the mono protected diol intermediate 93 previously synthe 
the group. Oxidation of the alcohol was then carried out using the TPAP meth 
previously described to give aldehyde 96. The radical oxidative amidation read 
then attempted.
5.6.1 Synthesis of N-3 - benzoyl uracil
To avoid N-3 alkylation, the uracil was protected at the N-3 position. T 
achieved by a two step procedure consisting of N-1,N-3 double protection with 
pyridine, followed by selective N-1 deprotection carried out using K2C 0 3 in ACN 
pure product was recrystalised from acetone/H20  1:1 in 53% overall yield.
O  O  O
II i) BzCI, ACN, Pyridine, RT 16h
rf'^ N H  ii) K2C 03, glacial acetic acid, 0.5h
iL  j L  ---------------------------------------------------
N " X )  53%
H H
92
Scheme 5-32: Synthesis of N-3 protected uracil
138 Frieden, M.; Giraud, M.; Reese, C. B.; Song, Q. L. Synthesis of 1 
(hydroxymethyl)cyclobutyl -uracil, -thymine and -cytosine. Journal of the Chemical 
Perkin Transactions 1 1998, 2827-2832.
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5.6.2 Coupling to protected diol 93
Compound 92 was then coupled to the mono protected diol intermediate 93 
which was previously synthesised in the group. The coupling procedure was carried out 
using Mitsunobu methodology on polymer supported PPh3 according to the procedure 
of Hernandez et a/;139 The use of polymer supported PPh3 avoided the contamination 
of the product with the side product triphenylphosphine oxide which can be sometimes 
difficult to remove. The reaction was shaken as opposed to conventional stirring so as 
to avoid destruction of the polymer beads. Following purification by column 
chromatography on silica gel, the product was isolated in 77% yield.
O O
PS-PPh3, DIAD, THF 
RT 16h
77%
94 o
Scheme 5-33: Mitsunobu coupling of protected uracil 92 and protected diol 93
5.6.3 Deprotection of compound 94
Both of the benzoyl groups were cleaved from compound 94 simultaneously by 
stirring the compound in MeOH with NaOMe at room temperature overnight. Following 
purification by column chromatography, the pure product was isolated but in a low yield 
of 35%. It was thought that this was due to the formation of salts which were retained 
on the silica gel. Neutralising the product with Dowex H+ resin before purification 
should solve this problem and increase yield.
139 Hernandez, A. I.; Balzarini, J.; Karlsson, A.; Camarasa, M. J.; Perez-Perez, M. J. Acyclic 
nucleoside analogues as novel inhibitors of human mitochondrial thymidine kinase. J. Med. 
Chem. 2002, 45, 4254-4263.
Single chain derivatives
O O
N
N ^ O
94 o
NH
NaOMe, MeOH 
RT 16h
35%
95
OH
Scheme 5-34: Deprotection of compound 94
5.6.4 Oxidation of alcohol 95
O TPAP, NMO, DCM 
RT 16h
Scheme 5-35: Oxidation of alcohol 95 by TPAP, NMO method
The alcohol 95 was oxidised to the corresponding aldehyde using the TPAP 
and NMO method described previously. Following column chromatography on silica 
gel, the product was isolated in 50% yield. The product was identified by 1H-NMR. 
However, the characteristic peaks of the hemi-acetal product could be seen by 1H-NMR 
at 3.21 ppm and 4.45 ppm, as well as the aldehyde peak at 9.60 ppm. This may have 
been due to the fact that CD3OD was the solvent used, therefore creating a hemi-acetal 
and aldehyde equilibrium.
O
NH
MeOH
N "O
O.
Aldehyde
Hemiacetal
NH
HO.
OMe
Scheme 5-36: The equilibrium between aldehyde and hemiacetal
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5.6.5 Oxidative amidation by a radical mechanism
The oxidative amidation procedure described previously was attempted using 
aldehyde 96. The mechanism of this reaction normally proceeds through initial 
formation of the acid bromide140 through a radical mechanism followed by nucleophilic 
attack of the amine to form the amide.109 Conventionally, AIBN is the radical initiator of 
choice. However, due to the explosive nature of this compound, it was not 
commercially available. A safer alternative, 2,2’-azo-bis-(2-methylpropionamidine) 
dihydrochloride was used.
N“
h 2n
Scheme 5-37: 2,2’-azo-bis-(2-methylpropionamidine) dihydrochloride
The radical initiator, NBS and the aldehyde 96 were dissolved in CCI4 and 
heated to 95°C for 12min. The reaction was cooled to 0°C in an ice bath and tritylamine 
was added. The reaction was allowed to come to room temperature and stirred for a 
further 10min.109 Following aqueous work up, however, only starting tritylamine was 
isolated from the organic layer. The aqueous layer was found to contain aldehyde 96 
and NBS. None of the trityl amide 97 was isolated.
O O
NH
i) NBS, radical initiator, 
CClo, 95°C, 12min
ii) 0 °CXrtN>^, 1 0 min
NH
NH
Scheme 5-38: Oxidative amidation through a radical mechanism
140 Cheung, Y. F. N-Bromosuccinimide - Direct Oxidation of Aldehydes to Acid Bromides. 
Tetrahedron Lett. 1979, 3809-3810.
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5.7 Biological results
The following compounds are currently awaiting biological evaluation:
HO
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O N ^ O
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o
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Figure 5-37: Acyclic uridine analogues currently awaiting biological evaluation
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5.8 Discussion
GRID calculations carried out on the PfdUTPase enzyme suggested that 
compounds such as those shown in Figure 5-38 would hold favourable interactions 
within the active site. The most favourable interactions, most likely would be due to
1. Hydrogen bonding between the carbonyl oxygen at position 10 or 11 with the 
side chain of Ser92.
2. Hydrogen bonding between the NH moiety of G and the negatively charged 
side chain of Asp109.
Additionally, GRID calculations also suggested that the S enantiomer of these 
branched compounds would bind more favourable than the R enantiomer if the trityl 
moiety is to bind in the usual trityl binding pocket. This is due to the presence of 
Tyr112, sterically hindering the binding of the side of the R enantiomer. This theory was 
supported by subsequent docking studies in which many of the R enantiomers of the 
docked compounds either did not dock into the active at all or did so in a conformation 
in which the trityl moiety was displaced to the phosphate binding region of the active 
site and the side chain was positioned in the trityl binding pocket. (Figure 5-19 and 5-
It remains to be seen, however, whether GRID calculations and docking studies 
will correlate with biological data and what the implications are that result from the 
modifications carried out.
O
G g  = c o 2h , c o n r 1r 2
Figure 5-38: Composed proposed by GRID
20)
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5.9 Conclusion
The elucidation of the crystal structure of the PfdUTPase enzyme provided an 
excellent chance for the use of structure based design approaches to the design of 
inhibitors of the PfdUTPase enzyme. GRID calculations which were carried out seemed 
to correlate well with docking studies using FlexX.
The syntheses of the proposed compounds proved challenging. Many oxidation 
procedures were attempted, eventually leading to a successful reaction. Orthogonal 
protecting group strategies also initially required some careful thought but finally were 
achieved.
Amide coupling was the final step and proved to be successful only in a few 
cases using the conditions reported. The reaction conditions used seemed to be quite 
unpredictable depending on the substrate. Purification of the final amides also proved 
to be problematic. However, it has been shown that the amide coupling procedure is 
possible, nevertheless, this crucial step requires optimisation which due to time 
constraints was not feasible.
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6 Uracil amino acid conjugates as 
inhibitors of the Trypanosoma Cruzi 
dUTPase enzyme141
6.1 Probing of the T. cruzi active site
It has been shown that relative to other eukaryotic dUTPase enzymes, a, (3- 
imido-dUTP is a strong inhibitor of the dimeric enzymes, it has therefore been 
proposed that the triphosphate moiety is necessary for inhibition of the dimeric 
enzymes.73 This has been emphasised by the previously described tritylated inhibitors 
synthesised by the group that inhibit the trimeric enzymes but not the dimeric enzymes. 
As described in section 2.3.4, in contrast to the trimeric enzymes where a glycine-rich 
site for phosphate binding is common, the phosphates in the dimeric enzymes are held 
in place with hydrogen bonds to charged side chains.52 65
Although a,|3-imido-dUTP inhibits the dimeric enzymes, it is not a good drug 
candidate as it is non-specific and would not cross the cell membrane of the parasite 
as it is a charged molecule. The purpose of this study was to probe the active site of 
the T. cruzi enzyme by designing libraries of potential inhibitors, docking them into the 
T. cruzi active site and comparing their docking scores as calculated by the docking 
programme FlexX.108 The synthesis of the compounds with the lowest (largest minus) 
scores would then be attempted.
Analogues of the natural substrate for the enzyme, where various amino acids 
were in place of the tri-phosphate moiety were thought to be a good starting point for 
design of possible inhibitors as they had potential for a wide range of structural and 
functional variability and were synthetically viable. It was thought that the polar amino 
acids might act as good substituents, which would exert selectivity for the dimeric 
dUTPases due to the presence of many charged and polar residues in their phosphate 
binding domains compared to the trimeric forms.
141 Me Carthy, O. K.; Schipani, A.; Musso Buendia, A.; Ruiz-Perez, L. M.; Kaiser, M.; Brun, R.; 
Gonzalez-Pacanowska, D.; Gilbert, I. H. Design, synthesis and evaluation of novel uracil amino 
acid conjugates for the inhibition of Trypanosoma cruzi dUTPase. Bioorg. Med. Chem. Lett. 
2006, 16, 3809-3812.
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Figure 6-1 shows the general structure of the compounds to be docked. R and 
R’ were side chains of a number of natural amino acids, varying in size, lipophilicity and 
charge.
O O
NH
o  .. " N ' ^ o  R' OH
HO N
R O
Z X
h 2n
Y R O Y = H, COOH, NH2 R °
Z = H, COOH, NH2 X = NH, COOH
Figure 6-1: Generic structures of compounds to be docked. R, R’ = various side chains of
natural amino acids
HO N
H
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H
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X = H C O O H  NH
NH
H
NH
H
N
The crystal structure of the dimeric T. cruzi dUTPase in its native and 
complexed form has been published.52 A detailed description of the secondary and 
tertiary structure of the enzyme can be found in section 2.3.2. In summary, the enzyme 
exists in two forms. With no substrate bound, the enzyme exists in an open 
conformation (native PDB 10GL). Binding of the substrate induces substantial 
structural changes to the enzyme, causing it to bury the substrate in the enzyme core. 
When complexed with substrate, it therefore exists in a closed conformation 
(complexed PDB 10GK).
Figure 6-2: a) open (native) conformation and b) closed (complexed) 
conformation of the T. cruzi dUTPase52
A detailed description of the T. cruzi active site, in the presence of dUDP as a 
substrate, is given in section 2.3.4 (Figure 2-20). The most important residues for 
interaction with dUDP are Asn26, Gln22 and Trp 61 which hydrogen bond to the uracil 
ring; Met26 which caps the uracil ring; Asn201, Phe84 and His83 which interact with 
the deoxyribose moiety and Trp62, Tyr209, Arg204, Lys197, Asn224, Lys216, Glu49,
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Glu52 and Glu77, all of which form an intricate network of hydrogen bonds to which the 
phosphate groups are tightly positioned.52 The presence of the uracil moiety in these 
compounds is an essential starting point as the enzyme is very selective towards dUTP 
over other nucleotide bases (see Table 2-1).
6.2 Molecular modelling studies
For the purpose of this study, docking was carried out on the closed form of the 
enzyme as it is in this form that most of the protein -  ligand interactions can be seen.
Figure 6-3: Surface representations of the TcdUTPase active sites in the A) open and B) closed
forms
The presence of Mg2+ ions is also required for enzyme activity. The crystal 
structure, however, was obtained in the absence of Mg2+ ions to prevent substrate 
hydrolysis. Mg2+ ions are therefore not present in the docking models used.
The absence of water molecules from the receptor ligand complex is another 
simplification made to the docking models. This assumption was made on the basis 
that if water molecules are to be taken into account in the binding of the substrate to 
the ligand, they need to be considered as discrete entities, this strategy cannot be 
employed using FlexX. Additionally, a ligand which replaced bound water molecules 
might also be an advantage as this may actually decrease binding energy.
The most restrictive limitation of FlexX is that it does not take into account the 
flexibility of the protein. However, previous studies carried out in the group confirmed 
that FlexX was a satisfactory program for docking studies of this nature and was 
therefore the program used for the purpose of this study.
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6.2.1 FlexX
FlexX is the docking programme used in this study. It is a programme which 
takes into account the flexibility of the ligand but not the receptor. The docking method 
it uses is based on an incremental construction algorithm.108
The incremental construction strategy consists of three phases 1) base 
selection 2) base placement and 3) complex construction.
In the first phase a base or anchor fragment of the ligand is chosen 
automatically by the programme or it can be defined manually by the user.142
The docking algorithm is quite sensitive to the selection of the base fragment as 
it is the core onto which the rest of the ligand is to be built. It must be large enough to 
make numerous and specific interactions with the protein so that a definite preference 
for binding orientation can be resolved. However, the larger the fragment, the more 
conformations in which it may exist, depending on its conformational flexibility. This 
increases run times significantly. The best base fragment therefore has the maximum 
number of interaction points and the fewest number of alternative conformations. The 
uracil ring was therefore the ideal selection for the base fragment as it is a small, rigid 
heterocycle with a fixed orientation in the active site due to a specific network of 
hydrogen bonds. It was manually defined as the base fragment in this case.
The placing of the base fragment uses a technique called pose clustering. The 
ligand is assumed to be a rigid object with defined interaction points. The interaction 
surface of the receptor is also represented as finite sets of interaction points. A 
transformation takes place by superimposing three interaction sites of the ligand onto 
three interaction sites of the receptor. Once all possible transformations have been 
identified, they are checked for angular constraints and for atom collision.
ReceptorLigand
Figure 6-4: Pose clustering108
142 Rarey, M.; Kramer, B.; Lengauer, T. Multiple automatic base selction: Protein-ligand docking 
based in incremental construction without manual intervention. J. Comput.-Aided Mol. Des. 
1997, 11, 369-384.
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The remaining parts of the ligand are divided up into small fragments and 
‘grown’ onto the base fragment. The incremental construction is formulated as a tree 
search problem. The first sets of branches represent each partial placement of the 
base fragment. Each fragment is then added to each placement in the same order to 
produce the following sets of branches, one after another. A node in the tree 
represents a placement of a connected part of the ligand.
Figure 6-5: Search tree during complex construction algorithm, BP = placing of base fragment, 
F1 = placing of fragment 1, F2 = placing of fragment 2108
A box hashing technique is used in detecting ligand receptor overlap and also 
in searching for new interactions. Placements are optimised using a weighted 
superposition of points. In this method /, are fitted onto r, so that YwflrrD2 is minimised 
where: /, is the interaction centre on the ligand
#7 is the interaction point on the receptor
-Wj is the energy contribution of the interaction, given optimal geometry
All placements produced are ranked by energy, and in a greedy heuristic 
method, only the k (usually set to 500) best partial placements are used for the next 
step. This reduces run time and prevents the algorithm from getting stuck in local 
minima.
As mentioned above, FlexX takes into account the conformational flexibility of 
the ligand. The programme assigns a set of up to 12 preferred dihedral angles to each 
acyclic bond in the ligand, and systematically generates any low energy conformations 
of the ligand. FlexX assigns the most highly populated dihedral angles for each 
fragment according to the Cambridge Structural Database.
Both the interaction type and scoring function used by FlexX are based on work 
by Bohm and Klebe.143 An interaction type (Table 6-1) and an interaction geometry is 
assigned to each interacting group of the molecule. The interaction geometry consists 
of the interaction centre c, an interaction radius r, and an interaction surface which has
143 BOhm, H.-J. The development of a simple empirical scoring function to estimate the binding 
constant for a protein-ligand complex of known three-dimensional structure. J. Comput.-Aided 
Mol. Des. 1994, 8, 243-256.
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the shape of a sphere, cone, capped cone or spherical rectangle and has radius r  
around c  (Figure 6-6). An interaction between two groups A  and B is formed if 1) the 
interaction types of A and B are com patible and 2) The interaction centre of A lies 
approximately on the interaction surface of B  and vice versa.
Interaction group 
(A)
Complimentary 
interaction group 
(B)
H-acceptor H-donor
Metal acceptor Metal
Aromatic-ring atom, 
methyl, amide
Aromatic-ring-centre
nteraction
center
interactior
Table 6-1: Interaction types in FlexX Figure 6 -6 : Interaction geometries in FlexX
The scoring function used to rank solutions is an estim ate of the free binding 
energy AG of the protein-ligand complex. The equation is as fo llo w s :108
AG = AGo + AG^  x Nrof + AGhb X f(AR, Aa) + AG*, X f(AR, Aa) + AGar0 X f(AR, Aa)
neutral H-bonds ionic int. aro. int
+ AGupo Y. f  (AR)
lipo. cont.
Nro, is the num ber of rotatable bonds that are immobilized in the com plex
AG0, AG rot, AGft6, AG*, are adjustable param eters taken as developed by 
Bohm 143
AGaro accounts for the interactions of arom atic groups, and is set to -0.7 kJ/mol
AG upo is a modified term that is calculated as a pairw ise sum over all atom-atom 
contacts
f(AR, Aa) is a scaling function that penalizes deviations from ideal geom etry
AR = R — R0
R is the distance between the atom centres
R0 is the ideal value, which is assum ed to be the sum of both van der W aals 
radii plus 0.6A
As with any docking programme, FlexX has lim itations. The most severe 
restriction placed on FlexX is receptor rigidity. The advantage however is greatly 
reduced run times and it can be regarded as a reasonable approximation where the 
input structure is given in the bound state.
FlexX is lim ited to medium sized ligands. This is a lim itation resulting from the 
greedy heuristic strategy used. Assum ptions that become more and more unrealistic as 
the num ber of fragm ents increases. It has been shown, however, that ligands w ith 17 
rotatable bonds are manageable. This num ber is sufficient for most practical purposes 
in drug design and certainly for the purpose of this study.
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6.2.2 Results and discussion of docking studies
6.2.2.1 Docking study 1
Compounds with the following generic structure were docked into the closed 
form of the T. cruzi dUTPase active site. In this study amino acids of various sizes and 
lipophilic character were used to investigate steric tolerance. (Figure 6-7)
O
Amino 
acid 2
Amino 
acid 1
NH
H
— N
Amino acid 1 = Trp, Pro, Ser, Tyr 
Amino acid 2 = Asp, Glu, Gin, His, Gly
O
Figure 6-7: Compounds docked in docking study 1
Results showed that only amino acids with small side chains were tolerated in 
amino acid position 1. All compounds except compound 98 docked outside the active 
site as their side chains were too bulky.
"NH
N -^O
98
-o l b *  ir
Figure 6-8: Superimposition of some of the compounds docked in docking study 1. dUDP 
(yellow), 98 (green), 99 (orange), 100 (violet)
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6.2.2.2 Docking study 2
Compounds with the follow ing generic structure were docked into the closed 
form  of the T. cruzi dUTPase active site. Am ino acid 1 was lim ited to am ino acids with 
sm aller side chains to determ ine the largest side chain that would be tolerated at this 
position (Figure 6-9). Am ino acid 2 was varied significantly w ith each o f these am ino 
acid 1 residues.
O
Amino acid 1 = Ala. Val, Pro, Gly, Ser
Amino acid 2 = Asp, Arg, His, Thr, Phe,
Tyr, Asn, Leu, Trp
___________________________O_____________________________________________|
Figure 6-9: General structure of compounds docked in docking study 2
The com pounds with the best docking scores were those where am ino acid 1 
was either alanine or glycine. These com pounds also showed the best superim position 
over the natural substrate especially on the uracil ring. Serine was also tolerated as the 
first amino acid but the com pounds did not dock as uniform ly as with the alanine or 
glycine.
Amino 
acid 1
Amino 
acid 2
Score
( - )
Amino 
acid 1
Amino 
acid 2
Score
( - )
Amino 
acid 1
Amino 
acid 2
Score
( - )
1 0 1 Ala Asp 48.5 107 Ser Arg 47.3 105 Ser Asp 37.6
1 0 2 Ala Arg 46.4 115 Ser Trp 47.3 119 Val Asp 39.7
1 1 1 Ala His 45.4 109 Ser Phe 42.8 106 Pro Asp 40.7
103 Ala Thr 43.1 108 Ser His 42.7 1 2 0 Gly Asp 49.7
1 1 2
<
Ala Phe 42.2 116 Ser Asn 41.7 1 2 1 Gly Asn 45.5
104 Ala Tyr 40.4 1 1 0 Ser Leu 40.9 123 Gly His 44.9
113 Ala Asn 40.3 117 Ser Trp 39.2 124 Gly Thr 42.8
114 Ala
_______I
Leu
-
34.4 118 Ser Tyr
- -----------
39.1 125 Gly Arg 37.8
Table 6-2: Table of docking scores of compounds docked in docking study 2. Other compounds 
with alternate amino acids (mainly Val and Pro) in amino acid position 1 did not dock into the
active site
Amino 
acid 2
Amino 
acid 1
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Figure 6-10: Docking study 2a. Superimposition of some of the best scoring compounds 
docked in docking study 2. dUDP (yellow), 101 (green), 102 (magenta), 103 (orange), 104
(purple), 105 (red/orange), 106 (white)
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Figure 6-11: Docking study 2b. Superimposition of some of the best scoring compounds docked 
in docking study 2. dUDP (yellow), 107 (green), 108 (orange), 109 (violet), 110 (cyan)
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6.2.2.3 Docking study 3
In the third docking study, optimal chain length and charge was investigated. 
The terminal group was either a simple amino acid with no side chain or an 
unbranched diamine of various chain length. The following structures were docked into 
the active site of the enzyme.
O
NH
nH
X = COOH, NH
n = 2, 3, 4, 5 
R = CH3, H
Figure 6-12: Generic structure of compounds docked in docking study 3
Results showed that compounds with n=3 had the best superimposition over 
the natural dUDP substrate and mimicked best the dUDP size. W here n=4/5, however, 
the chain term inus could extend out to within interaction distance of a Lys, Asn and Arg 
side chain in the active site. The best scoring compounds had carboxylic acid 
terminals. This was probably due to the interaction with either the Arg or Asn residue 
which was common to all of the ligands containing the carboxylic group and which 
would alter the calculated energy favourably.
Compound X n R Score ( - ) Compound X n R Score ( - )
126 COOH 3 c h 3 37.9 132 n h 2 2 CH3 32.6
127 COOH 4 c h 3 37.1 133 n h 2 3 c h 3 30.7
128 COOH 5 c h 3 36.9 134 n h 2 4 c h 3 29.9
129 COOH 2 c h 3 32.8 135 n h 2 5 c h 3 26.3
130 COOH 4 H 36.7 136 COOH 3 H 32.3
131 n h 2 3 H 35.1 137 NH2 4 H
.
31.7
Table 6-3: Docking scores of compounds docked in docking study 3
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Figure 6-13: Superimposition of some compounds docked in docking study 3. dUDP (yellow), 
132 (green), 129 (orange), 126 (violet), 127 (cyan). 128 (magenta)
6.2.2.4 Docking study 4
To further probe fo r interactions around the T. cruzi dUTPase active site, 
com pounds with the follow ing generic structure were docked into the closed form  of the 
enzyme. A lthough the structures of these com pounds deviated quite considerably from 
the amino acid backbone previously used, it was thought that com paratively it would 
prove interesting to investigate the effect of changing positions o f positively or 
negatively charged side chains.
R = CH3, H
X =  H, COOH, NH2
Y =  H, COOH, NH2
Z =  H, COOH, NH2 
Y R O
Figure 6-14: Generic structure of compounds docked in docking study 4
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These compounds docked with the lowest (highest minus) scores and also had 
the best superimposition in the docking studies performed. In general, the docking 
scores improved when X = COOH or Y = COOH or X = Y= COOH, supporting the fact 
that a terminal COOH group was advantageous for binding.
Comp. X Y z R Score
(-)
Comp. X Y z R Score
(-)
138 H C 02H c o 2h c h 3 45.0 150 H c o 2h n h 2 H 46.9
139 H c o 2h n h 2 c h 3 45.3 151 H n h 2 c o 2h H 46.4
140 c o 2h H H c h 3 41.5 152 H H c o 2h H 44.3
141 c o 2h C 02H H c h 3 41.0 153 c o 2h n h 2 H H 44.1
142 n h 2 c o 2h H c h 3 39.1 154 c o 2h c o 2h H H 43.6
143 H H c o 2h c h 3 36.8 155 c o 2h H H H 42.3
144 n h 2 H c o 2h c h 3 35.9 156 n h 2 c o 2h H H 41.9
145 H n h 2 c o 2h c h 3 35.9 157 H c o 2h H H 41.5
146 H c o 2h H c h 3 35.1 158 C 02H H n h 2 H 40.0
1 47“ c o 2h H n h 2 c h 3 34.4 159 n h 2 H c o 2h H 37.1
148 c o 2h H c o 2h c h 3 26.2 160 c o 2h H c o 2h H 35.5
149 H c o 2h c o 2h H 50.6
Table 6-4: Docking scores of compounds docked into active site in docking study 4
Figure 6-15: Superimposition of some of the compounds docked in docking study 4. dUDP 
(yellow), 136 (green), 135 (orange), 134 (violet), 142 (magenta)
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6.2.2.5 Docking study 5
For comparison, the best scoring com pounds were docked into the open form  
of the T. cruzi enzyme. Their superim position was measured by manually placing the 
dUDP ligand in the active site w ith the same coordinates as those given for the 
complexed form. However, the scores obtained were very low. None o f the com pounds 
docked with superim position over the natural ligand dUDP and many com pounds did 
not dock inside the active site at all and produced no conformations.
Compound Score ( - ) Compound Score ( - )
127 26.8 137 19.7
134 23.9 150 19.2
1 1 1 22.3 1 0 1 18.6
113 22.3 139 18.4
1 0 2 21.4 128 17.7
159 21.1 138 17.3
143 20.1 147 12.9
107 19.9
Table 6-5: Docking scores from attempted docking into open form of active site
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6.3 Solid phase amino acid uracil acetamide synthesis
Following molecular modelling and docking studies as discussed previously, 
amino acid uracil acetamide derivatives were synthesised to investigate their anti- 
parasitic action and inhibitory activity against dUTPase enzymes, especially against 
that of the T. cruzi parasite.
Amino 
acid 2
Amino 
acid 1 NH
HO.
Figure 6-16: General structure of amino acid uracil acetamide conjugates
These amino acid uracil conjugates are similar to PNAs (peptide nucleic acids) 
which are oligonucleotides with peptide bonds in place of the sugar and phosphate 
backbone. They are normally synthesised as DNA mimics and can bind sequence 
specifically to DNA and RNA. They have several unique properties and much of the 
methodology utilised for their synthesis could be applied to these compounds.144 145,146
To synthesise these compounds, a solid phase combinatorial strategy was used 
(Scheme 6-1). Solid phase peptide synthesis was first introduced by Merrifield147 and 
the general concept depends on the attachment of the substrate to a solid, insoluble 
and filterable polymer. The advantages of this method include ease of purification and 
possibility of semi-automation resulting in combinatorial libraries being synthesised in a 
short amount of time.
Wang resin was chosen for its ability to attach carboxylic acids and to release 
them again under acidic conditions milder than those needed for Merrifield resin.148
144 Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, O. Sequence-Selective Recognition of 
DNA by Strand Displacement with a Thymine-Substituted Polyamide. Science 1991, 254, 1497- 
1500.
145 Kosynkina, L.; Wang, W.; Liang, C. T. A convenint synthesis of chiral peptide nucleic 
acid(PNA) monomers. Tetrahedron Lett. 1994, 35, 5173-5176.
146 Corradini, R.; Sforza, S.; Dossena, A.; Palla, G.; Rocchi, R.; Filira, F.; Nastri, F.; Marchelli, R. 
Epimerization of peptide nucleic acids analogs during solid-phase synthesis: optimization of the 
coupling conditions for increasing the optical purity. J. Chem. Soc., Perkin Trans. 1 2001. 1, 
2690-2696.
147 Merrifield, R. B. Solid Phase Synthesis. I. The synthesis of a Tetrapeptide. J. Am. Chem. 
Soc. 1963, 85, 2149-2154.
148 Wang, S.-S. Solid phase synthesis of protected peptide hydrazides. preparation and 
application of hydroxymethyl resin and 3-(p-benzyloxyphenyl)-1,1- 
dimethylpropyloxycarbonylhydrazide resin. J. Org. Chem. 1975, 40, 1235-1239.
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All amino acids used were protected at the N positions by the base labile 9- 
fluorenylm ethyl-oxycarbonyl (Fm oc) group to control the coupling reactions.
The side chains of the amino acids used were orthogonally protected with acid 
labile groups (tert-butyl for Asp, Glu, Thr and Tyr, Boc for Orn and Lys, Pbf for Arg and 
Trt for Asn, Gin and His) that were sim ultaneously cleaved by TFA upon cleavage o f 
the product from the resin beads.
A  sem i-automated procedure was used where 16 com pounds could be made at 
once. Reaction vials were placed in a modified shaker. A  peristaltic pump was utilised 
to pump solvents through all vials sim ultaneously. Concurrent filtration was also 
achieved using a waste or collecting manifold and suction.
R‘
Fm ocH N ^Y
O
OH
3
1.Loading of resin
50% TFA, DCM. TES
?' 20% piperidine/DMF
Y ^N H Fm oc 
O 2. Deprotection
a
R'
3. Coupling of 
second amino 
acid
FmocHNV "
TBTU. HOBt. DIPEA. 
DMF
NHFmoc
---------------- . O  H R
yYVV 4. Deprotection j
5. Coupling of 
carboxy 
uracil
W W
O R O
20% piperidine/DMF
R* O
A s
NH,
HOVo
'NH
N ^ O
TBTU. HOBt, DIPEA. DMF
Scheme 6-1: Overview of solid phase synthetic strategy
6.3.3 Loading of resin
DIC/DMAP is used in this esterification reaction. The reaction proceeds via 
form ation of the anhydride as shown in Schem e 6-2.
The resin must first be swelled in DMF before the reagents were added. This is 
essential for the free access of the functional groups to the polymer. The less the
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reaction space is restricted by the polymeric support of the beads, the more favourable 
the reaction conditions and the higher the loading obtained.149
FmocHNNHFmoc
OH NHFmoc NHFmocNHFmoc
N=C=
R' DMAP
NHFmoc NHFmoc
Q Amino acid 2
Wang resin
Scheme 6-2: Loading of the resin
6.3.3.1 Estimation of level of first residue attachment
The resin loading (mg amino acid attached/g resin) was estimated manually. 
There are a number of reasons for this. The precise amount of functionality on the resin 
is not given by the manufacturer. Only a wide range of pre-measured loading values 
are given. The number of hydroxyl groups or reaction centres exposed on the surface 
of the beads may vary due to swelling conditions or amount of resin, therefore the 
quantity of first amino acid that becomes attached may vary.
An Fmoc UV absorbance test was used to monitor the attachment of the first 
amino acid to the resin. A weighed amount of resin was placed in a quartz cuvette in a 
solution of 20% piperidine in DMF. Under these conditions the Fmoc protected group of 
the attached amino acid is cleaved and its UV absorbance of the resulting 
dibenzofulvene (DBF) at 290nm is measured. Using the equation:
Fmoc loading: mmole/g = (Abs)/(1.65 x mg resin)150 
The Fmoc and therefore amino acid attachment can be calculated.
Conditions Calculated resin loading (mg/g)
1 Hour (DMAP present) 0.03-0.16
Overnight (no DMAP) 0.35-0.51
Overnight (DMAP present) 0.8-1.2
Table 6-6: Calculated resin loadings 
Therefore the resin was loaded in the presence of DMAP overnight.
149 Bayer, E. Towards the chemical synthesis of proteins. Angew. Chem. 1991. 30, 113-216.
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6.3.4 Coupling to amino acids
Deprotection o f the Fmoc protecting group was achieved by treating the 
derivatised resin beads with 20% piperidine in DMF. Subsequently coupling of the 
second amino acid was carried out using TBTU/ HOBt as coupling reagents.151 A  
proposed mechanism o f activation is as follows:
FmocHN
o  f l
DIPEA F m o c H N ^ X Q
R
' A t e
/ = * ( $ >  BF<‘ 
y j - v
TBTU
-OBt
o
Fm ocH N ^ilQOBt
NHFmoc
Amino 
acid 2
Amino 
acid 1
20% Piperidine/DMF
NHFmoc
Scheme 6-3: Proposed mechanism of activation/coupling by TBTU/HOBt/DIPEA combination
Following a second deprotection step, 1-carboxymethyl uracil was then coupled 
on to the derivatised resin. The TBTU/HO Bt/D IPEA method was again used. Coupling 
using the EDC method was also attem pted, however, the ninhydrin test was positive 
(blue), indicating that a free am ine was still present and that the coupling was not 
successful.
150 Merck Bioscience 2002/2003, Novabiochem catalogue
151 Knorr, R.; Trzeciak, A.; Bannwarth, W.; Gillessen, D. New Coupling Reagents in Peptide 
Chemistry. Tetrahedron Lett. 1989, 30, 1927-1930.
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a
0  H ? 
N
O ' " j  k '  'NHFmoc
R’ O
Piperidine
Amino Amino 
acid 2 acid 1
: o R :
^ 4 > A r NjirA (f
0  Hi! ?  ;o ,
, A ^ n ^ nh
TBTU
HOBt
DIPEA
Scheme 6-4: Coupling of carboxyuracil
6.3.5 Monitoring of the reactions
One of most difficult problems encountered in solid phase synthesis is the 
monitoring of the reactions. The progress of the reactions cannot be assessed by 
conventional TLC, mass spec or NMR without first cleaving the product from the resin 
beads. Therefore different procedures must be used.
The deprotection and coupling reactions were monitored using a modified 
ninhydrin test. This is a simple colour change test, which can detect the presence or 
absence of free amines on the beads.152
Deprotection of amino groups was monitored with a positive (blue resin beads) 
test, indicating that free amino groups were present. Coupling reactions were 
monitored with a negative (pink beads) test, showing all of the amino groups had 
reacted.
The ninhydrin reaction proceeds as follows:
OH OH
-CO­OH
NH-
OH
ninhydrin
NH2
purple coloured product
Scheme 6-5: Mechanism of the ninhydrin test
152 Sarin, V., K.; Kent, S., B. H.; Tam, J., P.; Merrifield, R. B. Quatitative Monitoring of Solid- 
Phase Peptide Synthesis by the Ninhydrin Reaction. Anal. Biochem. 1981, 117, 147-157.
- 153-
6 Uracil amino acid conjugates
6.3.6 Cleavage from the resin beads
W ang resin is cleaved under acidic conditions. As standard cleavage 
procedures of 95% TFA in DCM 150 seem ed to cause excess cleavage of peptide bonds 
in the molecule and resulted in undesired products, the cleavage conditions had to be 
optim ised. D ifferent cleavage conditions were attempted.
Cleavage procedure Time (mins) Conditions
Cleavage procedure A 60 95% TFA, 2.5% TES, 2.5% DCM
Cleavage procedure B 30 95% TFA, 2.5% TES, 2.5% DCM
Cleavage procedure C 60 50% TFA, 5% TES, 45% DCM
Cleavage procedure D 60 50% TFA, 2.5% TES, 47.5% DCM
Cleavage procedure E 30 50% TFA, 2.5% TES, 47.5% DCM
Table 6-7: Cleavage conditions attempted 
50% triflouroacetic acid (TFA) with the presence of a small am ount of 5% 
triethylsilane (TES) as an alkyl scavenger in DCM (cleavage procedure C) was found to 
be the optimal conditions fo r release of the desired products147 153 which were 
subsequently precipitated from cold ether after removal of the solvent in vacuo.
50% TFA, 45% DCM, 
5% TES
NH
Resin beads ;o u : n
w
HO
Amino Amino 
acid 2 acid 1
Scheme 6 -6 : Cleavage from resin beads
6.3.7 Results of solid phase synthesis
The com pounds were characterised by low resolution and high resolution mass 
spectrom etry and 1H NMR. Com pounds o f greater than 90% purity, as evaluated by 1H- 
NMR were subm itted fo r biological evaluation. Only 11 o f the 24 com pounds whose 
syntheses were attem pted were isolated in sufficient quantity and purity fo r b iological 
assays.
153 Pearson, D. A.; Blanchette, M.; Baker, M. L.; Guindon, C. A. Trialkylsilanes as Scavengers 
for the Triflouroacetic acid Deblocking of protecting Groups in Peptide Synthesis. Tetrahedron 
LettS9. 30, 2739-2742.
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Some of the compounds synthesised were not included in the docking studies 
but were synthesised never the less for comparative studies.
Compound Amino 
acid 1
Amino 
acid 2
No. times 
synthesis 
attempted
Outcome
101 Ala Asp 3 Tested in biological assays
102 Ala Arg 3 No product isolated. NMR showed a mixture 
of carboxyuracil and compound 165
103 Ala Thr 3 Tested in biological assays
104 Ala Tyr 2 Tested in biological assays
111 Ala His 2 Detected by mass spec but insufficiently 
pure by 1H NMR (peaks in 1-1.5ppm)
112 Ala Phe 1 No product isolated, just carboxyuracil
113 Ala Asn 3 Detected by mass spec but insufficiently 
pure by 1H NMR*
161 Ala Gin 3 Tested in biological assays
162
!
Ala Orn 1 Detected by mass spec but insufficiently 
pure by 1H NMR *
163 Ala Lys 4 Tested in biological assays
164 Ala Glu 4 Tested in biological assays
165 Ala 2 Detected by mass spec but insufficiently 
pure by 1H NMR *
166 Ala Gly 1 Tested in biological assays
120 Gly Asp 4 No product isolated, just carboxyuracil
121 Gly Asn 3 No product isolated. NMR showed a mixture 
of carboxyuracil and compound 172
123 Gly His 3 No product isolated. NMR showed a mixture 
of carboxyuracil and compound 172
124 Gly Thr 3 Tested in biological assays
125 Gly Arg 1 No product isolated
167 Gly Gin 2 Detected by mass spec but insufficiently 
pure by 1H NMR *
168 Gly Tyr 2 Tested in biological assays
169 Gly Glu 4 Detected by mass spec but insufficiently 
pure by 1H NMR *
170 Gly Orn 2 No product isolated, just carboxyuracil
171 Gly Lys 3 Tested in biological assays
172
... .. .  _
Gly 2 Tested in biological assays
Table 6-8: Compounds synthesised by solid phase methodology. * NMR showed a mixture of 
product, carboxyuracil and either compound 165 or 172
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6.4 Biological results: Dimeric dUTPases and
trypanosome parasites
Figure 6-17: Uracil amino acid conjugates
Enzyme assays (Kj = MM) In vitro  assays (IC5C, = pM)
Compound T. cruzi L. maj. P. talc. Hum. T. cruzi T. bruc. L  don. P. falc Tox.a
101 >1mM >1mM >1mM >1mM >84 >252 >84 >84 >252
103 >1mM >1mM >1mM >1mM >87 >262 >87 >14 >262
104 >1mM >1mM >1mM >1mM >74 >222 45.8 >12 214.4
i
161 >1mM >1mM >1mM >1mM >81 >243 >81 >14 >243
163 >1mM >1mM >1mM >1mM >81 >243 >81 >13 >243
164 >1mM >1mM >1mM >1mM >81 >243 37.0 >13 210.4
166 >1mM >1mM >1mM >1mM >100 >301 69.7 >16 >301
124 >1mM >1mM >1mM >1mM >91 >274 >91 >15 >274
168 >1mM >1mM >1mM >1mM >76 >230 >76 >12 >230
171 >1mM >1mM >1mM >1mM >84 >253 >84 >14 >253
172 >1mM >1mM >1mM >1mM >132 >396 95.1 >22 >396
Standard 18.40b 13.05b 0.38c 1.04d 0.008e 0.16f 0.149 0.15e
Table 6-9: Biological results of the uracil amino acid conjugates against the dimeric dUTPases 
and in vitro results against the trypanosome parasites.a Toxicity tests were carried out on rat L6 
cells bdUMP cDMT-dU dBenznidazole6Melarsoprol fMiltefosine 9Chloroquine ePodophyllotoxin
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6.4.8 Results and discussion
Biological results
1000
100
pM
Toxicity
T. cruzi
TcdUTPase
■ TcdUTPase
□ T. cruzi
C o m p o un ds □ Toxicity
Figure 6-18: Inhibitory activity of the uracil amino acid conjugates against the dimeric enzymes
and T. cruzi parasite
As can be seen from Table 6-9, none of the uracil amino acid conjugates 
synthesised inhibited the TcdUTPase enzyme at a concentration of 1mM. Neither did 
the compounds inhibit parasite growth at the maximum concentrations shown. In this 
case, molecular modelling studies did not correlate with biological data. There may be 
a number of possible reasons for this outcome.
Recently, the crystal structure of the dimeric Campylobacter je jun i dUTPase 
revealed the coordination of Mg2+ ions within the active site o f the enzyme.65 These 
ions are absent in the TcdUTPase crystal structure and it is unclear whether these 
Mg2+ ions are bound to the native enzyme but it is possible that the presence of these 
ions must be taken into account when designing inhibitors in silico.
As previously mentioned, FlexX does not take into account the flexibility of the 
protein in question. Although this approximation reduces run time significantly, in this 
case where binding of the ligand induces a large conformational change in protein 
structure it is possible that a docking program in which protein flexibility is taken into 
account should be used. It would be extremely challenging for a program to cope with 
the conformational flexibility shown by the dimeric dUTPases, however.
-157 -
6 Uracil amino acid conjugates
It is possible that for the dimeric dUTPases, the presence of the triphosphate 
moiety is essential for substrate or inhibitor binding itself. Two mechanisms of binding 
could be envisaged. Firstly, the uracil and deoxyribose moieties which bind to motifs 
from the rigid domain of protein would be recognised. The a, (3 and subsequently y 
phosphates, which are recognized by mobile domain motifs, would then bond to the 
Mg2+ ions and respective amino acid side chains sequentially and induce ‘active site 
closure’. Alternatively, the phosphate moieties would be recognised by the mobile 
domain first and then the protein would undergo such a conformational change as to 
encapsulate the uracil and sugar moieties. In the latter case, the phosphate moieties 
would be more essential for ligand recognition and therefore replacement of them 
would be detrimental to ligand recognition. This would explain the lack of activity of the 
uracil amino acid conjugates.
6.5 Conclusion
Following molecular docking and modelling studies that were carried out on the 
TcdUTPase enzyme using the program FlexX, several uracil amino acid conjugates 
were successfully synthesised by solid phase methodology. The sufficiently pure 
compounds were then tested for inhibition of the TcdUTPase and of parasite growth by 
our collaborators. Disappointingly, none of the compounds tested inhibited the dimeric 
dUTPase at concentrations greater then 1mM, nor did they inhibit parasite growth. 
Thus, the search so far for lead inhibitors of the dimeric dUTPase enzymes remains 
unsuccessful.
Molecular modelling studies did not correlate with biological data in this case. 
Many theoretical reasons may be envisaged for this. Ultimately, however, it is obvious 
from experimental biological data that the uracil amino acid compounds do not possess 
the required structure to bind to the open form of the enzyme sufficiently enough to 
induce the conformational change required for inhibition. Although the compounds 
docked with good superimposition and favourable binding energies into the 
TcdUTPase active site with FlexX, it is apparent that other factors such as protein 
flexibility and the presence of Mg2+ ions should be taken into account when designing 
competitive inhibitors for these enzymes in silico.
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7 Conclusions
This project was divided into two main studies; firstly, the modification of known 
and selective inhibitors of the trimeric PfdUTPase in an effort to increase their potency 
for use as anti malarials; secondly, the structure based design and synthesis of 
potential lead inhibitors of the dimeric TcdUTPase for use as trypanocides.
7.1 Trimeric PfdUTPase inhibitors for use as anti- 
malarials
The introduction of an amide bond into the scaffold of previously discovered 
selective inhibitors of the Plasmodium falciparum dUTPase led to the synthesis of a 
range of uracil acetamide derivatives. It was thought that through amide coupling 
methodology, a wide range of functional variability could be introduced to these 
molecules and therefore this modification would be advantageous for diversification 
studies and ultimately to increase the potency of our inhibitors.
Series of single chain and branched chain tritylamino and hydroxyl derivatised 
uracil acetamides were successfully synthesised. Selective protection and deprotection 
of polyamines and subsequent coupling to 1-methylcarboxy uracil was carried out to 
yield a wide range of these derivatives.
Unfortunately, these compounds were not potent inhibitors of the dUTPase 
enzymes. Introduction of an amide bond at the P-C to the N-1 of the uracil ring resulted 
in a loss of activity against the PfdUTPase enzyme. Molecular modelling and 
conformational studies showed that this may have been due to the fact that the low 
energy conformation of the uracil acetamide compounds must overcome an energy 
barrier to adopt the required binding conformation. Additionally, there may be an 
unfavourable interaction between the 0-2 of the uracil ring and the carbonyl oxygen of 
the amide bond in the proposed bound conformation leading to a decrease in potency 
of these compounds.
The uracil acetamide compounds do retain good activity in vitro. Their mode of 
action has not yet been ascertained, nonetheless, it is known that the presence of the 
uracil ring and the trityl or TBDPS moieties are required for activity.
- 159 -
7 Conclusions
Following the elucidation of the crystal structure of the PfdUTPase enzyme with 
a known inhibitor bound, structure based drug design approaches utilising this 
information were employed. Attention was focused on known branched, acyclic 
PfdUTPase inhibitors as a starting point for further inhibitor development. Molecular 
probe interaction calculations carried out by GRID, followed by docking studies gave 
rise to some observations that were utilised in the design of potentially more potent 
dUTPase inhibitors. The synthesis of the proposed modified compounds was carried 
out from intermediates kindly provided by Medivir and the successfully synthesised 
compounds were submitted for biological evaluation, the results of which are being 
awaited.
7.2 Dimeric TcdUTPase inhibitors as trypanocides
The crystal structure of the dUTPase from Trypanosoma cruzi revealed that the 
enzyme undergoes an extremely significant conformational change on ligand binding. 
In the unliganded form, the active site is large and exposed relative to that of the 
liganded conformation in which the substrate is effectively buried by the active site. No 
selective inhibitors of this enzyme were known.
Molecular docking and modelling studies were therefore carried out on the 
closed form of the TcdUTPase enzyme using the program FlexX, leading to the design 
of several uracil amino acid conjugates that docked with good superimposition over the 
natural ligand and seemed to bind in the active site. Some of these compounds were 
successfully synthesised by solid phase methodology. The sufficiently pure compounds 
were then tested for inhibition of the TcdUTPase and of parasite growth. 
Disappointingly, none of the compounds tested inhibited the dimeric dUTPase at 
concentrations greater then 1mM, nor did they inhibit parasite growth. Thus, the search 
so far for lead inhibitors of the dimeric dUTPase enzymes remains unsuccessful.
Molecular modelling studies did not correlate with biological data in this case. 
Many theoretical reasons may be envisaged for this. Ultimately, however, it is obvious 
from experimental biological data that the uracil amino acid compounds do not possess 
the required structure to bind to the open form of the enzyme sufficiently enough to 
induce the conformational change required for inhibition. Although the compounds 
docked with good superimposition and favourable binding energies into the 
TcdUTPase active site with FlexX, it is apparent that other factors such as protein 
flexibility and the presence of Mg2+ ions should be taken into account when designing 
competitive inhibitors for these enzymes in silico.
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8 Experimental I
8.1 General remarks
IR spectra were recorded at an FT-IR spectrometer 1600 from Perkin Elmer using the 
Diffuse Reflectance Accessory from Spectra Tech. (Refl.) and a potassium bromide 
pellet (KBr). The band positions were characterised by their wave numbers (v/cnrf1) and 
assignment. (For IR values obtained w= weak strength signal, m= medium strength 
signal, s = strong signal)
Mass spectra were recorded at a Platform II mass spectrometer (Micromass) from 
Fisons, a Mariner mass spectrometer or at a MicroTOF mass spectrometer from Bruker 
Daltonics where ionisation was achieved in the positive and negative electrospray 
modes using a 1:1 mixture of acetonitrile and water plus 0.2% formic acid or a 95:5 
mixture of methanol and water plus 0.2% formic acid as a mobile phase, m/z Values 
are given together with the assignment of ion peaks. High resolution mass spectra 
were recorded by the National Mass Spectrometry Service Centre in Swansea at a 
MAT 900 XLT high resolution double focussing mass spectrometer from Finnigan or by 
University of Birmingham at a Micromass LCT spectrometer. High resolution mass 
spectra were also recorded at a MicrOTOF mass spectrometer from Bruker Daltonics. 
Accurate mass measurement was performed by peak matching.
1H-NMR spectra were recorded at a Bruker 300 MHz NMR spectrometer or at a Bruker 
500 MHz NMR spectrometer using the applied solvent simultaneously as internal 
standard. Chemical shifts (5) are given in ppm together with the multiplicity, relative 
frequency, assignment and the coupling constants (nJ(H,H)/MHz) of the observed 
signals. Chemical shifts for AB-systems are directly deduced from Mestre-C free 
software or Bruker Topspin programme. (For NMR values given s = singlet, d = 
doublet, t = triplet, q = quartet, qn = quintet, m = multiplet, br = broad)
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13C-NMR spectra were recorded at a Bruker 300 MHz spectrometer or at a Bruker 500 
MHz spectrometer using the applied solvent simultaneously as internal standard. 
Chemical shifts (5) are given in ppm. Chemical shifts for AB-systems are directly 
deduced from Mestre-C free software or Bruker Topspin programme.
Purification by column chromatography was performed on Sorbosil C60A silica gel- 
40-60 pm from Merck. Flash chromatography was performed using the Flashmaster II 
from Jones Chromatography and Isolute® propylene columns which were prepacked 
with silica. Qualitative thin layer chromatography (TLC) was done on precoated 
aluminium sheets Silica gel 60 F254 from Merck. Compounds were detected either with 
ninhydrin, bromocresol green, iodine, KMn04or 254 nm UV light.
Elemental analysis was carried out by the analytical and chemical consultancy 
services MEDAC LTD. Found percentage values are reported together with calculated 
values for different salt compositions as indicated by the preceding formula.
Melting points were determined with a Gallenkamp melting point apparatus and are 
not corrected.
Solvents and reagents were purchased from Sigma-Aldrich, Fluka or Lancaster and 
were used without further purification. Dry solvents were purchased in sure sealed 
bottles stored over molecular sieves. Deuterated solvents were purchased from Goss. 
Resins and amino acids were purchased form Novabiochem.
All molecular modelling was carried out on a silicon graphics work station or a Mac 
OS using SYBYL 6.9 or 7.2. GRID calculations were carried out on a windows 
operating system using software obtained from Molecular Discovery.
The numbering and nomenclature system used for the drawn structures in the following 
chapters is to aid NMR interpretation and is not effectively referring to IUPAC 
nomenclature.
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8.2 General procedures
General procedure A: tert-Butyl diphenyl silylation of hydroxyl group using DMF 
and imidazole
TBDPSiCI (1.1 eq.) dissolved in DMF (0.2 mL/mmol) was added to a mixture of 
imidazole (2.2 eq.) and the alcohol (1 eq.) dissolved in DMF (0.1 mL/mmol) under N2 or 
Ar atmosphere. The mixture was left stirring at RT until the disappearance of the 
starting material was observed by TLC.
General procedure B: fe#f-Butyl diphenyl silylation of hydroxyl group using 
pyridine
TBDPSiCI (1.1 eq.) dissolved in pyridine was added to the alcohol (1 eq.) dissolved in 
pyridine. The solution was stirred at RT under N2 or Ar atmosphere until the 
disappearance of the starting material was observed by TLC.
General method C: EDC mediated coupling to form amide bonds
1-Carboxyuracil 1 (1.3 eq.) and EDC (1.4 eq.) dissolved in DMF (2 mL/mmol) was 
added to the amine (1 eq.) under N2 or Ar atmosphere. The reaction was left at RT, 
usually overnight. The solvent was evaporated off and the crude purified by column 
chromatography.
General procedure D: Mono-tritylation of diamines
TrtCI (0.1 eq.) dissolved in DCM (2.5 mL/mmol) was added to the diamines in DCM 
(0.1 mL/mmol) and left stirring under N2 at RT overnight. The mixture was poured into 
50mL ice water and extracted with ether (1 x 100 mL, 2 x 50 mL). The organic layer 
was washed with water (2 x 50 mL), brine (1 x 50 mL) and dried with MgS04. The 
solvent was evaporated off. The product was purified by flash chromatography.
General procedure E: Carbobenzoxy protection of terminal NH groups of 
triamines
The relevent triamine (1 eq.) and DMAP (0.2 eq.) were dissolved in DCM (0.7 
mL/mmol). 23 (2 eq.) in DCM (1 mL/mol) was added under N2 atmosphere. The 
reaction was left stirring overnight at 50°C. The solvent was evaporated off under 
reduced pressure and the product purified by flash chromatography.
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General procedure F: Removal of the CbZ protecting group by hygrogenation
5% Pd/C (0.1 eq w/w) was preactivated with hydrogen in a round bottomed flask using 
a hydrogen balloon. The relevant protected amine dissolved in either MeOH or a 1:1 
mixture of MeOH.EtOH was added. The mixture was flushed with hydrogen three times 
using a hydrogen balloon and finally left stirring under hydrogen until the dissaperance 
of the starting material was observed by TLC. The catalyst was removed by filtration 
after flushing the system with N2.
General procedure G: Removal of the silyl protecting group using TBAF
The relevant silyl protected alcohol was stirred in a solution of TBAF in THF (1M, 
2.0mL/mmole eq) at RT until the disappearance of the starting material was observed
Uracil (2.98 g, 26.64 mmol), chloroacetic acid (4.41g, 47.67mmol) and KOH (6.57 g, 
117.12 mmol) were dissolved in 100 mL water and refluxed for 1h. The reaction 
mixture was cooled to room temperature and acidified to pH 2 with HCI (32% w/w in 
water). The mixture was left at 4°C overnight. The white precipitate formed was 
collected by filtration and washed with water (50 mL), ethanol (50 mL) and EtOAc (50 
mL) to afford 3.16g of the product as a white powder.
Yield: 71%
Melting point: 287-290°C (Lit. 287°C80)
Rf: 0.1 in CHCIa/MeOH , 9:1
IR : (KBr)vmax/cm'1 3082.2 (m, OH), 1698.0 (s, C 02H), 1402.6 (m, OH bending),
1280.8 (m, CO), 845.9 (m, ring CH)
1H-NMR: (300 MHz, DMSO) 6 4.43 (2 H, s, C(7)H2), 5.60 (1 H, d J=7.9,C(5)H), 7.62 (1 
H, d J=7.9,C(6)H), 11.35(1 H, s, N(3)H), 13.13 (1 H, br, OH)
13C-NMR: (75 MHz, DMSO) 6 49.4 (C-7), 101.7 (C-5), 146.9 (C-6), 151.9 (C-2), 
164.7(C-4), 170.4 (C-8)
LRMS (ES ): m/z = 168.8 [M-H]'
by TLC.
8.3 (1) Synthesis of 1-carboxymethyluracil 80
o
o
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8.4 (3) Synthesis of 2-(ferf-butyldimethylsilanyloxy)-
ethylamine
TBDMSiCI (2.47 g, 16.39 mmol) dissolved in DMF (4 mL) and imidazole (2.90 g, 42.61 
mmol) were added to 1,2-ethanolamine (1.0 g, 16.39 mmol) under N2 atmosphere. The 
reaction was left for 7 h at RT. The mixture was poured into 200 mL water and 
extracted with EtOAc (300 mL). The crude product was washed with 5% NaHC03 (50 
mL) and dried with Na2S04. The solvent was was removed in vacuo and the product 
purified by column chromatography (CH2CI2/MeOH 9:1). The product was isolated in 
low yield as a clear oil. (<250mg).
Yield: <10%
Rf: 0.5 in CHCIa/MeOH , 9:1
’H-NMR: (300 MHz, MeOD) 6 0.10 (6 H, s, 2 x C(3)H3), 0.90 (9 H, s, 3 x C(6)H3), 2.65 
(2 H, m, C(1)H2), 3.58(2 H, m, C(2)H2)
3
5
6
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8.5 (4) Synthesis of 2-(fert-butyldiphenylsilanyloxy)
ethylamine
6
NH7 Si-O
Compound 4 was prepared according to the general procedure A using TBDPSiCI 
(4.50 g, 18.59mmol), imidazole (2.91 g, 42.61 mmol) and ethanolamine (1.00 g, 16.39 
mmol) The reaction was repeated according to general procedure B using TBDPSiCI 
(3.90 g, 36.07mmol) and ethanolamine (2.00 g, 32.79 mmol) in pyridine (20 mL) The 
solvent was was removed in vacuo. The crude was purified by flash chromatography 
(CH2CI2/MeOH/NH3100:0:0—>95:4:1) to yield a yellow oil (3.7g for procedure B and 3.4g 
for procedure A)
Yield: 35% (method A), 38% (method B)
Melting point: 104-106°C
Rf: 0.5 in CH2Cl2/MeOH/NH3 95:4:1
1H-NMR: (300 MHz, MeOD) 5 1.10 (9 H, s, 3 x C(8)H3), 2.76 (2 H, t 5.6 C(1)H2),
3.70 (2 H, t J= 5.6 C(2)H2), 7.39-7.71 (10 H, m, 4 x C(4)H, 4 x C(5)H, 2 x C(6)H) 
13C-NMR: (75 MHz, MeOD) 6 20.4 (C-7), 27.8 (3 x C-8), 44.9 (C-1), 66.9 (C-2), 129.2 
(4 x C-5), 131.3 (2 x C-6), 135.1 (4 x C-4), 137.0 (2 x C-3)
LRMS (ES+): m/z= 300.2 [M+H+], 600.3 2[M+H]+
HRMS (ES+): Found: 300.1792 [M+H]+ C^HzeONSi requires 300.1778
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8.6 (5) Synthesis of 3-(fert-butyldiphenylsilanyloxy)
-propylamine
7
8 Si-O NH
Compound 5 was synthesised according to the general procedure A using TBDPSiCI 
(12.10 g, 44.00 mmol), imidazole (6.00 g, 88.00 mmol) and 1-amino-3-propanol (3.00 
g, 40.00 mmol). The mixture was poured into water (150 mL) and extracted with EtOAc 
(2 x 100 mL). The organic layer was washed with NaHC03 (100 mL), dried with MgS04 
and the solvent was removed in vacuo. The product was purified by flash 
chromatography (CH2CI2/MeOH/NH3 100:0:0—>95:4:1) as a colourless oil (0.81 g).
Yield: 7%
Rf: 0.3 in CH2CI2/MeOH/NH3 90:8:2
1H-NMR: (300 MHz, MeOD) 6 0.95 (9 H, s, 3 x C(9)H3), 1.71 (2 H, qn J= 6.5, C(2)H2), 
2.78 (2 H, t J=6.5, C(1)H2), 3.73 (2 H, t J=6.5, C(3)H2), 7.36 (10 H, m, 4 x C(5)H, 4 x 
C(6)H, 2 x C(7)H)
13C-NMR: (75 MHz, MeOD) 6 20.5 (C-8), 27.9 (3 x C-9), 36.5 (C-2), 40.3 (C-1), 63.6 
(C-3), 129.3 (4 x C-6), 131.4 (2 x C-7), 135.2 (4 x C-5), 136.7-137.4 (2 x C-4)
LRMS (ES+): m/z= 314.2 [M+H]+, 627.9 2[M+H]+
HRMS (ES+): Found: 314.1935 [M+H]+ Ci9H28ONSi requires 314.1935
-  167 -
Experimental I
8.7 (6) Synthesis of 4-(tert-butyldiphenylsilanyloxy)-
butylamine
8
NHSi-O10
Compound 6 was synthesised according the general procedure A using TBDPSCI 
(10.19 g, 37.07 mmol), imidazole (5.08 g, 74.14 mmol) and 1-amino-4-butanol (3.00 g,
33.70 mmol). The mixture was poured into water (150 mL) and extracted with EtOAc 
(200 mL). The organic layer was washed with NaHC03, dried with MgS04 and the 
solvent was removed in vacuo. The product was purified by flash chromatography 
(CH2Cl2/MeOH/NH3 100:0:0—95:4:1) as a colourless oil (1.52 g).
Yield: 14%
Rf. 0.2 in CH2Cl2/MeOH/NH3 90:8:2
1H-NMR: (300 MHz, MeOD) 6 1.05 (9 H, s, 3 x C(10)H3), 1.61 (4 H, m, C(2)H2, C(3)H2),
2.63 (2 H, t J=6.7 C(1)H2), 3.69 (2 H, m, C(4)H2), 7.36-7.60 (10 H, m, 4 x C(7)H, 2 x 
C(8)H), 4 x C(6)H)
13C-NMR: (75 MHz, MeOD) 6 20.5 (C-9), 27.9 (3 x C-10), 30.5 (C-2), 31.5 (C-3) 42.8 
(C-1), 65.0 (C-4), 129.3 (4 x C-7), 131.3 (2 x C-8), 135.3 (4 x C-6), 137.1 (2 x C-5) 
LRMS (ES+): m/z= 328.2 [M+H]+
HRMS (ES+): Found: 328.2098 [M+H]+ C^HaoONSi requires 328.2091
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8.8 (8) Synthesis of N-[3-(fert-
butyldiphenylsilanyloxy)-propyl] uracil acetamide
o
Compound 8 was synthesised according to general procedure C using carboxyuracil 1 
(349 mg, 2.08 mmol), 5 (500 mg, 1.6mmol) and EDC (430 mg, 2.24 mmol). The 
product was purified by flash chromatography (CH2CI2/MeOH 100:0—>94:6) as a white 
solid (454 mg).
Melting point: 186°C 
Yield: 61%
Rf: 0.5 in CH2CI2/MeOH 90:10
1H-NMR: (300 MHz, MeOD) 6 1.05 (9 H, s, 3 x C(17)H3), 1.79 (2 H, qn J=6.5, C(10)H2), 
3.37 (2 H, m, C(9)H2), 3.75 (2 H, t J=6.5, C(11)H2), 4.35 (2 H, s, C(7)H2), 5.67 (1 H, d 
J= 7.9 C(5)H), 7.40 (6 H, m, 2 x C(15)H, 4 x C(14)H), 7.42 (1 H, d J= 7.9, C(6)H), 7.68 
(4 H, m, 4 x C(13)H)
13C-NMR: (75 MHz, DMSO) 6 18.8 (3 x C-17), 26.6 (C-16), 32.0 (C-10), 45.1 (C-9),
49.4 (C-7), 61.2 (C-11), 100.4 (C-5), 127.9 (2 x C-15), 129.8 (4 x C-14), 133.2 (4 x C- 
13), 135.0 (2 x C-12), 146.6 (C-6), 151.0, (C-2), 163.9 (C-4), 166.5 (C-8)
LRMS (ES ): m/z= 464.0 [M-H]'
HRMS (ES+): Found: 466.2159 [M+H]+ C25H3204N3Si+ requires 466.2157 
Analysis: Found: C, 64.4; H, 6.8; N, 8.9
Calc, for C25H31N3O4Si.0.1H20 C, 64.2; H, 6.7, N, 9.0
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8.9 (9) Synthesis of N-[4-{fert-
butyldiphenylsilanyloxy)-butyl] uracil acetamide
o
14
Si-O18
Compound 9 was synthesised according to general procedure C using carboxyuracil 1 
(349 mg, 2.08 mmol), 6 (523 mg, 1.6 mmol) and EDC (430 mgs, 2.24 mmol). The 
product was purified by flash chromatography (CFfeCl^eOH 100:0-*93:7) as a white 
solid (522 mg).
Yield: 68%
Melting point: 174°C 
R,: 0.5 in CHzClz/MeOH 9:1
1H-NMR: (300 MHz, MeOD) 6 1.05 (9 H, s, 3 x C(18)H3), 1.63 (4 H, m, C(10)H2
C(11)H2), 3.23 (2 H, t > 6 .5 , C(12)H2), 3.71 (2 H, t > 5 .8 , C(9)H2), 4.41 (2 H, s,
C(7)H2), 5.65 (1 H, d > 7 .7 , C(5)H), 7.40 (6 H, m, 2 x C(16)H, 4 x C(15)H), 7.51 (1 H,
d >7 .9 , C(6)H), 7.66 (4 H, m, 4 x C(14)H)
1JC-NMR: (75 MHz, MeOD) 5 20.4 (3 x C-18), 27.8 (C-17), 30.1, 31.3 (C-10, C-11),
40.8 (C-12), 51.6 (C-7), 65.0 (C-9), 102.6 (C-5) 129.2 (2 x C-16), 131.2 (4 x C-15),
135.4 (4 x C-14), 137.0 (2 x C-13), 148.3 (C-6), 153.1 (C-2) 156.7 (C-4) 169.5 (C-8) 
LRMS (ES*): m/z=478.2 [M-H*]
HRMS (ES*): Found: 480.2306 [M+H]* C a H ^ N s S r  requires: 480.2313 
Analysis: Found: C, 64.4; H, 6.9; N, 8.7
Calc, for C26H33O4N3Si.0.2H20: C, 64.6; H, 7.0; N, 8.7
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8.10 (10) Synthesis of N-(3-hydroxypropyl) uracil
acetamide
o
HCI (1 ml, 10M, 10 mmol) was added to 8 (350 mg, 0.75 mmol) dissolved in 25 mL 
MeOH. The reaction was left stirring at RT for 1.5 h and monitored by TLC. The solvent 
was removed in vacuo. The crude was washed with EtOAc (20 mL) to remove the 
silanol. The product (100 mg) was obtained as a white solid.
Yield: 65%
Rf. 0.2 in CH2CI2/MeOH 90:10
1H-NMR: (300 MHz, MeOD) 6 1.76 (2 H, qn J=6.6 C(10)H2), 3.34 (2 H, m, C(9)H2),
3.63 (2 H, t J= 6.6 C(11)H2), 4.45 (2 H, s, C(7)H2), 5.70 (1 H, d J=7.8 C(5)H), 7.57 (1 H, 
d J= 7.8 C(6)H)
13C-NMR: (75 MHz, MeOD) 6 33.5 (C-10), 38.0 (C-9), 51.7 (C-7), 60.7 (C-11),102.6 (C- 
5), 148.3 (C-6)
LRMS (ES+): m/z= 227.0 [M]+
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8.11 (11) Synthesis of N-(4-hydroxybutyl) uracil
acetamide
o
o
HCI (1 ml, 10M, 10mmol) was added to 9 dissolved in MeOH. (25 mL) The reaction 
was left stirring a RT for 1.5 h and monitered by TLC. The solvent was removed in 
vacuo. The product was recrystalised from ethanol. Small white crystals formed, were 
filtered off, washed with ethanol (10 mL) and dried to afford compound 11 (70 mg) 
Yield: 48%
Melting point: 193°C 
R,: 0.1 in CH2Cl2/MeOH9:1
1H-NMR: (300 MHz, MeOD) 6 1.59 (4 H, m, C(10)H2, C(11)H2), 3.26 (2 H. t J=6.5, 
C(9)H2>, 3.58 (2 H, t J=5.6, C(12)H2), 4.42 (2 H, s, C(7)H2), 5.69 (1 H, d J= 7.9, C(5)H), 
7.53 (1 H, d J= 7.8, C(6)H)
1SC-NMR: (75 MHz, MeOD) 6 27.2, (C-11) 31.2 (C-10), 40.8 (C-9), 51.6 (C-12), 62.9 
(C-7), 102.6 (C-5), 148.3 (C-6), 153.3 (C-2), 167.3 (C-4), 169.6 (C-8)
LRMS (ES ): m/z= 240 [M-H]'
Analysis: Found: C, 49.1; H, 6.2; N, 17.2
Calc, for C i0H15O4N3.0.2H20: C, 49.1; H, 6.3; N, 17.2
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Experimental I
8.12 (14) Synthesis of 2-(triphenylmethylamino)
ethylamine
Compound 14 was synthesised according to the general procedure D using TrtCI (3.50 
g, 12.55mmol) dissolved in DCM (30 mL) and ethylenediamine (8.4 mL, 125.55 mmol) 
dissolved in DCM (10 mL). Following the described work up, the product was purified 
by flash chromatography (CH2CI2/MeOH/NH3 100:0:0-^92:6.4:1.6) as a colourless oil 
(190 g)
Yield: 51%
Rf: 0.6 in CH2CI2/MeOH/NH3 90:7:3
1H-NMR: (300 MHz, MeOD) 6 2.14 (2 H, t J=6.2, C(2)H2), 2.64 (2 H, t 6.3, C(1)H2), 
7.19 (3 H, 3 x C(7)H), 7.29 (6 H, m, 6 x C(6)H), 7.5, (6 H, m, 6 x C(5)H)
13C-NMR: (75 MHz, MeOD) 6 43.4 (C-1), 47.6 (C-2), 83.3 (C-3), 127.7 (6 x C-5), 129.1 
(3 x C-7), 129.7 (6 x C-6), 147.9 (3 x C-4)
LRMS (ES+): m/z= 303 [M+H]+
HRMS (ES+): Found: 303.1853 [M+H]+ C2iH21N2+requires 303.1856
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Experimental I
8.13 (15) Synthesis of 3-triphenylmethylamino
propylamine
Compound 15 was synthesised according to the general procedure D using TrtCI (3.50 
g, 12.55 mmol) dissolved in DCM (30mL) and diaminopropane (10.80 mL, 125.55 
mmol) dissolved in DCM (10 mL). Following the described work up, the product was 
purified by flash chromatography (CH2Cl2/MeOH/NH3 100:0:0—*92:6.4:1.6) to afford a 
colourless oil (807 mg).
Yield: 20%
R 0.4 in CH2CI2/MeOH/NH3 92:6.4:1.6
1H-NMR: (300 MHz, MeOD) 6 1.63 (2 H, qn J=7.0, C(2)H2), 2.15 (2 H, t 7.0, C(3)H2), 
2.67 (2 H, t J= 7.0, C(1)H2), 7.15 (3 H, m, 3 x C(8)H), 7.24 (6 H, m, 6 x C(7)H), 7.42 (6 
H, m, 6 x C(6)H)
13C-NMR: (75 MHz, MeOD) 6 35.1 (C-2), 41.4 (C-1), 43.3, (C-3), 72.6 (C-4), 127.7 (3 x 
C-8), 129.1 (6 x C-6), 130.3 (6 x C-7), 147.9 (3 x C-5)
LRMS (ES+): m/z= 317 [M+H]+
HRMS (ES+): Found: 317.2015 [M+H]+ C^H^N^ requires 317.2012
8.14 (16) Synthesis of 4-(triphenylamino)butylamine
Compound 16 was synthesised according to the general procedure D using TrtCI (3.50 
g, 12.55 mmol) dissolved in DCM (30 mL) and 1,4-diaminobutane (12.62 mL, 125.55 
mmol) dissolved in DCM (10 mL). Following the described work up, the product was 
purified by flash chromatography (CHjOI^MeOH/NHs 100:0:0->93:6.4:0.6) to afford a 
colourless oil (1.30 g)
8
9
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Experimental I
Yield: 31%
Melting point: 63-64°C
Rf: 0.4 in CH2CI2/MeOH/NH3 90:7:3
1H-NMR: (300 MHz, MeOD) 6 1.51 (4 H, m, C(2)H2C(3)H2), 2.15 (2 H, t J= 6.8, C(2)H2), 
2.60 (2 H, t J=6.8, C(1)H2), 7.17 (3 H, m, 3x  C(9)H), 7.26 (6 H, m, 6 x C(8)H), 7.47, (6 
H, m, 6 x C(7)H)
13C-NMR: (75 MHz, MeOD) 6 29.3 (C-2), 31.7 (C-3), 42.8 (C-1), 45.2 (C-4), 72.6 (C-5), 
127.7 (3 x C-9), 129.1 (6 x C-8), 130.3 (6 x C-7), 147.9 (3 x C-6)
LRMS (ES+): m/z= 331 [M+H]+
HRMS (ES+): Found: 331.2005 [M+H]+ C23H27N2+ requires 331.2169
8.15 (17) Synthesis of 1-[N-(2-
triphenylmethylaminoethyl)-acetamide] uracil
Compound 17 was synthesised according to general procedure C using carboxyuracil 
(336 mg, 1.99 mmol) in DMF (10mL), 14 (500 mg, 1.66 mmol) dissolved in 1 mL DMF 
and EDC (430 mg, 2.24 mmol) in DMF (20 mL ) was added. The product was purified 
by flash chromatography (CH2CI2/MeOH 100:0—>92:8) to yield a white solid (251 mg). 
Yield: 33%
Melting point: 219°C 
Rf: 0.4 in CH2CI2/MeOH 95:5
1H-NMR: (300 MHz, MeOD) 6 2.28 (2 H, t J=6.3, C(11)H2), 3.37 (2 H, t J= 6.3, 
C(10)H2), 4.43 (2 H, s, C(7)H2), 5.66 (1 H, d, J= 7.9, C(5)H), 7.18 (1 H, m, C(6)H), 7.18 
(3 H, m, 3 x C(16)H), 7.29 (6 H, m, 6 x C(15)H), 7.45, (6 H, m, 6 x C(14)H)
13C-NMR: (75 MHz, MeOD) 6 41.4 (C-10), 45.5 (C-11), 50.3 (C-7), 70.5 (C-12), 100.8 
(C-5), 126.4 (6 x C-14), 128.1 (3 x C-16), 128.7 (6 x C-15), 145.4 (C-6), 146.4 (3 x C- 
13), 164.3 (C-4), 167.2 (C-8)
LRMS (ES ): m/z= 453 [M-H]+
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Experimental I
HRMS (ES): Found: 453.1940 [M+H]+ C27H25N4O3 requires 453.1927
Experimental I
8.16 (18) Synthesis of 1-[N-(3'
triphenylmethylaminopropyl)-acetamide] uracil
o
17
L’A
/ T a 14 1 3 H ,  H .
o
Compound 18 was synthesised according to general procedure C using carboxyuracil 
(383 mg, 2.28 mmol), EDC (510 mg, 2.66 mmol) and 15 (600 mg, 1.90 mmol) 
dissolved in DMF (30 mL). The product was purified by flash chromatography 
(CH2CI2/MeOH 100:0—►92:8) to yield a white solid (376 mg)
Yield: 42%
Melting point: 189°C
Rf: 0.6 in CH2CI2/MeOH 90:10
1H-NMR: (300 MHz, CDCI3) 6 1.62 (2 H, m, C(11)H2), 2.13 (2 H, m, C(12)H2), 3.31 (2 
H, m, C(10)H2), 4.18 (2 H, s, C(7)H2), 5.61 (1 H, d J=7.8, C(5)H), 7.19 (1 H, m, C(6)H), 
7.14 (3 H, m, 3 x C(17)H), 7.22 (6 H, m, 6 x C(16)H), 7.40, (6 H, m, 6 x C(15)H) 
13C-NMR: (75 MHz, CDCI3) 6 30.6 (C-11), 38.8 (C-12), 41.6 (C-10), 51.1 (C-7), 71.4 
(C-13), 102.9 (C-5), 126.8 (3 x C-17), 128.3 (6 x C-15), 129.1 (6 x C-16), 145.7 (C-6),
146.4 (3 x C-14), 151.7 (C-2), 164.5 (C-4),166.6 (C-8)
LRMS (ES+): m/z= 469 [M+H]+
HRMS (ES+): Found: 469.2239 [M+H]+ C28H28N403+ requires 469.2234 
Analysis: Found: C, 69.2; H, 5.9; N, 11.4
Calc, for C28H280 3N4.1.0H2O: C, 69.1; H, 6.2; N, 11.5
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Experimental I
8.17 (19) Synthesis of 1-[N-(3
triphenylmethylaminobutyl)- acetamide] uracil
Compound 19 was synthesised according to general procedure C, using carboxyuracil 
(336 mg, 1.99 mmol) dissolved in DMF (10 mL), 16 (547 mg, 1.66 mmol) and EDC 
(430 mg, 2.24 mmol) in DMF (20 mL). The product was purified by flash 
chromatography (CH2CI2/MeOH/NH3 100:0:0—►92:6.4:1.6) to yield a white solid (206 
mg).
Yield: 26%
Melting point: 180°C
R,: 0.3 in ChfeClz/MeOH 90:10
’H-NMR: (300 MHz, CDCIj) 6 1.57 (4 H, m, C(11)H2 C(12)H2), 2.19 (2 H, m. C(13)H2), 
3.27 (2 H, m, C(10)H2), 4.29 (2 H. s. C(7)H2), 5.75 (1 H. d J=7.9, C(5)H), 6.80 (1 H, m, 
N(9)H, 7.23 (3 H, m, 3 x C(18)H), 7.25 (1 H. m, C(6)H), 7.32 (6 H, m, 6 x C(17)H), 7.50, 
(6 H, m, 6xC(16)H)
13C-NMR: (75 MHz, CDCfe) 6 27.6, 28.6 (C-11, C-12), 40.4 (C-13), 43.6 (C-10), 51.3 
(C-7), 71.3 (C-14), 102.9 (C-5), 126.7 (6 x C-16), 128.2 (3 x C-18), 129.0 (6 x C-17),
145.6 (C-6), 146.5 (3 x C-15), 151.5 (C-2), 164.1 (C-4), 166.4 (C-8)
LRMS (ES*): m/z= 483 [M+H]*
HRMS (ES+): Found: 483.23996 [M+H]‘ CMH30N4O3* requires 483.2391 
Analysis: Found: C, 71.4; H, 6.2; N, 11.4
Calc, for C29H3QO3N4.0.3H20: C, 71.4; H, 6.3; N, 11.5
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Experimental I
8.18 (20) Synthesis of carbobenzoxyimidazole91
Benzyl chloroformate (19.92 g, 117.23 mmol) was cooled to 0°C in an ice bath. 
Imidazole (15.96 g, 234.47 mmol) in DCM (70 mL) was added slowly. The reaction was 
left at RT for 15 min. The mixture was washed with citric acid (3 x 150 mL) and the 
organic layer was dried to give the pure product as a colourless oil (20.60 g). The 
product could not be detected by ES MS as it more than likely too unstable to the 
ionisation conditions.
Yield: 87%
Melting point: 41 °C
Rf: 0.7 in CH2CI2/MeOH 90:10
1H-NMR: (500 MHz, CDCI3) 6 5.39 (2 H, s, C(7)H2), 7.02, 7.49, (2 H, m, C(4)H, C(5)H), 
7.34-7.43 (5 H, m, 2 x C(9)H, 2 x C(10)H, C(11)H), 8.20 (1 H, m, C(2)H)
13C-NMR: (125 MHz, CDCI3) 6 70.3, (C-7), 117.6 (C-4), 128.8-129.6 (C-11, 2 x C-10, 2 
xC-9), 131.1 (C-5), 134.4 (C-8), 137.6 (C-2), 149.1 (C-6)
O
10 3
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Experimental I
8.19 (21) Synthesis of N1,N1’-(dicarbobenzoxy)
diethylene triamine
8
Compound 21 was synthesised according to the general procedure E using 
diethylenetriamine (3.00 g, 29.08 mmol) and DMAP (0.70 mg, 5.74 mmol) dissolved in 
DCM (20 mL) and 20 (11.76 g, 58.16 mmol) in DCM (30 mL). The product was purified 
by flash chromatography (CH2Cl2/MeOH/NH3100:0:0->90:8:2) to yield a white solid 
(3.80 g)
Yield: 35%
Melting point: 53-55°C
Rf: 0.9 in CHzClz/MeOH 80:18:2
1H-NMR: (500 MHz, MeOD) 6 2.64 (4 H, t J=6.2, C(3)H2, C(3,)H2), 3.19 (4 H, t J=6.2, 
C(2)H2, C(2’)H2), 5.01 (4 H, s, C(5)H2> C(5’)H2), 7.28 (10 H, m, C(9)H, 2 x C(8)H, 2 x 
C(7)H, C(9’)H, 2 x C(8,)H, 2 x C(7’)H)
13C-NMR: (125 MHz, MeOD) 5 41.1 (C-3, C-3’), 49.5 (C-2, C-2’), 67.5 (C-5, C-5’) 
128.5-129.5 (C-9, 2 x C-8, 2 x C-7, C-9\ 2 x C-8’, 2 x C-7’), 138.3 (C-6 , C-6’), 158.9 (C- 
4, C-4')
LRMS (ES+): m/z= 372.2 [M+H]+
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Experimental I
8.20 (22) Synthesis of N1N1-(dicarbobenzoxy)di(n-
propyl) triamine
9
Compound 22 was synthesised according to the general procedure E using, Bis-(3- 
aminopropyl)amine (4.00 g, 30.48 mmol) and DMAP (10%w/w), DCM (150 mL) and 20 
(12.32 g, 60.96 mmol) in DCM (200 mL). The reaction was left stirring for 4 d at 50°C. 
The product was purified by flash chromatography (CH2Cl2/MeOH/NH3100:0:0—►90:8:2) 
and subsequently recrystalised from EtOAc to yield a white solid (4.60 g)
Yield: 38%
Melting point: 208°C 
Rf: 0.4in CH2CI2/MeOH 75:25
1H-NMR: (500 MHz, MeOD) 6 1.85 (4 H, qn J= 7.0, C(3)H2, C(3’)H2), 2.94 (4 H, t J=7.0, 
C(4)H2, C(4’)H2), 3.25 (4 H, t J=7.0, C(2)H2, C(2’)H2), 5.10 (4 H, s, C(6)H2, C(6’)H2), 
7.36 (10 H, m, C(10)H, 2 x C(9)H, 2 x C(8)H, C(10’)H, 2 x C(9’)H, 2 x C(8’)H) 
i3C-NMR: (125 MHz, MeOD) 6 26.4 (C-3, C-3’), 38.8 (C-4, C-4’), 46.2 (C-2, C-2’), 65.9 
(C-6, C-6’) 126.6-128.8 (C-10, 2 x C-9, 2 x C-8, C-10’, 2 x C-9’, 2 x C-8’), 138.3 (C-7, 
C-7’), 158.9 (C-5, C-5’)
LRMS (ES+): m/z= 399.4 [M+H]+
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Experimental I
8.21 (23) Synthesis of N1N1’-
dicarbobenzoxyspermidine
10
Compound 23 was synthesized according general procedure E using spermidine (0.70 
g, 4.82 mmol) and DMAP (5% w/w) in DCM (30 mL) and 20 (1.95 g, 9.64 mmol) The 
reaction was heated to 50°C and left stirring for 3 d. The crude product was purified by 
column chromatography in (CH2CI2/MeOH/NH3100:0:0—>90:8:2). The fractions 
containing the product were collected and washed with H20  (30 mL) and HCI (20 mL, 
0.5 M) solution. The precipitate collected was redissolved in MeOH:CHCI3. The residue 
which was not soluble was filtered off and the filtrate was dried in vacuo to yield the 
pure product as a white solid (758 mg).
Yield: 38%
Melting point: 175-177°C
Rf: 0.6 in CH2CI2/MeOH/NH380:16:4
1H-NMR: (500 MHz, MeOD) 5 1.54-1.66 (4 H, m, C(3)H2, C(3’)H2), 1.82 (2 H, qn J=7.1, 
C(4)H2), 2.79-2.87(4 H, m, C(4’)H2, C(5)H2), 3.14-3.25 (4 H, m, C(2)H2, C(2’)H2), 5.09 
(4 H, s, C(7)H2i C(7’)H2), 7.33-7.37 (10 H, m, 2 x C(9)H, 2 x C(10)H, C(11)H, 2 x 
C(9’)H, 2 x C(10’)H, C(11’)H)
i3C-NMR: (125 MHz, MeOD) 6 26.0, 28.3, 29.4 (C-3, C-3’, C-4), 38.9, 41.2 (C-5, C-4’), 
47.2 (C-2, C-2’), 67.4 (C-7, C-7’) 128.5-129.5 (C-11, 2 x C-10, 2 x C-9, C-11’, 2 x C-10’, 
2 x C-9’), 138.5 (C-8, C-8’), 159.2 (C-6, C-6’)
LRMS (ES*): m/z= 414.5 [M+H]*
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Experimental I
8.22 (24) Syntheis of 1-carboxymethyluracil
succinimdyl ester
o
1-Carboxymethyl uracil 1 (2.95 g, 17.35 mmol) and N-hydroxsuccinimide (2.21 g, 19.09 
mmol) were dissolved in DMF (20 mL) and cooled to 0°C in an ice bath. A solution of 
DCC (3.94 g, 19.09 mmol) in DMF (5 mL) was added to the mixture under N2 
atmosphere. The solution was left stirring at 0°C for 3 h and then at RT for a further 24 
h. The pure product was precipitated from MeOH to yield a white solid (4.70 g). The 
product could not be detected by ES MS as it was too unstable to ionization.
Yield: quantitative
Melting point: 218-222°C
Rf: 0.2 in CH2CI2/MeOH 80:18:2
1H-NMR: (500 MHz, DMSO) 6 2.83 (4 H, s, C(10)H2, C(11)H2), 5.02 (2 H, s, C(7)H2), 
5.85 (1 H, d J=7.9, C(5)H), 7.74 (1 H, d J= 7.9, C(6)H2)
13C-NMR: (125 MHz, DMSO) 5 25.8 (C-10, C-11), 46.9 (C-7), 102.1 (C-5), 145.6 (C-6), 
151.0 (C-2), 164.0 (C-4), 165.3 (C-8), 170.1 (C-9, C-12)
- 183 -
Experimental I
8.23 (25) Synthesis of 1-[N12N12-
(dicarbobenzoxy)diaminodi (n-propyl)acetamide] uracil
o
22 (1,67 g, 6.26 mmol) and DMAP (10% w/w) were dissolved in DMF 1.10 ml). 24 (2.50 
g, 6.26 mmol) was added under N2 atmosphere. The reaction was heated to 60°C and 
left stirring for 4 d. The solvent was removed in vacuo. White crystals were 
recrystalised from EtOAc and were washed with H20  (10 m l) to yield the pure product
(2.37 g).
Yield: 69%
Melting point: 141-144°C
R#; 0.4 in CH2CI2/MeOH 90:10
1H-NMR: (500 MHz, MeOD) 6 1.73, 1.88 (4 H. qn > 6 .5 , C(10)H2 C(10’)H2>. 3 11, 3.20 
(4 H, 2 x t J=  6.5 C(9’)H2, C(9)H2)s 3.38 (4 H, m. Ct11’)H2. C(11)H: l  4.58 |2 H s, 
C{7)H2), 5.08 (4 H. 2 x s. C(14)H2. C(14’)HZ). 5,67 (1 H, d J=7,8 C(S)H), 7.28-7.35 (10 
H, m, 2 x C(17)H, C(18)H. 2 x C(16)H, 2 x 0(17111, 0(18111, 2 x C(16’)H) 7 43 (1 H, d 
J=7.8 C(6)H)
13C-NMR: (125 MHz, MeOD) 6 27.2, 28.2 (0-10, 0-10'), 37.6 (C-9‘. C-97 43.3 (0-11’, 
C-11), 48,5 (C-7) 65.9 (C-14, 0-14’), 100 6 (0-57 127.3-128,0 (C-18, 2 x C-17, 2 x 0 -  
16, C-18’, 2 x 0 -1 7 ’, 2 x 0-161. 137,0 (0-15, 0-151, 146 6 (C-6), 151,4(0-2). 158,9 (0- 
13, C-13'), 165.4 (0-4), 167 2 (0-8)
LRMS (ES+): mlz= 552.4 [M+Hf
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Experimental I
8.24 (26) Synthesis of N-(l-carboxymethyluracil)-
N13N13-(dicarbobenzoxy) spermidine
A solution of 24 (430 mg, 0.72 mmol) in DMF (8 mL) was added to 23 (190 mg, 0.72 
mmol) under N2 atmosphere. The solution was heated to 70°C and DMAP (10% w/w) 
in DMF (2 mL) was added. The solution was left stirring at 70°C for 3 d. The solvent 
was vacuumed off under reduced pressure. On addition of EtOAc, a yellow oil formed 
which was removed by careful pippetting. Recrystalisation form EtOAc was carried out. 
The white crystals formed were washed with water (20 mL) and HCI solution (20 mL, 
0.5M) to yield the pure product as a white solid (340 mg)
Yield: 89%
Rf: 0.4 in CH2CI2/MeOH/NH3 90:9:2
1H-NMR: (500 MHz, MeOD) 6 1.59, 1.70, 1.87 (6 H, m, C(10)H2 C(10’)H2, C(11)H2), 
2.97(4 H, m, C(9’)H2, C(9)H2), 3.14-3.25 (4 H, 2 xt J=6.6, C(11’)H2,C(12)H2), 4.30 (2 H, 
s, C(7)H2), 5.09 (4 H, 2 x s, C(15)H2, C(15’)H2), 5.64 (1 H, d J= 7.8, C(5)H), 7.32-7.37 
(10 H, m, 2 x C(17)H, 2 x C(18)H, C(19)H, 2 x C(17’)H, 2 x C(18’)H, C(19’)H), 7.49 (1 
H, d J=7.8, C(6)H)
13C-NMR: (125 MHz, MeOD) 6 28.2-30.6 (C-10, C-10’, C-11), 45.8 (C-9\ C-9), 46.6 (C- 
11’, C-12), 57.0 (C-7), 67.7 (C-15, C-15’), 102.5 (C-5), 129.0-130.1 (C-19, 2 x C-18, 2 x 
C-17, C-19’, 2 x C-18’, 2 x C-17’), 138.5 (C-16, C-16’), 150.1 (C-6), 158.9 (C-14, C- 
14’), 168.8 (C-8)
LRMS (ES+): m/z= 556.2 [M+H]+
O
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Experimental I
8.25 (27) Synthesis of 1-[ N11N11'-
(dicarbobenzoxy)diamino diethyl acetamide] uracil
Compound 21 (1.53 g, 4.12 mmol) was dissolved in DMF (5 mL). 1- 
carboxymethyluracil (700 mg, 4.12 mmol) in DMF (5 mL) was added under N2 
atmosphere, followed by, DhbtOH (770 mg, 4.74 mmol) in DMF (5 mL). The solution 
was cooled to 0°C and DCC (1.02 g, 4.95 mmol) in DMF (5 mL) was added under N2 
atmosphere. The mixture was left stirring at 0°C for 1 h and then at RT for 48 h after 
which time a precipitate had formed. The solvent was evaporated off under reduced 
pressure and DCU was precipitated out using EtOAc. On addition of diethyl ether to the 
EtOAc solution, a further gel precipitate formed. This was collected by decantation. On 
evaporation of the remaining solvent, a foamy white solid formed and identified as the 
pure product (783 mg).
Yield: 36%
Rfi 0.4 in CH2Cl2/MeOH 90:10
’H-NMR: (500 MHz, MeOD) 6  3.25-3.30 (4 H, m, C(10)H2, CCIO’JHj), 3.40-3.45 (4 H, 
m, C(9)H2, C(9’)H2), 4.57 (2 H, s, C(7)H2), 5.10 (4 H, m, C(13)H2 C(13')H2), 5.65 (1 H, 
C(5)H), 7.25-7.39 (11 H, m, C(6)H, C(17)H, 2 x C(16)H, 2 x C(15)H, C(17')H, 2 x 
C(16’)H, 2 x C(15’)H)
1JC-NMR: (125 MHz, MeOD) 6 39.4, 40.0 (C-10, C-10), 44.2 (C-9, C-9’), 49.5 (C-7),
67.6 (C-13, C-13’), 102.2 (C-5), 129.0-130.0 (C-17, 2 x C-16, 2 x C-15, C-17', 2 x C- 
16’, 2 x C-15’), 138.3 (C-14, C-14’), 147.9 (C-6), 154.7 (C-4), 159.0 (C-12, C-12’)
LRMS (ES‘): m/z= 524 [M+H]*
HRMS (ES*): Found: 546.1953 [M+Na]* C26H29N507Na* requires 546.1965
O
16
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8.26 (28) Synthesis of 1-[ diaminodiethylacetamide]
uracil
o
Compound 28 was synthesised according to the general procedure F using 27 (500 
mg, 0.956 mmol) dissolved in MeOH (15 mL) and 5% Pd/C (10% w/w). The catalyst 
was removed by filtration and the solvent evaporated off under reduced pressure to 
yield a sticky gel which was identified as a mixture of the product and the mono­
protected side product. The mono-protected side product was removed by washing 
with DCM to yield the product as a cream/yellow solid (100 mg). By NMR, however it 
could be seen that some N,N acyl migration had occurred.
Yield: 41%
Rf\ 0.2 in CH2CI2/MeOH/NH3 80:16:4
1H-NMR: (500 MHz, MeOD) 6 2.70-2.97 (4 H, m, C(10)H2, C(10’)H2), 3.30-3.59 (4 H, 
m, C(9)H2i C(9’)H2), 4.46, 4.75(2 H, 2 x s, C(7)H2), 5.70 (1 H, m, C(5)H), 7.53 (1 H, m, 
C(6)H)
13C-NMR: (125 MHz, MeOD) 6 39.8-41.2 (C-10, C-10’), 49.1-51.3 (C-9, C-9’), 102.2 (C- 
5), 147.9 (C-6), 154.7 (C-4), 159.0 (C-8)
LRMS (ES+): m/z= 256 [M+H]+
HRMS (ES+): Found: 256.1400 [M+H]+ CioH18N503+ requires 256.1404
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8.27 (29) Synthesis of 1-[diaminodi(n-
propyl)acetamide] uracil
o
11’ 9' 9 11
Compound 29 was synthesised according the general procedure F using 25 (800 mg, 
1.45 mmol) dissolved in EtOH:MeOH (50 mL) and 5% Pd/C (5% w/w). The catalyst 
was removed by filtration and the solvent was removed in vacuo to yield a white foamy 
solid (143 mg). By NMR it was observed that some acyl migration had occurred.
Yield: 35%
Rf: 0.2 in CH2Cl2/MeOH/NH380:16:4
1H-NMR: (500 MHz, MeOD) 5 1.78-1.94 (4 H, m, C(10)H2, C(10’)H2), 2.70-2.83 (4 H, 
m, C(11)H2, C (ir )H 2), 3.40-3.51 (4 H, m, C(9)H2. C(9’)H2), 4.34, 4.72 (2 H, 2 x s, 
C(7)H2), 5.69 (1 H, m, C(5)H), 7.51 (1 H, d J=7.8, C(6)H)
13C-NMR: (125 MHz, MeOD) 6 25.1-26.0 (C-10, C-10’), 38.1-38.8 (C-11, C-11’), 45.1-
45.7 (C-9, C-9’), 48.5 (C-7), 101.2 (C-5), 147.6 (C-6), 150.4 (C-2), 165.4 (C-4), 167.2 
(C-8)
LRMS (ES+): m/z= 284 [M+H]+
HRMS (ES+): Found: 284.1715 [M+H]+ Ci2H22N50 3+ requires 284.1717
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8.28 (30) Synthesis of N-(l-carboxymethyluracil)
spermidine
Compound 30 was synthesised according the general procedure F using 26 (250 mg, 
0.44 mmol) dissolved in MeOH (30 mL) and 5% Pd/C (5% w/w). The catalyst was 
removed by filtration and the solvent was removed in vacuo to yield a white foamy solid 
(90 mg). By NMR it was seen that N,N acyl migration had occurred to some extent. 
Yield: 69%
Rf! 0.1 in CH2CI2/MeOH/NH380:16:4
1H-NMR: (500 MHz, MeOD) 6 1.67, 1.80, 1.90 (6 H, 3 x m, C(10)H2 C(10’)H2, C(11)H2), 
2.82-2.92 (4 H, m, C (ir)H 2, C(12)H2), 3.41-3.53 (4 H, 2 x t J=6.6, C(9')H2, C(9)H2), 
4.30, 4.72 (2 H, 2 x s, C(7)H2), 5.65, 5.70 (1 H, d J= 7.8 C(5)H), 7.52 (1 H, d J= 7.8 
C(6)H)
LRMS (ES+): m/z= 298 [M+H]+
O
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8.29 (31), (31b) and (33) Synthesis of 1-[N,N'
(triphenylmethyl)diaminodi(n-propyl)acetamide]uracil, 
1-[N-(carboxybenzyl)-N-(triphenylmethyl)diaminodi(n- 
propyl) acetamide] uracil and 1-[N' 
(triphenylmethyl)diaminodi(n-propyl)acetamide]uracil
Compound 29 (140 mg, 0.49 mmol) and Et3N (0.03 mg, 0.25 mmol) were dissolved in 
pyridine (50 mL). TrtCI (138 mg, 0.49 mmol) in pyridine (10 mL) was added over 3 h. 
After 1 h the solution had begun to turn cloudy. After addition had ceased the mixture 
was heated to 70°C, left stirring for 2 d and monitored periodically b TLC. The solvent 
was evaporated off under reduced pressure. The remaining starting material was 
removed by precipitation firstly form EtOH (10 mL) and subsequently EtOAc (10 mL). 
The remaining filtrate was purified by flash chromatography (CH2Cl2/MeOH/NH3 
100:0:0->97:2.4:0.6) to yield 31 (fraction 5, 45 mg) as a yellow crystalline solid, 33 
(fraction 2, 50 mg) as a white solid and 31b (fraction 3, 25 mg) as a white crystalline 
solid.
31
N 2 0
Yield: 17%
Melting point: 103-105°C 
Rf: 0.1 in CH2CI2/MeOH/NH3 85:14:1
’H-NMR: (500 MHz, MeOD) 6 1.75-1.80 (4 H, m, C(11)H2, C(15)H2), 2.23-2.29 (2 H, m, 
C(16)H2), 2.75-2.81 (4 H, m, C(12)H2, C(14)H2), 3.37-3.51 (2 H, m, C(10)H2), 4.41 (2 
H, s, C(7)H2), 5.67 (1 H, d J=7.9, C(5)H), 7.19-7.52 (16 H, m, 6 x C(20)H, 6 x C(21)H, 3 
x C(22)H, C(6)H)
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13C-NMR: (125 MHz, MeOD) 5 29.2, 30.0 (C-11, C-15’), 38.0 (C-16), 43.1 (C-12, C-14),
51.5 (C-7), 58.6 (C-10), 72.3 (C-18), 102.3 (C-5), 127.3-129.9 (6 x C-20, 6 x C-21, 3 x 
C-22), 147.9 (C-6), 147.4 (3 x C-19), 169.8 (C-8)
LRMS (ES+): m/z= 526 [M+H]+
HRMS (ES+): Found: 548.2639 [M+Na]+ C3iH36N503Na+ requires 548.2632 
33
4 NH
17'
16' o
15*
14'
12'
1010 '
11
17
Yield: 13%
Melting point: 162-165°C
Rf: 0.9 in CH2CI2/MeOH/NH385:14:1
1H-NMR: (500 MHz, CDCI3) 5 1.72-1.82 (4 H, m, C(10)H2, C(10’)H2), 2.13-2.23 (4 H, 
m, C(11)H2, C (ir )H 2), 3.35-3.39 (4 H, m, C(9)H2, C(9’)H2), 4.22, 4.60 (2 H, 2 x s, 
C(7)H2), 5.67 (1 H, d J=7.9, C(5)H), 7.16-7.20, 7.43-7.47 (30H, m, 6 x C(15)H, 6 x 
C(15’)H, 6 x C(16)H, 6 x C(16’)H, 3 x C(17)H, 3 x C(17’)H), 7.30 (1 H, d J=7.9, C(6)H) 
13C-NMR: (125 MHz, CDCI3) 6 28.8-30.3 (C-10, C-10’), 40.9 (C-11, C-11’), 44.9, 45.7 
(C-9, C-9’), 47.7(C-7), 71.5 (C-13, C-13’), 101.9 (C-5), 126.2-128.6 (6 x C-15, 6 x C- 
15’, 6 x C-16, 6 x C-16’, 3 x C-17, 3 x C-17’), 145.3 (C-6), 145.7, 146.0 (3 x C-14, 3 x 
C-14’), 148.1 (C-2), 166.9 (C-4), 168.7 (C-8)
LRMS (ES+): m/z= 768 [M+H]+
HRMS (ES+): Found: 768.3904 [M+H]+ CsoHsoNsCV requires 768.3908
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31b
O
6
26o. 277
H
N
21
13 H 24
2320
Yield: 8%
Melting point: 91-95°C
Rf: 0.8 in CH2Cl2/MeOH/NH385:14:1
1H-NMR: (500 MHz, MeOD) 6 1.69-1.86 (4 H, m, C(10)H2 C(19)H2), 2.13-2.52 (2 H, 2 x 
t J=6.4, C(11)H2), 3.12-3.20 (2 H, 2 x m, C(20)H2), 3.44-3.47(4 H, m, C(9)H2 C(18)H2), 
4.52, 4.67 (2 H, 2 x s, C(7)H2), 5.05, 5.08 (2 H, 2 x s, C(23)H2), 5.67 (1 H, m C(5)H), 
7.17-7.21, 7.44-7.48 (20 H, m, 6 x C(15)H, 6 x C(16)H, 3 x C(17)H, 2 x C(25)H, 2 x 
C(26)H, C(27)H), 7.33 (1 H, m, C(6)H)
13C-NMR: (125 MHz, MeOD) 5 28.8, 29.5, 29.8, 30.7 (C-10, C-19), 39.1, 39.3 (C-11, C- 
20), 42.3 (C-20), 45.1, 45.7 (C-9, C-18), 48.7 (C-7), 67.4 (C-23), 71.5 (C-13), 102.1 (C- 
5), 127.3-129.5 (6 x C-15, 6 x C-16, 3 x C-17, 2 x C-25, 2 x C-26, C-27), 147.6 (C-14),
148.1 (C-6), 157.2 (C-24), 166.9 (C-4), 168.4 (C-22), 168.7 (C-8)
LRMS (ES+): m/z= 660 [M+H*]
HRMS (ES+): Found: 660.3187 [M+H *] Cs^NgOs* requires 660.3180
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8.30 Synthesis of 1-[N-di(triphenylmethylaminoethyl) 
acetamide] uracil (36) and 1-[N- 
(triphenylmethyaminoethyl)-N-(aminoethyl) acetamide] 
uracil (35)
A suspension of 28 (100 mg, 0.39 mmol) in DCM (30 mL) was placed under N2 
atmosphere and Et3N (80 mg, 0.78 mmol) in DCM (2 mL) was added followed by TrtCI 
(110 mg, 0.39 mmol) in DCM (10 mL). The solution which became cloudy was left 
stirring at RT for 2 h. The solvent was removed in vacuo and both mono and di 
tritylated products were observed by mass spectrometry. The crude was washed with 
diethyl ether and water and purified by flash chromatography (CH2CI2/MeOH/NH3 
100:0:0—>80:18.6:0.4). The di-substituted product was collected as the first fraction and 
was precipitated from ether as a white solid (15 mg). The mono-substituted product 
was also collected as a white solid (11 mg).
35
20
4 NH
N 2 ' O
10 1 °
Yield: 6%
Rfi 0.5 in CH2CI2/MeOH/NH3 85:14:1
1H-NMR: (500 MHz, MeOD) 6 2.39 (2 H, m, C(14)H2), 2.88 (4 H, m, C(11)H2, C(13)H2), 
3.42 (2 H, m, C(10)H2), 4.45 (2 H, s, C(7)H2), 5.67 (1 H, d J=7.9, C(5)H), 7.18-7.50 (16 
H, m, 6 x C(18)H, 6 x C(19)H, 3 x C(20)H, C(6)H)
13C-NMR: (125 MHz, MeOD) 6 30.7 (C-14), 39.1, 43.2 (C-11, C-13), 51.4 (C-7), 54.8 
(C-10), 72.1 (C-16), 102.3 4 (C-5), 127.5-129.9 (6 x C-18, 6 x C-19, 3 x C-20), 147.2
(3 x C-17), 147.8 (C-6), 170.2 (C-8)
LRMS (ES+): m/z= 498 [M+H]+
HRMS (ES+): Found: 498.2498 [M+H]+ C29H32N50 3+ requires 498.2500
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36
O
16'  16
Yield: 5%
Rf: 0.7 in CH2Cl2/MeOH/NH3 85:14:1
1H-NMR: (500 MHz, CDCI3) 6 2.21-2.28 (4 H, m, C(10)H2, C(10’)H2), 3.26-3.38 (4 H, 
m, C(9)H2. C(9’)H2), 4.04, 4.61 (2 H, 2 x s, C(7)H2), 5.62 (1 H, d 7.9, C(5)H), 7.08- 
7.40 (30H, m, 6 x C(14)H, 6 x C(14’)H, 6 x C(15)H, 6 x C(15’)H, 3 x C(16)H, 3 x 
C(16’)H), C(6)H)
13C-NMR: (125 MHz, CDCI3) 6 41.7 (C-10, C-10’), 46.5 (C-9, C-9’), 48.0, 48.2 (C-7),
70.8, 71.1 (C-12, C-12’), 102.0 (C-5), 126.4-128.5 (6 x C-14, 6 x C-14’, 6 x C-15, 6 x C- 
15’, 3 x C-16, 3 x C-16’), 145.1 (C-6), 145.3, 145.8 (3 x C-13, 3 x C-13’), 150.5 (C-2),
162.9 (C-4), 166.7 (C-8)
LRMS (ES+): m/z= 740 [M+H]+
HRMS (ES+): Found: 740.3596 [M+H]+ C48H46N5CV requires 740.3595
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8.31 (37) Synthesis of N -{tert-
butyldiphenylsilyloxy)ethyl ethylendiamine
Si-O
| 9
12
Compound 37 was synthesised according to general procedure B using N-(2- 
hydroxyehtyl)ethylenediamine (2.13 mL, 21.07 mmol) in pyridine (20 mL), and tert- 
butyldiphenylsilyl chloride (5.50 ml, 21.15 mmol) in pyridine (30 mL). The reaction was 
left stirring at RT overnight. The solvent was removed in vacuo and the crude product 
was purified by column chromatography (CH2CI2/MeOH/NH3100:0:0—>90:8:2) to yield 
the pure product as a yellow oil (2.27 g).
Yield: 32%
R 0.7 in CH2CI2/MeOH/NH380:18:2
1H-NMR: (300 MHz, MeOD) 6 1.08 (9 H, s, 3 x C(8)H3), 2.76, 2.80, 2.84 (6 H, 3 x t J= 
6.0 , J= 6.0, J= 5.7, C(2)H2, C(3)H2, C(5)H2), 3.81 (2 H, t J= 5.7 C(6)H2), 7.42-7.71 (10 
H, m, 4 x C(10)H, 4 x C(11)H, 2 x C(12)H)
13C-NMR: (75 MHz, MeOD) 6 20.1 (C-7), 27.4 (3 x C-8), 41.1 (C-2), 50.5, 52.0 (C-3, C- 
5), 64.2 (C-6), 128.9, (4 x C-11), 131.1 (2 x C-12), 136.7 (4 x C-10), 134.6 (2 x C-9) 
LRMS (ES+): m/z= 343.4 [M+H]+
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8.32 (38) Synthesis of N-(terf-butyldiphenylsilyloxy)
ethyl -N-(triphenylmethylamino)ethyl amine
A solution of 37 (500 mg, 1.46 mmol) in DCM (50 mL) was cooled to 0°C under N2 
atmosphere. TrtCI (407 mg, 1.46 mmol) in DCM (80 mL) was added slowly. The 
reaction was brought to RT and Et3N was added (0.20 mL, 1.46 mmol). The reaction 
was left stirring at RT overnight over which time the solution turned cloudy. The solvent 
was removed in vacuo. The crude was redissolved in DCM (30 mL), washed with H20  
and dried with MgS04 to yield a sticky yellow oil (613 mg). This crude product was 
used for the subsequent synthetic step without further purification.
Yield: 72%
R 0.6 in CH2Cl2/MeOH/NH3 95:4.5:0.5
1H-NMR: (300 MHz, MeOD) 8 0.97 (9 H, s, 3 x C(8)H3), 2.20 (2 H, t J= 6.2 C(2)H2) 
2.57, 2.61 (4 H, 2 x t, J= 6.2, J= 5.7, C(3)H2, 0 ( 5 ) ^ ,  3.70 (2 H, t J= 5.7 C(6)H2>, 7.05- 
7.37 (25 H, m, 4 x C(10)H, 4 x C(11)H, 2 x C(12)H, 6 x C(15)H, 6 x C(16)H, 3 x 
C(17)H)
1JC-NMR: (75 MHz, MeOD) 6 20.1 (C-7), 27.4 (3 x C-8), 44.2 (C-2), 50.7, 52.1 (C-3, C- 
5), 63.9 (C-6), 72.1 (C-13), 127.4, 130.5 (3 x C-17, 6 x C-16, 6 x C-15), 128.9, (4 x C- 
11), 130.5 (2 x C-12), 136.7 (4 x C-10), 134.6 (2 x C-9), 147.5 (3 x C-14)
LRMS (ES*): m/z= 585 [M+H]*
12
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8.33 (39) Synthesis of 1-[N-(ferf-butyldiphenylsilyloxy)
ethyl- N-(triphenylmethylamino)ethyl-acetamide] uracil
Compound 38 (614 mg, 1.05 mmol) was dissolved in DMF (3 mL) and cooled to 0°C 
under N2 atmosphere. A solution of 1 (180 mg, 1.05 mmol) and DhbtOH (200 mg, 1.21 
mmol) in DMF (3 mL) was added while stirring under N2 atmosphere followed by a 
solution of DCC (260 mg, 1.25 mmol) in DMF (6 mL). The mixture was left stirring at 
0°C for 1 h and then at RT overnight. The solvent was evaporated off under reduced 
pressure. The crude was redissolved in DCM (30 mL) and washed with NaHC03 (3 x 
30 mL), NaCI (2 x 30 mL) and dried with MgS04. The solvent was removed in vacuo 
and the pure product was precipitated from MeOH as a white solid (365 mg). NMR 
showed splitting of peaks due to restricted rotation about the amide bond.
Yield: 52%
Rf: 0.8 in CH2CI2/MeOH 95:5
1H-NMR: (300 MHz, MeOD) 6 1.02, 1.08 (9 H, s, 3 x C(13)H3), 2.15, 2.22 (2 H, m, 
C(19)H2), 3.41, 3.47 (4 H, 2 x m, C(10)H2, C(18)H2), 3.71, 3.85 (2 H, m, C(11)H2), 4.58, 
4.75 (2 H, 2 x s, C(7)H2), 5.56, 5.66 (1 H, 2 x d J= 7.8, C(5)H), 7.20-7.69 (26 H, m, 
C(6)H, 4 x C(15)H, 4 x C(16)H, 2 x C(17)H, 6 x C(23)H, 6 x C(24)H, 3 x C(25)H) 
13C-NMR: (75 MHz, MeOD) 6 19.8, 20.3 (C-12), 26.5, 27.0 (3 x C-13), 43.2, 43.6 (C- 
19), 47.3, 48,2 (C-10, C-18), 50.5, 51.6 (C-7), 63.7, 64.3 (C-11), 72.3 (C-21), 101.3 (C- 
5), 127.4-135.0 (2 x C-17, 4 x C-16, 4 x C-15, 6 x C-23, 6 x C-24, 3 x C-25, 2 x C-14),
147.5 (3 x C-22), 147.7 (C-6), 154.2 (C-2), 166.5 (C-4), 168.8 (C-8)
LRMS (ES+): m/z= 738 [M+H]+
O
13
17
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8.34 (40) Synthesis of 1 -[N-hydroxyethyl-N-
(triphenylmethyl amino)ethyl-acetamide] uracil
Compound 40 was synthesised according to general procedure G using 39 (365 mg, 
0.495 mmol) in THF (5 mL) and TBAF in THF (1.0 mL, 1.0 mmol). After 30mins, no 
starting material could be seen by TLC. The solvent was removed in vacuo and purified 
by flash chromatography (CFfeCla/MeOHI00:0—^ 95:5) and the pure product was 
isolated as a white solid (200 mg). NMR again showed peak splitting. It was proven, 
however, by variable temperature NMR that this was due to restricted rotation around 
the nitrogen bond as J C(7)H2 reduced from 0.4 to 0.1 ppm on heating to 40°C.
Yield: 79%
Rfi 0.25 in ChfeCI^MeOH 95:5
1H-NMR: (300 MHz, MeOD) 6 2.38, 2.41 (2 H, 2 x t J=6.0, C(13)H2), 3.45, 3.55 (4 H, 2 
x m, C(10)H2, C(12)H2), 3.63, 3.73 (2 H, 2 x t J=5.4, C(11)H2), 4.78, 4.79 (2 H, 2 x s, 
C(7)H2), 5.57 (1 H, d J=7.9, C(5)H), 7.17-7.48 (16 H, m, C(6)H, 6 x C(17)H, 6 x 
C(18)H, 3 x C(19)H)
13C-NMR: (75 MHz, MeOD) 6 43.1, 43.7 (C-13), 48.7 (C-10, C-12), 50.4, 51.2 (C-7),
60.4 (C-11), 72.6 (C-15), 102.1 (C-5), 127.4, 128.9, 129.9 (6 x C-17, 6 x C-18, 3 x C -  
19,), 147.4 (3 x C-16), 147.9 (C-6), 152.9 (C-2), 166.9 (C-4), 169.7 (C-8)
LRMS (ES*): m/z= 499 [M+H]*
HRMS (ES*): Found: 499.2361 [M+H ]* C ^ H j^ C V  requires 499.2340
O
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8.35 (41) Synthesis of 1-[N-(dibenzylphosphoxy)
ethyl-N-(triphenylmethylamino)ethyl acetamide] uracil
24
o -p -o
17
Compound 40 (60 mg, 0.12 mmol) and 1-H-tetrazole (0.45 M soln. in THF, 0.3 mL, 
0.14 mmol) were partially dissolved in DCM (10 mL) under N2 atmosphere. Dibenzyl 
N,N-diisopropyl phosphoramidite (249 mg, 0.72 mmol) in DCM (2 mL) was added and 
the solution became a little less cloudy though a precipitate still remained. The solution 
was left stirring at RT for 90 min, after which time the solution was clear. The solution 
was cooled to -40°C using CH3CN/dry ice bath. 7ert-BuOOH (70% in H20, 0.96 mmol) 
was added slowly to the solution which was left stirring at 40°C for 15 min and then 
allowed to come to RT over 20 min and finally was left stirring for a further 20 min 
under N2 at RT. The solvent was removed in vacuo. The crude was washed with H20  
and redissolved in MeOH. On addition of diethyl ether a precipitate formed. This was 
shown by NMR to be a mixture of the phosphoramidite starting material and the 
desired product. After purification by flash chromatography (CH2CI2/MeOH 
100:0—>90:10) the pure product was isolated as a white solid (50 mg). 13C NMR peaks 
did show splitting for up to 5 bonds from P.
Yield: 55%
Rf: 0.7 in CH2CI2/MeOH 90:10
'H-NMR: (300 MHz, MeOD) 6 2.35, 2.39 (2 H, 2 x t >5 .6 , C(19)H2), 3.39 (2 H, m, 
C(10)H2), 3.47, 3.64 (2 H, m, C(18)H2), 4.07, 4.16 (2 H, m, C(11)H2),4.57, 4.78 (2 H, 2 
x s, C(7)H2), 5.02, 5.07 (4 H, m, 2 x C(13)H2), 5.59 (1 H, m, C(5)H), 7.18-7.47 (26 H, m, 
C(6)H, 2 x C(17)H, 4 x C(15)H, 4 x C(16)H, 3 x C(25)H, 6 x C(23)H, 6 x C(24)H) 
13C-NMR: (75 MHz, MeOD) 6 43.3, 43.8 (C-19), 47.8 (C-10), 48.1 (C-18), 49.9, 50.2 
(C-7), 66.3, 66.4 (C-11), 71.0, 71.2 (C-13), 102.2 (C-5), 129.0-129.9 (6 x C-23, 6 x C- 
24, 3 x C-25), 137.0, 137.1 (2 x C-17, 4 x C-16, 4 x C-15, 2 x C-14), 147.3 (3 x C-22),
147.8 (C-6), 152.7 (C-2), 166.9 (C-4), 169.6, 169.7 (C-8)
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31P-NMR: (202MHz, MeOD) 5 8.5 (P-12)
LRMS (ES*): m/z= 760 [M+H]*
HRMS (ES*): Found: 759.2911 [M+H]* C43H„N40 7P* requires 759.2942
8.36 (42) Synthesis of 1-[N-(phosphoxy)ethyl-N-
(triphenylmethylamino) ethyl acetamide] uracil
Compound 41 (50 mg, 0.07 mmol) was dissolved in MeOH (15 mL) and placed first 
under vacuum and then N2. 5% Pd/C (15 mg, 0.01 mmol) was added. The system was 
placed under vacuum and flushed with N2 3 times and finally placed under vacuum 
again. The system was exposed to H2 by piercing the septum with a H2 filled balloon. 
The solution was left stirring for 2 h. The solvent was was removed in vacuo. The crude 
plus the catalyst was taken up in DMF (5 mL) and filtered through celite. The solvent 
was again removed in vacuo and the crude was again taken up in DMF (5 mL) and 
filtered through celite in order to remove catalyst. A white solid was obtained (19 mg). 
Yield: 50%
Rf. 0 in CH2Cl2/MeOH 70:30
1H-NMR: (300 MHz, MeOD) 6 2.29 (2 H, m, C(14)H2), 3.38 (2 H, m, C(10)H2), 3.69 (2 
H, m, C(13)H2), 3.86, 3.93 (2 H, m, 0 (1 1 )^ , 4.69, 4.72 (2 H, 2 x s, C(7)H2), 5.57 (1 H, 
m, C(5)H), 7.18-7.44 (16 H, m, C(6)H, 6 x C(18)H, 6 x C(19)H, 3 x C(20)H)
1JC-NMR: (75 MHz, MeOD) S 42.1, (C-14), 46.1 (C-10), 47.9 (C-13), 49.0 (C-7), 62.2 
(C-11), 70.1 (C-16), 100.5 (C-5), 127.8, 128.3, 128.4 (6 x C-18, 6 x C-19, 3 x C-20),
145.8 (3 x C-17), 146.8 (C-6), 151.0 (C-2), 163.9 (C-4), 167.0 (C-8)
LRMS (ES*): m/z= 580 [M+2H]*
HRMS (ES*): Found: 579.2009 [M+H]* CjgHajN^P* requires 579.2003
O
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9.1 GRID calculations
The PDB file 1VYQ was downloaded from the protein data bank. The reference 
molecule was removed by deleting all HETATM in the text file to create the file 
plasmlessligand.pbd. GRID was run from the directory in which the .pdb file was saved. 
GRIN calculations were run in order to prepare the protein for GRID calculations using 
the automatic filtering option. All GRIN warnings were ignored. Coordinates were 
defined in which the calculations were to be carried out as BOTX 26.34, BOTY -17.35, 
BOTZ -18.40, TOPX 42.56, TOPY -1.03, TOPZ -4.63. Default settings and keywords 
were used. The directive MOVE which controls the flexibility of the target was set to 0. 
This allowed for lone pairs and tautomeric hydrogens to move in response to the probe. 
The directive NPLA which determines the resolution of the computation i.e. the 
distance between each GRID point was set to 4, therefore, each GRID point in the 
defined region was 0.25A apart. The directive LEVL which controls the amount of 
information in the the output file GRINLOUT was set to 3 and the directive ALMD was 
set to 1 which allowed for extra information to be written to the GRID output file 
GRIDKONT. The probes to be used were chosen, these are listed in table 5-1 and the 
GRID calculations were carried out and visualised using the integrated program using 
GVIEW.
9.2 FlexX docking
Compounds 47-56 were drawn and minimised using Sybyl 6.9.1. Minimisation was 
carried out using the TRIPOS force field in a dielectric constant of 80, the conjugated 
gradient method was used with a gradient of 0.05kcal/mol and 1000 iterations. Charges 
were not assigned as FlexX assigns formal charges to the ligand before docking 
calculations are carried out. The compounds were then docked using FlexX. The uracil 
ring was manually defined as the base fragment and the active site was defined as 8A 
around the reference molecule. The conformations generated were ranked by FlexX by 
decreasing FlexX total score (increasing AG) and visualised using Sybyl 6.9.1 and 
VMD 1.8.4.
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9.3 General procedures
General procedure H: Parallel amide synthesis using DhbtOH and DCC in a 
Rad ley’s reduced temperature carousel
The relevant amine (1.2 eq), 58 (1 eq) and DhbtOH (1.2eq) was stirred in a Radley’s 
threaded glass reaction tube in DMF (6 mL/mmol). Et3N (1.5 eq) was added in cases 
where the hydrochloride amino salt was used. The reactions were cooled to 0°C under 
argon and DCC (1.2eq) in DMF (1 mL/mmol) was added. The reactions were stirred at 
0°C for 1 h and then at RT overnight. The DCU precipitate which formed was removed 
by filtration and the crude mixtures were purified by flash chromatography on silica gel.
9.4 (58) 1-[2-{carboxy)-4-{tert-butyldiphenylsilyloxy)butyl]
uracil or 1-[2-(carboxy)-4-(fe/t-butyldimethylsilyloxy)butyl]
uracil
Method 1 PDC/DMF: Previously supplied intermediate TBDMS protected intermediate 
57 (500 mg, 1.52 mmol) was dissolved in DMF (2 mL) under argon at RT. PDC (5.86 g, 
7.61 mmol) in DMF (5 mL) was added. The solution was stirred overnight at RT. 
Bromocresol green stained TLC showed the presence of the acid on the base line as a 
bright yellow spot. Diethyl ether (30 mL) was added and the solution was washed with 
saturated NaHC03 (2 x 50 mL). The aqueous layer was acidified to pH 2 with 0.2 M 
HCI and extracted with diethyl ether (4 x 50 mL). The organic layer was dried with 
MgS04 and evaporated in vacuo. No product, however was isolated from this 
extraction. TLC stained with bromocresol green showed the acid was still present in the 
aqueous phase, however, separation from the excess PDC was not possible using any 
organic solvents. Furthermore, NMR analysis did not show the presence of any 
product.
O O
15
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Method 2 Cr03, H5I06, H20, ACN: A solution of CrO3(0.5 mg, 0.01 mmol) and H5I06 
(252 mg, 1.11 mmol) in ACN:H20  3:1 (1 mL) was added over 15 min using a syringe 
pump to a solution of TBDPS protected intermediate 57 (200 mg, 0.44 mmol) in 
ACN:H20  3:1 (1 mL) at 0°C. The reaction was stirred for 30min at 0°C and then 
allowed to warm to RT. The precipitate which had formed was filtered and identified as 
periodic acid. The solvent was removed from the filtrate and DCM (5 mL) was added to 
form an insoluble yellow gel which was removed by trituration. This insoluble material 
was identified by 1H-NMR as starting material in which the silyl protecting group had 
been cleaved. The DCM soluble material was identified by 1H-NMR as silanol. None of 
the desired product was isolated from the reaction.
Method 3 TEMPO, BAIB: The TBDPS protected intermediate 57 (1.5 g, 3.31 mmol), 
BAIB (2.35 g, 7.29 mmol) and TEMPO (104mg, 0.66 mmol) were dissolved in 
ACN:H20  1:1 (10 mL). The yellow solution was stirred at RT for 3 h. The solvent was 
removed under reduced pressure and the desired product was triturated from diethyl 
ether as a white solid (1.31 g).
Melting point: 65-66°C 
Yield: 85%
Rf. 0 in CH2CI2/MeOH 90:10
*H-NMR: (500 MHz, CD,CN) 5 1.01 (9 H, s, 3 x C(17)H3), 1.75, 1.88 (2 H, m, C(9)H2), 
3.06 (1 H, m, C(8)H), 3.74 (2 H, m, C(7)H2), 3.85-3.94 (2 H, m, C(10)H2), 5.58 (1 H, d 
J= 7.7 C(5)H), 7.43-7.68 (10 H, m, 2 x C(15)H, 4 x C(14)H, 4 x C(13)H), 7.76 (1 H, d 
J= 7.7, C(6)H)
13C-NMR: (125 MHz, CD3CN) 5 18.2 (C-16), 25.8 (3 x C-17), 31.7 (C-9), 40.8 (C-8),
49.8 (C-7), 61.0 (C-10), 100.4 (C-5), 127.5 (2 x C-15), 129.5 (4 x C-14), 135.0 (4 x C- 
13), 133.0 (2 x C-12), 146.1 (C-6), 150.8, (C-2), 164.2 (C-4), 174.6 (C-11)
LRMS (ES*): m/z= 467.0 [M+H]*
HRMS (ES'): Found: 465.1834 [M-H]' C26H280 5N2Si' requires 465.1840
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9.5 (59) 1-[2-{acetaldehyde)-4-{tert-butyldimethylsilyloxy) 
butyl] uracil
o
< NH
J.A,
13 Si-O
14
Method 1 Swern oxidation: Oxalyl chloride (212 mg, 1.67 mmol) was dissolved in 
DCM (10 mL) under argon and cooled to -70°C. DMSO (262 mg, 3.35 mmol) in DCM (5 
mL) was added drop-wise so that the temperature remained constant. After 10min, 
previously supplied intermediate 57 (500 mg, 1.52 mmol) in 3 mL DCM was added 
slowly. The reaction was left stirring for a further 15 min at -70°C and became cloudy. 
NEt3 (616 mg, 6.09 mmol) was added at -70°C and the solution became clear. The 
solution was warmed to 0°C and stirred for 5 min. The mixture was then allowed to 
reach RT over 45 min. H20  (20 mL) was added and separated from the organic layer 
which was washed with brine (2 x 75 mL), dried with MgS04and evaporated in vacuo. 
A number of spots could be seen by permanganate stained TLC. A precipitate formed 
on addition of diethyl ether which was identified by 1H-NMR as uracil. The diethyl ether 
filtrate showed to be a mixture of products which were purified by flash chromatography 
(EtOAc:Hexane 50:50—>90:10). The major product isolated, however was identified by 
1H NMR and mass spectrometry as the enal, 60 produced from a reverse Michael 
addition across the N-1, C-7 bond.
60
'H-NMR: (500 MHz, CDCIj) 6 0.05 (6 H, s, 2 x C(6)H3), 0.91 (9 H, s, 3 x C(8)H3), 2.30 
(2 H, m, C(3)H2), 3.71 (2 H, m, C(4)H2), 6.01, 6.37 (2 H, 2 x s, C(1)H2), 9.51 (1 H, s, 
C(5)H)
LRMS (ES*): m/z= 215.2 [M+H]*
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Method 2 PCC, DCM: PCC (177 mg, 0.82 mmol) and TBDMS protected intermediate 
57 were stirred in 3 mL dry DCM with 3 A molecular sieves (120 mg) under argon at RT 
overnight. No starting material could be seen by TLC. The solution was filtered through 
celite to remove the catalyst which was further washed with DCM (300 mL). However, 
no product was isolated from the filtrate. The product could not be isolated from the 
chromium salts.
Method 3 TPAP, NMO: Previously supplied TBDMS intermediate 57 (100mg, 0.30 
mmol) and 3A molecular sieves (112 mg) were stirred in dry DCM (1 mL) under argon 
at RT. A/-metylmorpholine-A/-oxide (53 mg, 0.46 mmol) in DCM (0.5 mL) was added, 
followed by tetrapropylammonium peruthenate (5 mg, 0.02 mmol) in DCM (1 mL). The 
solution was left stirring for 5 h. The solvent was evaporated under reduced pressure 
and the crude residue was purified by flash chromatography (EtOAc/Hexane 
0:100—>50:50) to yield the product as a white solid (50 mg).
Yield: 50% (method 3)
Rf. 0.4 in EtOAc/Hexane 9:1
1H-NMR: (500 MHz; CDCI3) 6 0.02 (6 H, s, 2 x C(12)H3 ), 0.83 (9 H, s, 3 x C(14)H3), 
1.89 (2 H, q J=6.0, C(9)H2), 2.90 (1 H, m, C(8)H), 3.69 (2 H, t J=6.0, C(10)H2), 3.86 (2 
H, m, C(7)H2), 5.61 (1 H, d J=7.5, C(5)H), 7.35 (1 H, d J=7.5, C(6)H), 8.57 (1 H, s, 
C(11)H), 9.66(1 H, s, N(3)H)
13C-NMR: (125 MHz; CDCI3) 6 -5.5 (2 x C-12), 18.2 (C-13), 25.8 (C-14), 30.8 (C-9),
47.7 (C-8), 49.0 (C-7), 60.1 (C-10), 101.8 (C-5), 145.9 (C-6), 150.9 (C-2), 165.8 (C-4),
202.2 (C-11)
LRMS (ES+): m/z= 327.2 [M+H]+
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9.6 (61) 1-[2-(acetamide)-4-(fert-butyldiphenylsilyloxy)butyl]
uracil
Compound 58 (300 mg, 0.64 mmol), NH4CI (42 mg, .77 mmol) and DhbtOH (121 mg, 
0.74 mmol) were dissolved in DMF (5 mL) under argon at 0°C. NEt3 (96 mg, 0.96 
mmol) was added, followed by DCC (159 mg, 0.77 mmol) in DMF (2 mL). The reaction 
was stirred at 0°C for 1 h and then at RT overnight. A precipitate which was identified 
by 1H NMR as DCU was filtered off. Following removal of solvent, further DCU side 
product was removed by precipitation from acetone. The crude was purified by flash 
chromatography (EtOAc/Hexane 0:100—>50:50, CHCIs/MeOH 100:0—>90:10) to yield 
the product as a yellow solid (240 mg).
Yield: 80%
R 0.4 in CH2CI2/MeOH 90:10 
Melting point: 90-93°C
'H-NMR: (500 MHz, (CD3)2CO) 6 1.01 (9 H, s, 3 x C(17)H3), 1.61, 1.79 (2 H, m, 
C(9)H2), 2.78 (1 H, m, C(8)H), 3.64, 3.85 (4 H, m, C(7)H2, C(10)H2), 5.52 (1 H, d J= 7.7 
C(5)H), 6.34, 6.89 (2 H, 2 x s, N(18)H2), 7.44-7.64 (11 H, m, 2 x C(15)H, 4 x C(14)H, 4 
x C(13)H, C(6)H), 11.30 (1 H, s, N(3)H)
"C-NMR: (125 MHz, (CD3)2CO) 8 19.7 (C-16), 27.5 (3 x C-17), 34.1 (C-9), 42.0 (C-8),
51.8 (C-7), 62.6 (C-10), 101.5 (C-5), 128.8 (2 x C-15), 130.6 (4 x C-14), 134.4 (4 x C-
13), 136.2 (2 x C-12), 147.0 (C-6), 151.8 (C-2), 164.1 (C-4), 175.7 (C-11)
LRMS (ES*): m/z= 466.0 [M+H]*
HRMS (ES*): Found: 488.1970 [M+Na]* C25H30O4N3SiNa* requires 488.1976
O
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9.7 (62) 1-[2-(methylamido)-4-(fert-butyldiphenylsilyloxy)butyl] 
uracil
Compound 62 was synthesised according to general procedure C (Chapter 8) of EDC 
mediated amide coupling using 58 (200 mg, 0.43 mmol), methyl amine hydrochloride 
(24mg, 0.36 mmol) and EDC (89mg, 0.46mmol). The amine was neutralised by 
prestirring with Et3N. The crude was purified by flash chromatography (EtOAc/Hexane 
0:100—>50:50, CHCIs/MeOH 100:0—>90:10) to yield the product as a clear wax (12 mg). 
Yield: 7%
Rf: 0.4 in CH2CI2/MeOH 95:5
1H-NMR: (500 MHz, CDCI3) 6 1.00 (9 H, s, 3 x C(17)H3), 1.66-1.70 (2 H, m, C(9)H2), 
2.55 (3 H, C(19)H3), 2.91 (1 H, m, C(8)H), 3.55-3.95 (4 H, m, C(7)H2, C(10)H2), 5.50 (1 
H, d J= 7.8 C(5)H), 5.67 (1 H, s, N(18)H), 7.19-7.57 (11 H, m, 2 x C(15)H, 4 x C(14)H, 4 
x C(13)H, C(6)H), 8.87 (1 H, s, N(3)H)
13C-NMR: (125 MHz, CDCI3) 6 18.1 (C-16), 25.3 (C-19), 25.9 (3 x C-17), 32.0 (C-9),
41.4 (C-8), 50.5 (C-7), 60.2 (C-10), 100.3 (C-5), 126.8 (2 x C-15), 128.9 (4 x C-14),
132.2 (2 x C-12), 134.5 (4 x C-13), 145.1 (C-6), 149.7 (C-2), 162.7 (C-4), 172.0 (C-11) 
LRMS (ES+): m/z= 480.1 [M+H]+
HRMS (ES+): Found: 502.2139 [M+Na]+ CzeH^C^SiNa* requires 502.2133
O
16
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9.8 (64) 1-[2-(ethylamido)-4-(fert-butyldiphenylsilyloxy) butyl]
uracil
The synthesis of 64 was carried out according to general procedure H using ethyl 
amine hydrochloride (42 mg, 0.52 mmol), DhbtOH (81 mg, 0.49 mmol), 58 (200 mg, 
0.43 mmol), Et3N (65 mg, 0.64 mmol) and DCC (106 mg, 0.52 mmol). The crude was 
purified by flash chromatography (EtOAc/Hexane 0:100—>50:50, CHCIa/MeOH 
100:0-^90:10) to yield the desired product as a yellow wax (34 mg)
Yield: 16%
Rf: 0.6 in CH2Cl2/MeOH 90:10
1H-NMR: (500 MHz, (CD3)2CO) 5 0.86 (3 H, t J= 7.3, C(20)H3), 0.90 (9 H, s. 3 x 
C(17)H3). 1.57- 1.80 (2 H, m, C(9)H2), 2.80 (1 H. m, C(8)H), 2.94-3.08 (2 H, m, 
C(19)H2), 3.51-3.90 (4H, m, C(7)H2, C(10)H2), 5.35 (1 H, d J= 7.9, C(5)H), 7.21-7.58 (12 
H, m, 2 x C(15)H, 4 x C(14)H, 4 x C(13)H, C(6)H, N(18)H), 9.90 (1 H, s, N(3)H) 
1JC-NMR: (125 MHz, (CD3)2CO) 6 15.2 (C-20), 19.4 (C-16), 27.1 (3 x C-17), 33.7 (C-9),
34.8 (C-19), 43.7 (C-8), 51.4 (C-7), 61.8 (C-10), 101.0 (C-5), 128.8 (2 x C-15), 130.7 (4 
x C-14), 134.5 (2 x C-12), 136.3 (4 x C-13), 146.6 (C-6), 152.0 (C-2), 164.6 (C-4), 
173.1 (C-11)
LRMS (ES*): m/z= 494.2 [M+H]*
HRMS (ES*): Found: 494.2482 [M+H]* C27H320„N3Si* requires 494.2470
O
16
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9.9 (65) 1-[2-(diethylamido)-4-(fert-butyldiphenylsilyloxy) 
butyl] uracil
sr f^ N HI , I
20
The synthesis of 65 was carried out according to general procedure H using diethyl 
amine hydrochloride (56 mg, 0.52 mmol), DhbtOH (81 mg, 0.49 mmol), 58 (200 mg, 
0.43 mmol), Et3N (65 mg, 0.64 mmol) and DCC (106 mg, 0.52 mmol). The crude was 
purified by flash chromatography (EtOAc/Hexane 0:100-»50:50, CHCIs/MeOH 
100:0—>90:10) to yield the desired product as a yellow wax (85mg)
Yield: 38%
Rf: 0.5 in CH2CI2/MeOH 95:5
1H-NMR: (500 MHz, CDCI3) 6 0.94-1.00 (15 H, m, 2 x C(20)H3, 3 x C(17)H3), 1.60, 1.76 
(2 H, m, C(9)H2), 3.06 (1 H, m, C(8)H), 3.16-4.03 (8 H, m, 2 x C(19)H3, C(7)H2, 
C(10)H2), 5.50 (1 H, d J= 7.9, C(5)H), 7.19-7.61 (11 H, m, 2 x C(15)H, 4 x C(14)H, 4 x 
C(13)H, C(6)H), 9.06 (1 H, s, N(3)H)
13C-NMR: (125 MHz,CDCI3) 6 13.3, 14.9 (2 x C-20), 19.2 (C-16), 26.9 (3 x C-17), 34.1 
(C-9), 37.2 (C-8), 41.2, 42.3 (2 x C-19), 51.9 (C-7), 60.8 (C-10), 101.3 (C-5), 128.4 (2 x 
C-15), 130.3 (4 x C-14), 133.5 (2 x C-12), 135.9 (4 x C-13), 146.6 (C-6), 150.6 (C-2),
163.9 (C-4), 172.6 (C-11)
LRMS (ES+): m/z= 522.2 [M+H]+
HRMS (ES+): Found: 522.2795 [M+H]+ C zg H ^ N ^ i* requires 522.2783
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9.10 (67) 1-[2-{N-Z-piperazinamido)-4-(fert-butyldiphenyl
silyloxy) butyl] uracil
* NH
N 2 O
9 \ i o
23 21 g  ] 13 14
0 ^ 0 15
16
17
The synthesis of 67 was carried out according to general procedure H using N-Cbz- 
piperazine (113 mg, 0.515 mmol), DhbtOH (81 mg, 0.494 mmol), 58 (200 mg, 0.429 
mmol) and DCC (106 mg, 0.515 mmol). The crude was purified by flash 
chromatography (EtOAc/Hexane 0:100-^50:50, CHCIs/MeOH 100:0—>90:10) to yield 
the desired product as a yellow wax (233 mg)
Yield: 81%
Rfi 0.2 in CH2Cl2/MeOH 95:5
1H-NMR: (500 MHz, CDCIj) 5 1.04 (9 H, s, 3 x C(17)H3), 1.67, 1.85 (2 H, m, C(9)H2),
3.25-3.77 (13 H, m, C(8)H, C(7)H2, C(10)H2, 2 x C(18)H2, 2 x C(19)H2), 5.16 (2 H, s, 
C(21)H3), 5.60 (1 H, d J= 7.7, C(5)H), 7.29-7.66 (16 H, m, 2 x C(15)H, 4 x C(14)H, 4 x 
C(13)H, C(6)H, 2 x C(23)H, 2 x C(24)H, C(25)H), 9.82 (1 H, s, N(3)H)
13C-NMR: (125 MHz ,CDCI3) 5 19.1 (C-16), 26.9 (3 x C-17), 33.4 (C-9), 36.6 (C-8),
41.8, (2 x C-18), 45.4 (2 x C-19), 51.8 (C-7), 61.5 (C-10), 68.1 (C-21), 101.3 (C-5),
127.8 (C-25), 128.1 (2 x C-15), 128.3 (2 x C-24), 130.3 (2 x C-23), 133.0 (2 x C-12),
135.5 (4 x C-13), 136.3 (C-22), 146.2 (C-6), 150.8 (C-2), 154.0 (C-20), 164.1 (C-4),
171.7 (C-11)
LRMS (ES*): m/z= 669.3 [M+H]*
HRMS (ES*): Found: 669.3128 [M+H]* C37H4506N4Si* requires 669.3157
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9.11 (70) 2-(1-methyluracil)-4-hydroxybutyanal
o
1M TBAF solution in THF (0.61 mL, 0.61mmmol) was added to 48 (100mg, 
0.307mmol). The yellow solution was left stirring at RT for 1h. The solvent was 
removed in vacuo and the crude was purified by flash chromatography (EtOAc/Hexane 
1:4—>4:1, then MeOH/CHCI3 0:100—>5:95) to give the product as a clear oil (56 mg) 
Yield: 72%
Rf: 0.00 in MeOH/CHCI3 1:4
1H-NMR: (500 MHz; D20) 6 1.68, 2.05 (2 H, m, C(9)H2), 2.51 (1 H, m, C(8)H), 3.76-
4.07 (4 H, m, C(7)H2, C(10)H2), 5.69-5.77 (1 H, d J=7.7 C(5)H), 7.40-7.46 (1 H, m,
C(6)H), 8.01-8.04 (1 H, br, N(3)H), 8.73 (1 H, s, C(11)H)
13C-NMR:(125 MHz ; D20) 6 27.4 (C-9), 41.2 (C-7), 44.5 (C-8), 66.5 (C-10), 100.3 (C- 
5), 141.3 (C-6), 153.1 (C-2), 166.5 (C-4)
LRMS (ES+): m/z= 213.0 [M+H]+
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9.12 (73) 1-[2-(carbobenzoxymethyl)-4-aminobutyl] uracil
Intermediate 72 (3 g, 8.04 mmol) supplied by Medivir was dissolved in pyridine (40 mL) 
under argon and triphenylphosphine (3.4 g, 12.87 mmol) was added. The solution was 
stirred at RT for 2.5 h after which time only starting material could be seen by TLC. 
NH4OH conc. (117 mL) was added. The solution was stirred at 50° C for 2 d. the 
solvent was removed under reduced pressure and redissolved in CHCI3 (30 mL). A 
precipitate formed which was identified by 1H NMR as the phosphoimine intermediate. 
The filtrate was purified by flash chromatography on silica gel (NH3/MeOH/CHCI3 
0:0:100—►1.2:6:94) to afford the product as a white solid (1.02 g).
Yield: 37%
Rfi 0.4 in CH2Cl2/MeOH 90:10
’H-NMR: (500 MHz, pyridine) 5  1.73, 1.87 (2 H, m, C(9)H2), 2.27 (1 H, m, C(8)H), 
3.49, 3.56, 3.95 (6 H C(7)H2, C(10)H2, C(11)H2), 5.24 (2 H, m, C(13)H3), 5.70 (1 H, d 
> 7 .7 , C(5)H), 7.11-7.53 (6 H, m, 2 x C(15)H, 2 x C(16)H, C(17)H, C(6)H), 8.07, 13.28 
(2 H, 2 x s, 2 x NH)
” C-NMR: (125 MHz,pyridine) 5 30.4 (C-9), 39.0 (C-8), 39.7, (C-11), 49.9 (C-7), 61.5 
(C-10), 66.6 (C-13), 102.0 (C-5), 128.6-129.4 (C-17, 2 x C-16, 2 x C-15), 138.7 (C-14),
146.6 (C-6), 153.1 (C-2), 157.6 (C-12), 165.3 (C-4)
LRMS (ES*): m /z- 348.1 [M+H]*
HRMS (ES+): Found: 370.1357 [M+H]* C17H210 5N3Na* requires 370.1373
o
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9.13 (74) 1-[2-(carbobenzoxymethyl)-4-(triphenylmethyl)amino 
butyl] uracil
o
4 NH
23
22
17
73 (1 g, 2.88 mmol) and trityl chloride (1.2 g, 4.32 mmol) were dissolved in pyridine (12 
mL). The solution was divided into 3 equal batches in 5 mL reaction vials and DMAP 
(1mg, 0.3%w/w) was added to each batch. The solutions were exposed to MW 
radiation for 15min at 160°C twice after which time no starting material was observed 
by TLC. The crude was purified by flash chromatography on silica gel (EtOAc/Hexane 
50:50—>100:0, then MeOH/CHCI3 0:100—>8:92) to yield the pure product as a sticky 
gum (1.69 g).
Yield: 100%
Rf. 0.5 in EtOAc/Hexane 50:50
1H-NMR: (500 MHz, CD2CI2) 5 1.59, 1.71 (2 H, m, C(9)H2), 2.06 (1 H, m, C(8)H), 3.11- 
3.27 (4 H, m, C(7)H2, C(10)H2), 3.72, 3.89 (2 H, m, C(11)H2), 5.10 (2 H, m, C(19)H3), 
5.30 (1 H, d > 7 .7  C(5)H), 6.75 (1 H, m, N(12)H), 7.32-7.44 (21 H, m, 6 x C(16)H, 6 x 
C(15)H, 3 x C(15)H, 2 x C(21)H, 2 x C(22)H, C(23)H, C(6)H), 9.47 (1 H, s, N(3)H) 
1SC-NMR: (125 MHz, CD2CI2) 6 30.1 (C-9), 37.0 (C-8), 39.0, (C-11), 49.4 (C-7), 62.7 
(C-10), 66.7 (C-19), 101.7 (C-5), 87.1 (C-13), 127.7-129.0 (3 x C-17, 6 x C-16, 6 x C- 
15, C-23, 2 x C-22, 2 x C-21), 137.5 (C-20), 144.0 (3 x C-14), 145.6 (C-6), 151.7 (C-2),
156.7 (C-18), 163.9 (C-4)
LRMS (ES*): m/z= 612.3 [M+H]*
HRMS (ES*): Found: 612.2475 [M+H]* C ^ s O ^ N a *  requires 612.2469
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Experimental II
9.14 (75) 1-[2-(hydroxymethyl)-4-(triphenylmethyl)aminobutyl] 
uracil
o
HO
13 NH / = ,
18
75 was synthesised according to the general procedure H for the removal of the CbZ 
protecting group by hydrogenation using 74 (1.5 g, 2.55 mmol) and Pd/C (28 mg, 0.26 
mmol) in MeOH:EtOH 1:1. The crude was purified by flash chromatography on silica 
gel (EtOAc/CHCIs 100:0—50:50, then MeOH/CHCI3 0:100— 10:90) to give the product 
as a sticky gum (616 mg)
Yield: 53%
Rfi 0.4 in CH2CI2/MeOH 95:5
1H-NMR: (500 MHz, DMSO) 6 1.57-1.67 (2 H, m, C(9)H2), 2.14 (1 H, m, C(8)H), 2.94-
3.02 (4 H, m, C(7)H2, C(10)H2), 3.69-3.76 (2 H, m, C(11)H2), 5.42 (1 H, d J= 7.8 C(5)H),
7.26-7.35 (18 H, m, 6 x C(16)H, 6 x C(17)H, 3 x C(18)H, C(6)H, 2 x NH)
13C-NMR: (125 MHz, DMSO) 6 30.1 (C-9), 36.4 (C-8), 47.7 (C-7), 62.4 (C-10), 78.6 (C- 
11), 85.9 (C-14), 100.8 (C-5), 128.2, 126.9, 127.8 (3 x C-18, 6 x C-17, 6 x C-16), 143.6 
(3 x C-15), 145.8 (C-6), 150.9 (C-2), 163.4 (C-4)
LRMS (ES+): m/z= 456.2 [M+H]+
HRMS (ES+): Found: 456.2277 [M+H]+ C28H30O3N3+ requires 456.2282
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Experimental II
9.15 (76) 1-[2-(carboxy)-4-(triphenylmethyl)aminobutyl] uracil
75 (600 mg, 1.30 mmol), BAIB (921 mg, 2.86 mmol) and TEMPO (41 mg, 0.26 mmol) 
were stirred in ACN:H20  50:50 overnight at RT. The crude was purified by flash 
chromatography on silica gel (MeOH/CHCI3 7:93) to yield the product as a white solid 
(350 mg)
Yield: 57%
Melting point: 71-75°C 
Rf: 0.4 in CH2CI2/MeOH 90:10
1H-NMR: (500MHz, CDCI3) 6 1.24 (2 H, m, C(9)H2), 2.34 (1 H, m, C(8)H), 3.14-3.80 (4 
H, m, C(7)H2, C(10)H2), 5.32 (1 H, d J= 7.7 C(5)H), 6.65 (1 H, m, N(13)H), 7.14-7.31 (17 
H, m, 6 x C(16)H, 6 x C(17)H, 3 x C(18)H, C(6)H, N(3)H), 9.39 (1 H, br, 0(12)H) 
13C-NMR: (125MHz, DMSO) 6 30.8 (C-9), 35.1 (C-8), 47.9 (C-7), 62.7 (C-10), 86.3 (C-
14), 100.6 (C-5), 127.2-128.5 (3 x C-18, 6 x C-17, 6 x C-16), 143.8 (3 x C-15), 145.5 
(C-6), 151.7 (C-2), 163.5(C-4), 172.1 (C-11)
LRMS (ES ): m/z= 469.2 [M-H+], 227.0 [77-H]+
LRMS (ES+): m/z= 452.1 [78+H]+
O
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Experimental II
9.16 (79) 1-[2-(acetamide)-4-(triphenylmethyl)aminobutyl] uracil
79 was synthesised according to general procedure H using ammonium hydrochloride 
(7 mg, 0.13 mmol), 76 (50 mg, 0.11 mmol), DhbtOH (20 mg, 0.12 mmol), NEU (16 mg, 
0.16 mmol) and DCC (26 mg, 0.13 mmol) in DMF (3 mL). The crude was purified by 
flash chromatography on silica gel (EtOAc/Hexane 50:50—>100:0, EtOAc/CHCI3 
100:0->0:100, MeOH/CHCI3 0:100—>10:90) to yield the product as a white solid (5 mg). 
Yield: 10%
R 0.8 in CH2CI2/MeOH 90:10
'H-NMR: (500 MHz, (CD,)2CO) 5 2.37, 2.43 (2 H, m, C(9)H2), 2.61 (1 H, m, C(8)H), 
3.14-3.87 (4 H, m, C(7)H2, C(10)H2), 5.37 (1 H, d J=7.7 C(5)H), 6.25, 6.89 (2 H, 2 x s, 2 
x N(13)H), 7.24-7.46 (17 H, m, 6 x C(16)H, 6 x C(17)H, 3 x C(18)H, C(6)H, N(3)H) 
13C-NMR: (125 MHz, (CD3)2CO) 6 35.8 (C-9), 40.0 (C-8), 50.0 (C-7), 63.8 (C-10), 87.5 
(C-14), 102.0 (C-5), 127.5-129.5 (3 x C-18, 6 x C-17, 6 x C-16), 144.8 (3 x C-15), 146.2 
(C-6), 151.8 (C-2), 164.2 (C-4), 173.3 (C-11)
LRMS (ES*): m /z- 492.0 [M+H+Na]*
O
18
- 216 -
Experimental II
9.17 (81) Attempted synthesis of 1-[2-(piperazinamido)~4- 
(triphenylmethyl)aminobutyl] uracil
o
The synthesis of 80 was attempted according to general procedure H using piperazine 
(11 mg, 0.13 mmol), 76 (50 mg, 0.11 mmol), DhbtOH (20 mg, 0.122 mmol) and DCC 
(26 mg, 0.13 mmol) in DMF (3 mL). The crude was purified by flash chromatography on 
silica gel (EtOAc/Hexane 50:50—100:0, EtOAc/CHCI3 100:0—0:100, MeOH/CHCI3 
0:100—10:90). Although the product was detected by mass spectrometry in one of the 
fractions, it was not pure and further purification on silica gel resulted in no product 
being isolated from the column. The dimer 84 was isolated from the column as a white 
solid (11 mg) and characterised by 1H-NMR and 13C-NMR.
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Experimental II
84
18'
17’
16’
15’ 14’
13’NH
Yield: 10%
Rf: 0.7 in CHzCI^MeOH 95:5 
Melting point: 95-97°C
1H-NMR: (500 MHz, (CD3)2CO) 6 1.59-1.75 (4 H, m, C(9)H2l C(9’)H2), 2.33 (2 H, m, 
C(8)H, C(8’)H), 3.07-3.80 (16 H, m, C(7)H2, C(10)H2, C(7’)H2i C(10’)H2, 4 x C(12)H2, 
5.35 (2 H, m, C(5)H, C(5’)H), 7.09-7.33 (35 H, m, 12 x C(16)H, 12 x C(17)H, 6 x 
C(18)H, C(6)H, C(6’)H, 2 x N(3)H, 2 x N(13)H)
13C-NMR: (125 MHz, (CD3)2CO) 6 35.8 (C-9), 40.0 (C-8), 50.0 (C-7), 63.8 (C-10), 87.5 
(C-14), 102.0 (C-5), 127.5-129.5 (3 x C-18, 6 x C-17, 6 x C-16), 144.8 (3 x C-15), 146.2 
(C-6), 151.8 (C-2), 164.2 (C-4), 173.3 (C-11)
LRMS (ES+): m/z= 990.2 [M+H]+
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Experimental II
9.18 (85) 1-[2-(hydroxymethyl)-4-(ferf-butyldimethylsilyl
oxy)butyl]-3-(para-methoxyphenyl) uracil
o
Si-O.
14 12
HO
Previously supplied intermediate 57 (200 mg, 0.61 mmol) was dissolved in THF (5 mL) 
and cooled to 0°C under argon. NaH (22 mg, 0.92 mmol) was added. After 15min tert- 
butylammonium iodide (11 mg, 0.03 mmol) in THF (1 mL) was added, followed by 4- 
methoxybenzyl chloride (191 mg, 1.22 mmol) in THF (1 mL). The reaction was stirred 
overnight at RT. After 24 h starting material could still be detected by TLC. The reaction 
was heated to 40°C and left stirring for a further 18 h, after which time the solution 
turned milky and no starting material could be seen by TLC. The solvent was removed 
under reduced pressure. The crude was dissolved in EtOAc (10 mL), washed with 
brine ( 1 x 1 0  mL) and water ( 2 x 1 0  mL) and dried with MgS04. The organic fraction 
was concentrated to afford the product as a clear oil (270 mg).
Yield: 100%
Rf: 0.4 in EtOAc/Hexane 1:1
1H-NMR: (500 MHz; CDCI3) 6 0.02 (6 H, s, 2 x C(12)H3 ), 0.84 (9 H, s, 3 x C(14)H3), 
1.53 (2 H, m, C(9)H2), 1.96 (1 H, m, C(8)H), 3.39-3.45(2 H, m, C(11)H2), 3.68-3.73 (7 
H, m, C(7)H2, C(10)H2, C(20)H3), 4.97(2 H, s, C(15)H2), 5.65 (1 H, d J= 7.8 C(5)H), 
6.74-6.79 (2 H, m, C(17)H), 7.14-7.22 (2 H, m, C(16)H), 7.34 (1 H, d J=7.8 C(6)H) 
13C-NMR: (125 MHz; CDCI3) 6 -3.6 (C-12), 18.0 (C-13), 25.9 (3 x C-14), 29.7 (C-9), 
38.2 (C-8), 46.3 (C-15), 50.2 (C-7), 55.3 (C-19), 60.0 (C-11), 61.3 (C-10), 102.0 (C-5),
113.9 (2 x C-17), 128.7-130.3 (2 x C-16), 143.2 (C-6), 152.5 (C-2), 159.1-159.7 (C-18),
162.9 (C-4)
LRMS (ES+): m/z= 449.6 [M+H]+
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Experimental II
9.19 (87) 1-[2-(dihydropyranyloxy)-4-(teft-butyldimethylsilyl 
oxy)butyl] uracil and (88) 1-[2-(dihydropyranyloxy)-4-(fert- 
butyldiphenylsilyl oxy)butyl] uracil
To a solution of previously supplied intermediate 57 (100 mg, 0.30 mmol for 87 and 1 
g, 2.21 mmol for 88) and dihydropyran (0.07 mL, 0.91 mmol for 87 and 0.6 mL, 6.63 
mmol for 88) in DCM (1.5 mL for 87 and 20 mL for 88) was added p-toluene sulfonic 
acid hydrate (10% w/w) under argon. The solution was exposed to MW radiation at 
100°C for 15 mins. Purification was carried out by flash chromatography in stepwise 
gradients (EtAc/Hexane 0:100-^50:50) to yield the product as a clear oil (692 mg)
87
O
4 NH
12
Si-O.
13
15
18
Yield: 72%
Rf: 0.2 in EtOAc/Hexane 1:1
1H-NMR: (500 MHz; CDCIj) 6 0.00 (6 H, s, 2 x C(11)H3 ), 0.85 (9 H, s, 3 x C(13)H3), 
1.40-1.59 (6 H, m, C(16)H2, C(17)H2, C(18)H2), 1.65, 1.72 (2 H, m, C(9)H2), 2.19 (1 H, 
m, C(8)H), 3.27, 3.41 (2 H, m, C(14)H2), 3.60-3.87 (6 H, m, C(7)H2, C(10)H2, C(19)H2), 
4.45 (1 H, m, C(15)H), 5.60 (1 H, d J= 7.8, C(5)H), 7.26 (1 H, d > 7 .8 , C(6)H), 9.22 (1 
H, s N(3)H)
13C-NMR: (125 MHz; CDCI3) 5 -5.4 (2 x C-11), 18.3 (C-12), 19.7, 20.0, 25.3, 25.4, 
32.0, 32.1 (3 x C-12, C-16, C-17, C-18), 32.0, 32.1 (C-9), 35.4, 35.8 (C-8), 50.4, 50.5 
(C-7), 60.8 (C-10), 62.7, 63.0 (C-14), 67.1, 67.7 (C-19), 99.1, 99.8 (C-15), 101.4, 101.5 
(C-5), 145.6, 145.7 (C-6), 151.1, 151.2 (C-2), 163.9, 164.0 (C-4)
LRMS (ES*): m/z= 435.2 [M+Na]*
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Experimental II
88
O
Si-O.16
20
21
Yield: 100%
Rf: 0.5 in EtOAc/Hexane 1:1
1H-NMR: (500 MHz; CDCI3) 6 0.98 (9 H, s, 3 x C(16)H3), 1.40-1.70 (8 H, m, C(9)H2i 
C(19)H2, C(20)H2, C(21)H2), 2.23 (1 H, m, C(8)H), 3.24-3.76 (8 H, m, C(7)H2, C(10)H2, 
C(17)H2, C(22)H2), 4.35, 4.42 (1 H, m, C(18)H), 5.56 (1 H, d J= 7.8, C(5)H), 7.10-7.59 
(11 H, C(6)H, 4 x C(12)H, 4 x C(13)H, 2 x C(14)H )
13C-NMR: (125 MHz; CDCI3) 5 19.5 (C-15), 22.8 (3 x C-16), 25.3, 26.9, 30.7 (C-19, C- 
20, C-21), 31.8 (C-9), 35.2, 35.6 (C-8), 50.5, 50.6 (C-7), 61.4, 61.5 (C-10), 62.7, 63.0 
(C-17), 67.1, 67.7 (C-22), 99.1, 99.9 (C-18), 101.4 (C-5), 127.7 (4 x C-13), 129.7 (2 x 
C-14), 133.6(4x0-12), 135.6 (2xC-11), 145.6 (C-6), 150.8 (C-2), 163..3(C-4)
LRMS (ES+): m/z= 537.2 [M+H]+
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Experimental II
9.20 (89) 1-[2-(dihydropyrayloxy)-4-hydroxybutyl] uracil
89 was synthesised according to general procedure G (Chapter 8) and the crude was 
purified by column chromatography on silica gel (MeOH/CHCI3 5:95) to isolate the pure 
product as a clear oil.
Yield: 93%
R,: 0.2 in DCM/MeOH 95:5
1H-NMR: (500 MHz; MeOD) 6 1.41-1.79 (8 H. m, C(9)H2, C(13)H2, C(14)H2, C(15)H2), 
2.21 (1 H, m, C(8)H), 3.24-3.82 (8 H. m. C(7)H2, C(10)H2, C(11)H2 C(16)H2), 4.48 (1 H, 
dd J=7.8, 3.5 C(12)H), 5.59 (1 H. dd J= 7.8, 3.5 C(5)H), 7.51 (1 H, d J= 7.6 C(6)H) 
13C-NMR: (125 MHz; MeOD) 5 26.6. 31.7, 31.9 (C-13, C-14, C-15), 33.1 (C-9), 36.3, 
36.6 (C-8), 51.8, 52.1 (C-7), 60.5, 60.6 (C-10), 63.5, 63.7 (C-11), 68.5, 69.5 (C-16), 
100.4, 100.9 (C-12), 101.7, 101.8 (C-5), 148.1, 148.2 (C-6), 153.1 (C-2), 166.9 (C-4) 
LRMS (ES*): m/z= 299.1 [M+H]*
HRMS (ES*): Found: 321.1409 [M+Na]* C,4H220 5N2Na* requires 321.1421
O
OH
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Experimental II
9.21 (90) 1-[2-(dihydropyrayloxy)-4-carboxybutyl] uracil
89 (300 mg, 1.0 mmol), BAIB (709 mg, 2.20 mmol) and TEMPO (31 mg, 0.20 mmol) 
were stirred in ACN:H20  1:1 (20 mL) for 5 h. The solvent was removed in vacuo and 
the desired product was triturated from diethyl ether as a sticky gum (310 mg).
Yield: 100%
Rf. 0.0 in DCM/MeOH 80:20
1H-NMR: (500 MHz; CD3CN) 6 1.44-1.67 (6 H, m, C(13)H2, C(14)H2, C(15)H2), 2.11 (2 
H, m, C(9)H2), 2.41 (1 H, m, C(8)H), 3.20-3.68 (6 H, m, C(7)H2, C(11)H2, C(16)H2), 
4.45(1 H, m, C(12)H), 5.46 (1 H, m, C(5)H), 7.26 (1 H, m, C(6)H)
13C-NMR: (125 MHz; CD3CN) 6 24.9 (C-9), 29.6, 29.9, 30.2, 31.6, 32.8, 33.1 (C-13, C- 
14, C-15), 34.6, 35.0 (C-8), 49.8, 50.3 (C-7), 61.4, 61.6 (C-11), 66.6, 67.3 (C-16), 98.4, 
98.8 (C-12), 101.1, 101.6 (C-5), 145.7 (C-6), 151.1 (C-2), 163.2 (C-4), 171.4 (C-10)
O
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Experimental II
9.22 (92) 3-benzoyl uracil131
o o
H
Uracil (5.00 g, 44.64 mmol) was stirred in a mixture of acetonitrile (40 mL) and pyridine 
(16 mL) under argon. Benzoyl chloride (89.61 mmol, 10.4 mL) was added and the 
yellow solution was left stirring overnight during which time a precipitate formed. After a 
total of 24 h the solvent was evaporated off under reduced pressure and the residue 
was partitioned between DCM (200 mL) and water (200 mL). The organic layer was 
vacuumed down under reduced pressure and the mixture was taken up in dioxane (80 
mL) and 0.5M K2C 03 in water (50 mL) and was stirred for 30 min. The pH of the 
solution was reduced to 5 and the solution concentrated and taken up in saturated 
NaHC03 (200 mL). The mixture was stirred at RT for 1 h and the precipitate which 
formed was filtered off and washed with cold water. The pure product was recrystalized 
from the precipitate in acetone/water 3:2 to yield a white solid (5.14 g)
Yield: 53%
Rfi 0.1 in DCM/MeOH 80:20
’H-NMR: (500 MHz; DMSO) 6 5.89 (1 H, d J= 7.8, C(5)H), 7.65 (2 H, t J=8.1 2 x 
C(10)H), 7.71 (1 H. d J=7.8, C(6)H), 7.81 (1 H, t J=6.3, C(11)H), 7.99 (2 H ,d J = 8 .1 ,2 x  
C(9)H), 11.65(1 H, br, N(1)H)
13C-NMR: (125 MHz; CDCI,;) 6 100.1 (C-5), 129.5 (2 x C-10), 130.2 (2 x C-9), 131.3 
(C-11), 135.4 (C-8) 143.7(C-6), 150.1 (C-2), 162.9(0-4), 170.0(0-7)
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Experimental II
9.23 (94) 1-(4-benzoylbutyl)-3- benzoyl uracil
o o
o
92 (300 mg, 1.3 9mmol) and 93 135 mg, 0.70 mmol) in THF (10 mL) were added to 
polymer bound Ph3P (0.33 g/mmol) which had been swelled in THF for 15 min. DIAD 
(281 mg, 1.39 mmol) was then added and the mixture was left shaking overnight. The 
polymer was filtered off and washed with THF and MeOH and the crude product was 
purified by flash chromatography (Hexane:EtOAc 100:0—>20:80) to afford the product 
as a colourless oil (211 mg).
Yield: 77%
Rf: 0.2 in EtOAc/Hexane 2:3
1H-NMR: (500 IWIHz; CDCI3) 6 1.68-1.72 (4 H, m, C(8)H2, C(9)H2), 3.76 (2 H, t J= 6.9, 
C(7)H), 4.25 (2 H, t J= 6.0, C(10)H2), 5.67 (1 H, d J= 7.9, C(5)H), 7.29-7.95 (11 H, m, 
C(6)H, 2 x C(13)H, 2 x C(14)H, C(15)H, 2 x C(18)H, 2 x C(19)H, C(20)H)
13C-NMR: (125 MHz; CDCI3) 6 25.7 (C-8), 31.3 (C-9), 48.6 (C-7), 63.9 (C-10), 102.0 
(C-5), 128.4-129.5 (2 x C-13, 2 x C-14, 2 x C-18, 2 x C-19), 130.3, 131.4 (C-12, C-17), 
133.2, 135.1 (C-15, C-20), 144.7 (C-6), 149.8 (C-2), 162.5 (C-4), 166.4, 169.0 (C-11, 
C-16)
LRMS (ES+): m/z= 392.9 [M+H]+
- 225 -
Experimental II
9.24 (95) 1-(4-hydroxybutyl) uracil
o
OH
Compound 94 (211 mg, 0.54 mmol) was dissolved in 0.2 M NaOMe in MeOH (40 mL) 
and left stirring overnight at RT. Dowex H+ resin was added to the mixture to neutralise 
excess base. The resin was filtered off and the solvent removed under reduced 
pressure. The crude was purified by column chromatography (MeOH/CHCI3 1:9) to 
yield the product as a clear oil (35 mg).
Yield: 35%
Rf. 0.4 in MeOH/CHCI3 1:9
1H-NMR: (500 MHz; MeOD) 6 1.48 (2 H, m, C(8)H2), 1.57 (2 H, m, C(9)H2), 3.51 (2 H, t 
J=6.3, C(7)H), 3.70 (2 H, t J= 7.3, C(10)H), 5.55 (1 H, d J=7.9, C(5)H), 7.51 (1 H, d 
J= 7.9, C(6)H)
LRMS (ES+): m/z= 185.7 [M+H]+
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Experimental II
9.25 (96) 1-(4-butanal) uracil
o
7\ 8 
9 \ 1 0
o
Compound 95 (35 mg, 0.190 mmol) was dissolved in a mixture of ACN/DCM/DMF 
2:2:1 (5 mL) and stirred with 4 A molecular sieves under argon at RT. NMO (34 mg, 
0.29 mmol) in dry DCM (1 mL) was added, followed by TPAP (3.5 mg, 1.01 mmol). The 
reaction was stirred at RT overnight. The mixture was filtered through celite and silica 
using MeOH/CHCI3 as eluent. After filtration, the crude was pushed through a short 
silica plug in a PD-10 column containing a PTFE sieve. Although the product (yellow 
wax, 18 mg) was still contaminated with some tetrapropylammonium, it was carried on 
to the next step.
Yield: 51%
1H-NMR: (500 MHz; MeOD) 6 1.34-1.62 (4 H, m, C(8)H2, C(9)H2), 3.70 (2 H, t J= 7.3, 
C(7)H), 5.57 (1 H, d J=7.9 C(5)H), 7.49 (1 H, d J=7.9 C(6)H)
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Experimental II
Experimental III
10 Experimental III
10.1 Docking of amino acid uracil conjugates
Compounds 98-160 were drawn and minimised using Sybyl 6.9. Minimisation was 
carried out using the TRIPOS force field in a dielectric constant of 80. The method 
used was conjugated gradient with a gradient of 0.05 kcal/mol and the number of 
iterations was set to 1000. Charges were not assigned as FlexX assigns formal 
charges to the ligand before docking calculations are carried out.
The pdb file of the protein was extracted and the water molecules removed. The active 
site was defined as being 6.5 A around the reference ligand which had been co- 
crystalised with the protein and was part of the PDB file. In the case of the open form T. 
cruzi dUTPase, which had no co-crystalised ligand, the natural ligand dUDP was 
manually placed in the PDB file and the active site defined as 6.5 A around it.
The compounds were then docked using FlexX. The uracil ring was manually defined 
as the base fragment. The calculations carried out by FlexX were not done on the 
whole proteins. Instead, to save time, the calculations were carried out 10 A distance 
around the active site. The conformations generated were ranked by FlexX by 
decreasing FlexX total score (increasing AG) and visualised using Sybyl 6.9.
10.2 General solid phase synthesis
10.2.1 Loading of resin procedure
Wang resin (500mg) was weighed into each empty PD-10 column and allowed to swell 
in DMF for 30min. The appropriate amino acid (2 eq) and DIC (1 eq) were dissolved in 
DMF (6mL) and left for 1h at RT. The beads were dried by suction and the anhydride 
solutions and DMAP (0.05 eq) were added to the resin beads. The mixtures were left 
shaking overnight. The beads were dried by suction and washed with DMF using a 
peristaltic pump.
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Experimental III
10.2.1.1 Measuring of resin loading
0.2-0.5 mg of washed derivatised resin was weighed into a quartz cuvette. 20% 
piperidine in DMF (3 mL) was added and the mixture agitated with a pipette. The UV 
absorbance was measured and the resin loading calculated according to the equation: 
Fmoc loading: mmole/g = (Abs)/(1.65 x mg resin)
10.2.2 Fmoc deprotection procedure
20% piperidine in DMF (6 mL) was added to each column and the mixtures left shaking 
for 1 h. The derivatised beads were washed with 20% piperidine in DMF (approx. 20 
ml_/g) either with or without the use of the peristaltic pump. The beads were washed 
with DMF and dried by suction.
10.2.3 Ninhydrin test procedure
A small amount of resin beads were placed into a glass vial. EtOH/H20 2:1 (3 mL) was 
added. Ninhydrin reagent (0.5 mL) was added and the solution was heated to 100 C for 
5 min. A positive result (blue beads) indicated the presence of a free amine and 
therefore the success of the deprotection procedure. If <60% of the beads were blue, 
the deprotection was repeated.
10.2.4 Coupling procedure
The appropriate amino acid or carboxyuracil (4 eq/mol loaded), TBTU (4 eq/mol 
loaded), HOBT (4 eq/mol loaded), and DIPEA (8 eq/mol loaded), were dissolved in 
DMF (3 mL). The solutions were added to the columns and the mixtures were left 
shaking overnight. The beads were dried by suction and washed with DMF with the aid 
of the peristaltic pump. The ninhydrin test was carried out and a negative result 
(colourless/pink beads) indicated absence of a free amine and therefore success of the 
coupling procedure.
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Experimental III
10.2.5 Cleavage from the resin
10.2.5.1 Preparation procedure
The derivatised beads were washed with DMF (2 x 20 mL), DCM (2 x 20 mL) and 
MeOH (2 x 20 mL) to shrink the beads with or without the use of the peristaltic pump. 
The beads were dried by suction.
10.2.5.2 Cleavage procedure A
A solution of 95 % TFA, 2.5% TES and 2.5% DCM (7 mL) was added to each column. 
The mixtures were left shaking for 1 h. The solutions were collected via suction and the 
beads were washed with DCM which was also collected. The solvents were removed in 
vacuo and the samples dried using an ACTEvac chamber. The products were triturated 
from cold ether.
10.2.5.3 Cleavage procedure B
A solution of 95 % TFA, 2.5% TES and 2.5% DCM (7 mL) was added to each column. 
The mixtures were left shaking for 30min. The solutions were collected via suction and 
the beads were washed with DCM which was also collected. The solvents were 
removed in vacuo and the samples dried using an ACTEvac chamber. The products 
were triturated from cold ether.
10.2.5.4 Cleavage procedure C
A solution of 50 % TFA, 5% TES and 45% DCM (7 mL) was added to each column. 
The mixtures were left shaking for 1 h. The solutions were collected via suction and the 
beads were washed with DCM which was also collected. The solvents were removed in 
vacuo and the samples dried using an ACTEvac chamber. The products were triturated 
from cold ether.
10.2.5.5 Cleavage procedure D
A solution of 50% TFA, 2.5% TES and 47.5% DCM (7 mL) was added to each column. 
The mixtures were left shaking for 1 h. The solutions were collected via suction and the 
beads were washed with DCM which was also collected. The solvents were removed in 
vacuo and the samples dried using an ACTEvac chamber. The products were triturated 
from cold ether.
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Experimental III
10.2.5.6 Cleavage procedure E
A solution of 50 % TFA, 2.5% TES and 47.5% DCM (7 ml) was added to each column. 
The mixtures were left shaking for 30 min. The solutions were collected via suction and 
the beads were washed with DCM which was also collected. The solvents were 
removed in vacuo and the samples dried using an ACTEvac chamber. The products 
were triturated from cold ether.
10.3 Results of amino acid uracil acetamide conjugate 
syntheses
Compounds were characterised by 1H-NMR and LRMS and also by HRMS where 
possible. All NMR experiments were carried out in D20  and mass spectrometry 
experiments were carried out in MeOH or MeOH/D20.
101
o
’H-NMR: (300 MHz, D2OJ 6 1.28 (3 H, d > 7 .1 , C(13)H3), 2.83 (2 H, m, C(14)H2), 4.28 
(1 H, q >7 .2 , C(9)H), 4.45 (2 H, m, C(7)H2), 4.63 (1 H, m, C(11)H), 5.75 (1 H, d > 7 .9 , 
C(5)H), 7.48 (1 H, d > 7 .9 , C(6)H)
LRMS (ES'): mlz= 297.1 [M-H]‘
HRMS (ES ): Found: 297.0842 [M-H]' CnHuOeN.' requires 297.0835
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103
O
5ff4 'NH
15
H0^ 0r \\ H N 2 O
HOf ^ N ^ N' 8'
°  H  13 °
1H-NMR: (300 MHz, D20) 6 1.08 (3 H, d J=6.6, C(15)H3), 1.28 (3 H, d J= 7.3, C(13)H3), 
4.38-4.40 (3 H, m, C(9)H, C(11)H), C(14)H), 4.48 (2 H, m, C(7)H2), 5.71 (1 H, d J= 7.9 
C(5)H), 7.44 (1 H, d J=7.9 C(6)H)
LRMS (ES ): m/z= 341.2 [M-H]'
104
1H-NMR: (300 MHz, D20  6) 1.15 (3 H, d J=7.1, C(13)H3), 2.81, 3.05 (2 H, m, C(14)H2), 
4.18 (1 H, q J-7.1, C(9)H), 4.35 (2 H, m, C(7)H2), 4.58 (1 H, m, C(11)H), 5.75 (1 H, d 
J=7.8 C(5)H), 6.65-6.95 (4 H, 2 x C(16)H, 2 x C(17)H), 7.39 (1 H, d J=7.8, C(6)H)
LRMS (ES ): m/z= 403.1 [M-H]‘
124
O
1H-NMR: (300 MHz, D20 ) 5 1.11 (3 H, d J=6.4, C(14)H3), 3.94 (2 H, s, C(9)H2), 4.30- 
4.34 (2 H, m, C(11)H, C(13)H), 4.51 (2 H, s, C(7)H2), 5.73 (1 H, d J= 7.9 C(5)H), 7.52 (1 
H, d J= 7.9 C(6)H)
LRMS (ES+): m/z= 351.1 [M+Na]+
HRMS (ES+): Found: 351.0910 [M+H]+ Ci2Hi60 7N4Na+ requires 351.0917
- 233 -
Experimental III
161
O
1H-NMR: (300 MHz, D20 ) 6 1.31 (3 H, d J=7.3. C(13)H3), 1.95, 2.15 (2 H, m, C(14)H2), 
2.69 (2 H, t J=7.0, C(15)H2), 4.30 (1 H, m, C(9)H), 4.39 (1 H, m, C(11)H), 4.49 (2 H, s, 
C(7)H2), 5.75 (1 H, d J= 7.9, C(5)H), 7.51 (1 H, d J=7.9, C(6)H)
LRMS (ES): m/z= 368.1 [M-H]'
HRMS (ES ): Found. 368.1202 [M-H]' CuH^OyNg' requires 368.1206 
163
1H-NMR: (300 MHz, D20 ) 6 1.30 (3 H, d J= 7.3, C(13)H3), 1.58, 1.69, 1.81 (6 H, m, 
C(14)H2, C(15)H2j C(16)H2), 2.92 (2 H, t J=7.7, C(17)H2), 4.25 (2 H, m, C(9)H, C(11)H), 
4.42 (2 H, s, C(7)H2), 5.73 (1 H, d J= 7.9, C(5)H), 7.45 (1 H, d J=7.9, C(6)H)
LRMS (ES+): m/z= 370.2 [M+H]+
HRMS (ES+): Found: 370.1707 [M+H]+ C^H^OeNg* requires 370.1721
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164
O
C 02H 5fX'4^NH 
N"2^0
HO
O
13
1H-NMR: (300 MHz, D20) 6 1.32 (3 H, d J=7.3, C(13)H3), 1.91-2.13 (2 H, m, C(14)H2), 
2.27 (2 H, t J= 7.5, C(15)H2), 4.31 (2 H, m, C(9)H, C(11)H), 4.49 (2 H, m, C(7)H2), 5.78 
(1 H, d J= 7.9, C(5)H), 7.48 (1 H, d J= 7.9, C(6)H)
LRMS (ES ): m/z= 369.1 [M-H]'
HRMS (ES*): Found: 369.1055 [M-H]' C14H170 8N4' requires 369.1046
166
O
12 || H
o
3
NHa
I T S
o
10
O
1H-NMR: (300 MHz, D20) 6 1.45 (3 H, d J=7.3, C(13)H3), 3.82 (2 H, s, C(12)H2), 4.28 
(1 H, m, C(9)H), 4.41 (2 H, s, C(7)H2), 5.74 (1 H, d J= 7.9, C(5)H), 7.47 (1 H, d J= 7.9, 
C(6)H)
LRMS (ES ): m/z= 297.1 [M-H]'
HRMS (ES'): Found: 297.0842 [M-H]' CnH130 6N4' requires 297.0835
1H-NMR: (300 MHz, D20) 6 2.91-3.15 (2 H, m, C(13)H2), 3.89 (2 H, s, C(9)H2), 4.40 (2 
H, s, C(7)H2), 4.67 (1 H, m, C(11)H), 5.79 (1 H, d J= 7.9, C(5)H), 6.80 (2 H, m, 2 x 
C(15)H), 7.07 (2 H, m, 2 x C(16)H), 7.35 (1 H, d J=7.9, C(6)H)
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LRMS (ES ): m/z= 389.2 [M-H]' 
171
1H-NMR: (300 MHz, D20 ) 6 1.32, 1.55, 1.69-1.80 (6 H, m, C(13)H2, C(14)H2, C(15)H2), 
2.82 (2 H, m, C(16)H2), 3.88 (2 H, s, C(9)H2), 4.25 (1 H, m, C(11)H), 4.48 (2 H, s, 
C(7)H2), 5.72 (1 H, d J=7.9, C(5)H), 7.45 (1 H, d J= 7.9, C(6)H)
LRMS (ES*): m/z= 356.2 [M+H]*
HRMS (ES*): Found: 356.1557 [M+H]* C14H220 6N5* requires 356.1565
172
3
NH• A -
1H-NMR: (300 MHz, D20 ) 6 3.95 (2 H, s, C(9)H2), 4.50 (2 H, s, 0 ( 7 ^ ,  5.79 (1 H, d 
J= 7.9, C(5)H), 7.52 (1 H, d J= 7.9, C(6)H)
LRMS (ES ): m/z= 226.1 [M-H]'
HRMS (ES*): Found: 228.0622 [M+H]* CsH^Os^* requires 228.0615
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11 Appendix 1: Biological assays
11.1 Enzyme assays
All enzyme inhibition assays were carried out at Instituto de Parasitologia y 
Biomedicina “Lopez-Neyra”, Granada, Spain.
Nucleotide hydrolysis was monitored by mixing enzyme and substrate with a rapid 
kinetic accessory (Hi-Tech Scientific) attached to a Cary 50 (Varian) stopped-flow 
spectrophotometer connected to a computer for data acquisition and storage. Assays 
contained 30nM purified recombinant enzyme, 50pM dUTP, 5nM MgCI2 and 2.5mM 
DTT, 1.25 mg/mL bovine serum albumin and 100mM KCI.
Changes in absorbance were directly proportional to the amount of product generated 
according to the equation:
[P]t = { (A o -A t)/(Ao-A«)}[S]o 
where: Ao, At, A„ denote the absorbance of the indicator at the start, time t and end of 
the reaction and [S0] I the initial concentration of dUTP.
Kinetic parameters Kmapp and Vmax were calculated using the Michaelis-Menten 
integrated rate equation:
[PM = Kmapp(2.3/t log[S]o/[S]) + Vmax/(1 -  KJK) 
where. Kmapp KmKKjj) + [S]o)/(KjP — Km)}
The different apparent Km values attained were plotted against inhibitor concentration 
and Kj values were obtained according to the following equation:
Kmapp= -Km[l]/Kj + Km
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11.2 In vitro assays
Compounds were screened against parasites for in vitro activity at The Swiss Tropical 
Institute, Basel, Switzerland.
11.2.1 T r y p a n o s o m a  b r u c e i  (Sleeping sickness)
The bloodstream form trypomastigotes of the Trypanosoma brucei rhodesiense STIB 
900 and Trypanosoma brucei brucei STIB 950 were maintained in MEM medium with 
Earle’s salts supplemented with 25 mM HEPES, 1g/l additional glucose, 1% MEM non- 
essential amino acids (100x), 0.2 mM 2-mercaptoethanol, 2mM Na-pyruvate, 0.1 mM 
hypoxanthine and 15% heat inactivated horse serum.
All cultures and assays were conducted at 37°C under an atmosphere of 5% C02 in air. 
Assays were performed in 96-well microtiter plates, each well containing 100 pL of 
culture medium with 8 x 103 bloodstream forms with or without a serial drug dilution. 
The highest concentration for the test compounds was 90 pg/mL. Seven 3-fold dilutions 
of compounds were used covering a range from 90 pg/L to 0.123 jig/mL. Each drug 
was tested in duplicate and each assay was repeated at least once.
After 72 hrs of incubation the plates were inspected under an inverted microscope to 
assure growth of the controls and sterile conditions. 10pL of Alamar Blue (12.5 mg 
resazurin dissolved in 100 mL distilled water) was added to each well and the plates 
incubated for another 2 hours. The plates were read with a Spectramax Gemini XS 
microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an 
excitation wave length of 536 nm and an emission wave length of 588 nm.
Data was analysed using the microplate reader software Softmax Pro (Molecular 
Devices Cooperation, Sunnyvale, CA, USA).
The reference drug used was Melarsoprol with an IC50 of 1.6 ng/mL.
11.2.2 T r y p a n o s o m a  c r u z i  (Chagas’ Disease)
The infective amastigote and trypomastigote stages were cultivated in L-6 cells (rat 
skeletal myoblast cell line) in RPMI 1640 supplemented with 2 mM L-glutamine and 
10% heat-inactivated foetal bovine serum in 12.5 cm2 tissue culture flasks. 
Intracellularly developed amastigote differentiated into trypomastigotes and left the host 
cell. The trypomastigotes infected new L-6 cells and were the stages used to initiate an 
infection in the assay. All cultures and assays are conducted at 37°C under an 
atmosphere of 5% C02 in air.
Appendix 1: Biological assays
Assays were performed in sterile 96-well microtiter plates, each well containing 100 pL 
medium with 2x103 L-6 cells. After 24 hours 50 pL of a trypanosome suspension 
containing 5 x 103 trypomastigote bloodstream forms from culture were added to the 
wells. 48 hours later the medium was removed from the wells and replaced by 100 pL 
fresh medium with or without a serial drug dilution.
Seven 3-fold dilutions of the compounds were used covering a range from 90 pg/mL to 
0.123 pg/mL. Each drug was tested in duplicate. After 96hours of incubation the plates 
were inspected under an inverted microscope to assure growth of the controls and 
sterility.
The substrate CPRG/ Nonidet (50 pL) was added to all wells. A colour reaction became 
visible within 2-6 hours and was read photometrically at 540nm. Data was transferred 
into graphic programme (e.g. EXCEL), sigmoidal inhibition curves determined and IC5o 
values calculated.
Benznidazole was the reference drug used with an IC50 0.34 pg/mL
11.2.3 L e is h m a n ia  d o n o v a n i  (Leishmaniasis)
The Leishmania donovani MHOM/ET/67/L82 strain was maintained in the hamster. 
Amastigotes were collected from the spleen of an infected hamster and adapted to 
axenic culture conditions at 37°C. The medium was a 1:1 mixture of SM medium and 
SDM-79 medium at pH 5.4 supplemented with 10% heat-inactivated FBS under an 
atmosphere of 5% C02 in air.
Assays were performed in 96-well microtiter plates, each well containing 100 pL of 
culture medium with 105 amastigotes from axenic culture with or without a serial drug 
dilution. The highest concentration for the test compounds was 90 pg/mL. Seven 3-fold 
dilutions were used covering a range from 30 pg/mL to 0.041 pg/mL. Each drug was 
tested in duplicate and each assay repeated at least once. After 72hours of incubation 
the plates were inspected under an inverted microscope to assure growth of the 
controls and sterile conditions.
10pL of Alamar Blue (12.5 mg resazurin dissolved in 1L distilled water) was added to 
each well and the plates incubated for another 2 hours. The plates were read with a 
Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an emission wave 
length of 588 nm. Data was analysed using the microplate reader software Softmax 
Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA).
Miltefosine was used as the reference drug with an IC50 value of 0.12 pg/mL.
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11.2.4 P la s m o d iu m  f a l c i p a r u m  (Malaria)
The parasite strains were maintained in RPMI-1640 medium with 0.36 mM 
hypoxanthine supplemented with 25 mM HEPES, 25 mM NaHC03, neomycin (100 
U/mL) and AlbumaxR (lipid-rich bovine serum albumin) (GIBCO, Grand Island, NY) 
(5g/l), together with 5% washed human A+ erythrocytes. All cultures and assays were 
conducted at 37°C under an atmosphere of 4% C02, 3% 02 and 93% N2. Cultures were 
kept in incubation chambers filled with the gas mixture. Subcultures were diluted to a 
parasitaemia of 0.1-0.5% and the medium changed daily.
Assays were performed in sterile 96-well microtiter plates, each well containing 200 pL 
of parasite culture (0.15% parasitaemia, 2.5% hematocrit) with or without serial drug 
solutions. Seven 2-fold dilutions were used covering a range from 5 pg/mL to 0.078 
pg/mL. For active compounds the highest concentration was lowered (e.g. to 100 
ng/mL). Each drug was tested in duplicate and repeated once for active compounds 
showing an IC50 below 0.5 pg/mL.
After 48 hours of incubation at 37°C, 0.5 pCi 3H-hypoxanthine was added to each well. 
Cultures were incubated for a further 24 h before they were harvested onto glass-fiber 
filters and washed with distilled water. The radioactivity was counted using a 
BetaplateTM liquid scintillation counter (Wallac, Zurich, Switzerland). The results were 
recorded as counts per minute (CPM) per well at each drug concentration and 
expressed as a percentage of the untreated controls. From the sigmoidal inhibition 
curves IC50 values were calculated.
Cloroquine and artemesnin were the reference drugs used with respective IC50 values 
2.9ng/mL and 1.9 ng/mL against the NF54 strain and 48ng/mL and 0.8ng/mL against 
the K1 strains.
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Abstract—Potential inhibitors of the Trypanosoma cruzi dUTP nucleotidohydrolase were docked into the enzyme using the program 
FlexX. Compounds that docked selectively were then selected and synthesized using solid phase methodology, giving rise to a novel 
library of amino acid uracil acetamide compounds which were evaluated for enzyme inhibition and anti-parasitic activity.
© 2006 Elsevier Ltd. All rights reserved.
The protozoan parasite Trypanosoma cruzi is the 
causative agent of Chagas’ disease, also called American 
trypanosomiasis. The parasite is transmitted by blood 
sucking triatomine insects and is one of three species 
of the genus Trypanosoma that are pathogenic to 
humans. Chagas’ disease occurs mainly in South and 
Central America. It is estimated that 16—18 million peo­
ple are infected with the disease, of which approximately 
50,000 will die each year.1 Although the number of inci­
dences of the disease has declined over the past 20 years 
due to vector control initiatives,2 there is still no satisfac­
tory cure for American trypanosomiasis and current 
drug treatment is only effective against the early stages 
of the disease. The need for new drugs to treat this dis­
ease is therefore urgent.
Recently, deoxyuridine 5'-triphosphate nucleotidohy­
drolase (dUTPase) has been identified as a novel and 
valid target against trypanosomatidae.3 The enzyme is 
essential in both eukaryotes and prokaryotes, where 
investigated.4,5 dUTPase catalyses the hydrolysis of 
dUTP to dUMP in the presence of Mg2+ and plays a 
critical role in maintaining the level of dUTP in the cell 
10-5 times lower than that of dTTP. In doing so, incor­
Keywords: dUTPase; Structure-based drug design.
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poration of uracil into DNA is minimized, excessive 
incorporation of which would normally lead to DNA  
fragmentation and cell death. dUTPases are known to 
exist in several oligomeric forms. Monomeric enzymes 
are encoded by herpes virus and Epstein-Barr virus, 
while the homotrimeric forms are present in mammals, 
various bacteria and viruses and also in the Plasmodium 
falciparum parasite, the causative agent for malaria. The 
homodimeric enzymes have been found in Leishmania 
major, T. cruzi and Campylobacter jejuni. The 
dimeric enzymes show no similarity in sequence or 
structure to the monomeric or trimeric forms and are 
thought to have reached their catalytic potential 
through a different evolutionary route. Crystal 
structures of seven trimeric (Escherichia coli,6 human,7 
equine infectious anemia virus,8 feline immunodeficien­
cy virus,9 Methanococcus jannaschii,10 Mycobacterium 
tuberculosis,n and P. falciparum12) and two dimeric 
(T. cruzi13 and C. jejuni14) dUTPases have been pub­
lished to date.
It has been shown that relative to other eukaryotic 
dUTPase enzymes, a,|3-imido-dUTP is a strong 
inhibitor of the dimeric enzymes. It has been proposed 
therefore that the triphosphate moiety is necessary for 
inhibition of the dimeric dUTPases.15 To emphasise 
the difference, tritylated nucleoside derivatives prepared 
by our group were good inhibitors of the trimeric 
enzymes12 but are inactive against the dimeric parasitic
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dUTPases. In contrast to the trimeric dUTPases where a 
glycine-rich site for phosphate binding is common, the 
phosphates in the dimeric enzymes are held in place with 
hydrogen bonds to charged side chains.13 Taking 
advantage of the structural differences between these 
enzymes, it was thought that selective inhibitors for 
the dimeric T. cruzi dUTPase (TcdUTPase) could be 
designed and synthesized as lead compounds for the 
treatment of Chagas’ disease.
Considering the hydrophilic nature of the TcdUTPase 
active site, compounds in which chains with good 
hydrogen bond donating or hydrogen bond accepting 
capability attached to N1 of the uracil ring were consid­
ered as potential inhibitors. Ease of synthesis of uracil 
acetamide derivatives, to which were attached one or 
two amino acids (Fig. 1), by the Fmoc solid phase strat­
egy allowed for a wide range of structural diversity to be 
implemented and were therefore chosen for further 
study. Compounds such as those shown in Figure 1 were 
drawn, minimized and docked into the active site of 
TcdUTPase using the program FlexX. The ligand-free 
(native) TcdUTPase exists in an open form (pdb 
lOGL). Binding of the substrate induces substantial 
structural changes so that the enzyme closes over the li­
gand (pdb lOGK).13 Docking studies were carried out 
on the closed (complexed) form of the enzyme. The com­
pounds which docked with the best superimposition 
over the endogenous dUDP ligand were synthesized 
using solid phase chemistry and tested for biological 
activity.
FlexX is a docking program that takes into account the 
flexibility of the ligand but not that of the receptor. The 
docking method it uses is based on an incremental con­
struction algorithm which consists of three phases: (1) 
base selection, (2) base placement, and (3) complex con­
struction.16 The interaction types and scoring functions 
in FlexX are based on work by Bohm and Klebe.17
Docking studies showed that: (1) the R side chain 
should be H or CH3. Structures where the side chains, 
R, were bigger than those of Ala or Gly were too bulky 
to fit into the active site. (2) The optimum distance be­
tween the carbonyl marked with an * (Fig. 1) and the 
terminal atom was 2 or 3 but no more than 5 atoms. 
(3) The best scoring compounds were those where R' 
was a charged residue. A large degree of variation of 
the R' side chain without effecting the superimposition 
was, however, allowed. Compounds 1 11 (Table 1) were 
among those which docked best into the TcdUTPase ac­
tive site (Fig. 2).
Compounds 1-11 were synthesized by solid phase Fmoc 
chemistry as shown in Scheme 1. Amino acids 12-19
Table 1. Compounds docked into the TcdUTPase active site using 
F lexX  and subsequently synthesized
Com pound R R' C olour
1 c h 3 v ~ v ° Ho
Orange
2 c h 3
o
Red
3 c h 3 O Green
4 c h 3 H Blue
5 c h 3 y ~ > ^ nh2 Purple
6 c h 3 OH Magenta
7 c h 3 V ' Q » . V iolet
8 H — Green blue
9 H Redorange
10 H OH By atom type
11 H
^ ^ O H
W hite
d U D P Yellow
X . >
r i w
V  ,
AI
HO.
NH
R’ O  H C
’( W
8 1-7,9-11
Figure 1. Structure o f potential TcdUTPase inhibitors.
NH
O H N^O
HO"VNTJ
Figure 2. Docking o f  compounds 1-11 in TcdU TPase active site. 
Superimposition w ith d U D P .
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£ _ 0H    W '°Y ^N H Fm oc  “ W -0 ^
FmocHN"SfOH 
O
.. NH2
R' O  O
12-19
F m o cH N 'S rOH
O
12,13
il !NH
HCV
O
20
^  R' o  d A  R' o
W ° Y ^ N A r NHFmoc ---------- " ® _ 0 Y ^ N A r NH2
o  H R  o  H R
O
NH jf^N H
R* O H .  R' 9  H NA 0
-V V V V  ro/NArV
O H r o  o  h  r  o
1-11
Scheme I .  General synthesis o f  compounds 1-11: (a) D IC , 12-19, D M A P , D M F  (12, A la; 13, G ly; 14, Asp; 15, G in; 16, G lu; 17, Lys; 18, Thr; 19, 
Tyr); (b ) 20% piperidine, D M F ; (c) T B T U , H O B t, 12-13, D IP E A , D M F ;  (d) 20% piperidine, D M F ;  (e) T B T U , H O B t, 20, D IP E A , D M F  (0 ; 50%  
T F A , D C M , TES.
were first converted to the appropriate anhydrides using 
DIC. The anhydrides and DMAP were then added to 
Wang resin18 and the percentage loading was calculated 
by UV absorption.19 Subsequent deprotection of the 
Fmoc group with piperidine was then followed by cou­
pling to the second amino acid using TBTU and 
HOBt.20,21 A final deprotection and coupling to 1-carb- 
oxymethyl uracil, 20,22 followed by cleavage from the 
resin beads using 50% TFA released the desired com­
pounds 1-11. All final compounds were analysed and 
characterized by *H NM R and MS.
Compounds 1-11 were tested for both TcdUTPase en­
zyme inhibition23 and in vitro effects on parasite 
growth.24 As can be seen from Table 2, none of the com-
Table 2. Biological activity o f compounds 1-11
Com pound Enzyme 
inhibition Kt
In  vitro  
ICso (p M )
Cytotoxicity  
ICso* (p M )
1 >1 m M >84 >252
2 >1 m M >81 >243
3 >1 m M >81 210
4 >1 m M >100 >301
5 >1 m M >81 >243
6 >1 m M >87 >262
7 >1 m M >74 214
8 >1 m M >132 >396
9 >1 m M >84 >253
10 >1 m M >91 >274
11 >1 m M >76 >230
Standard 18.40b p M 1.04c 0.15d
* Cytotoxicity tests were carried out on rat L6 cells. 
b d U M P . 
c Benznidazole. 
d Podophyllotoxin.
pounds inhibited the TcdUTPase enzyme at a concen­
tration of 1 mM. Neither did the compounds inhibit 
parasite growth at the maximum concentrations shown.
Thus, the search so far for lead inhibitors of the dimeric 
dUTPase enzymes remains unsuccessful. There are a 
number of reasons why this design paradigm was not 
successful in this case, (i) Recently, the crystal structure 
of the dimeric C. jejuni dUTPase revealed the coordina­
tion of Mg2+ ions within the active site of the enzyme.14 
These ions are absent in the TcdUTPase crystal struc­
ture. It is unclear if the Mg2+ ions are bound to the 
un-liganded enzyme, but it is possible that the presence 
of these ions must be taken into account when designing 
inhibitors in silico.
(ii) As previously mentioned, FlexX does not take into 
account the flexibility of the protein in question. 
Although this approximation reduces run time signifi­
cantly, in this case where binding of the ligand induces 
a large conformational change in protein structure it is 
possible that a docking program in which protein flexi­
bility is taken into account should be used.
(iii) There must be a mechanism by which the dUTPase 
undergoes the large conformational change on binding 
dUTP. Two mechanisms of binding could be envisaged. 
First, the uracil and deoxyribose moieties, which bind to 
motifs from the rigid domain of protein, would be rec­
ognized. The a, P, and subsequently y phosphates, 
which are recognized by mobile domain motifs, would 
then bond to the Mg2+ ions and respective amino acid 
side chains sequentially and induce ‘active site closure’. 
Alternatively, the phosphate moieties would be recog­
nized by the mobile domain first and the protein would 
then undergo such a conformational change so as to
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encapsulate the uracil and sugar moieties. In the latter 
case, the phosphate moieties would be more essential 
for ligand recognition and therefore replacement of 
them would be detrimental to ligand recognition. This 
would explain the lack of activity of compounds 1-11. 
In either case, the experimental biological data indicate 
that compounds 1-11 do not possess the required struc­
ture to bind to the open form of the enzyme sufficiently 
enough to induce the conformational change required 
for inhibition.
Although compounds 1-11 docked with good superim­
position and favourable binding energies into the 
TcdUTPase active site with FlexX. it is apparent that 
other factors such as protein flexibility and the presence 
of Mg2+ ions should be taken into account when design­
ing competitive inhibitors for these enzymes in silico.
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